BIO MEDICA LABORATORIES LTD.
(FORMERLY BIO MEDICA LABORATORIES PVT. LTD.)

Date- 04th September, 2026

To,
The Manager,
National Stock Exchange of India Limited
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E), Mumbai – 400051

Reference: ISIN: INE1BKA01015; Symbol: BMLL

Subject - Filing of 11th Annual Report of Bio Medica Laboratories Limited for the Financial Year 2025-26.

Dear Sir/Madam,

We are pleased to submit copy of the Annual Report of the company for the Financial Year 2025-26. The 11th Annual General Meeting is to be held on 28th September, 2026 at 02:00 P.M (IST) Through Online Mode. You are requested to take on record above said document.

Thanking You,

For Bio Medica Laboratories Limited
(Formerly Known as Bio Medica Laboratories Private Limited)

MUKESH MEHTA
Digitally signed by MUKESH MEHTA
Date: 2026.09.04 16:40:16 +05'30'

Mukesh Mehta
Whole-time Director
DIN: 03187420

BIO MEDICA LABORATORIES LTD.

(FORMERLY BIO MEDICA LABORATORIES PVT. LTD.)

CIN: U20293MP2015PLC034576

11TH

ANNUAL REPORT 2025-26

CORPORATE INFORMATION

Pradeep Mehta (DIN: 07254802) - Managing Director Appointed with effect from 14th August, 2015. **Mukesh Mehta (DIN: 03187420)** - Whole Time Director appointed with effect from 14th August, 2015. **Surabhi Mahajan (DIN: 10771559) -** Non-Executive Director appointed with effect from 07th September, 2024. **Divya Khandelwal (DIN: 08444385)** - Non-Executive Independent Director appointed with effect from 28th October, 2024. **Sumeet Bansal (DIN: 10822898) -** Non-Executive Independent Director appointed with effect from 28th October, 2024	**STATUTORY AUDITOR** **M/s Vijay K. Jain & Associates** **Chartered Accountants** **FRN No.:** 006719C Appointed on 12.06.2025 due to casual vacancy caused by the resignation of M/s Satyanarayan Goyal & LLP. Further, appointed in Annual General Meeting held for the FY 2024-25 for 5 FY from 01.04.2025 to 31.03.2030. **M/s Satyanarayan Goyal & LLP** **Chartered Accountants** **FRN No.:** 006636C (Resigned w.e.f. 01st June, 2025)
REGISTERED OFFICE Plot No. 11B-11C, Sector-E, Sanwer Road, Industrial Area, Industrial Estate, Indore, Madhya Pradesh, India, 452015 **E-mail:** bmlpl2014@gmail.com **Website:** www.biomedica.co.in	**COMPANY SECRETARY & COMPLIANCE OFFICER** **Mr. Rahul Kumar** (Appointed w.e.f. 22.07.2025 and Resigned w.e.f. April 01, 2026) **Ms. Pratiksha Bhandari** (Appointed w.e.f. April 03, 2026 and Resigned w.e.f. August 13, 2026) **Ms. Khushi Gupta** (Appointed w.e.f. August 14, 2026)
BANKER **AXIS BANK LIMITED** **Address:** Prabhat Apartment, Gunpower & Sardar Balwant Singh Dhondy Marg, Mazgaon, Mumbai 400010.	**REGISTRAR AND TRANSFER AGENT** **Skyline Financial Services Private Limited** **Address**: D-153 A, 1st Floor, Okhla Industrial Area, Phase – I, New Delhi-110020 Tel: +91-011-40450193-97 Email: info@skylinerta.com Website: www.skylinerta.com

KOTAK MAHINDRA BANK LTD. **Address:** 2nd Floor Block B, Metro Tower, Near Managal City Vijayanagar 452010	
<u>SECRETARIAL AUDITOR</u> **Vishakha Agrawal & Associates** **(Practising Company Secretaries)**	**<u>STOCK EXCHANGE</u>** **<u>NSE Limited</u>** Exchange Plaza Plot No. C/1, G Block Bandra Kurla Complex Bandra (E) Mumbai – 400051, Mumbai, Maharashtra**.**
<u>CHIEF FINANCIAL OFFICER</u> **Mr. Santosh Kale** **Address:** Plot No. 11B-11C, Sector-E, Sanwer Road, Industrial Area, Industrial Estate, Indore, Madhya Pradesh – 452015, India (Appointed w.e.f. October 28, 2024)	

TABLE OF CONTENT

NOTICE

Notice is hereby given that the 11th Annual General Meeting (AGM) of the Members of **Bio Medica Laboratories Limited** will be through Video Conferencing/ Other Audio-Visual Mode on Monday, 28th September, 2026 at 02.00 P.M. to transact the following businesses:

Details of the meeting are as follows:
Topic: 11th Annual General Meeting

Time: Monday, 28th September, 2026 at 02.00 P.M

Following business shall be transacted at the meeting:

ORDINARY BUSINESS:

1. **TO RECEIVE, CONSIDER AND ADOPT THE AUDITED FINANCIAL STATEMENTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED MARCH 31, 2026 TOGETHER WITH THE REPORTS OF THE BOARD OF DIRECTORS AND THE AUDITORS THEREON;**

To consider, and if thought fit, to pass, with or without modification(s), the following resolution, as an Ordinary Resolution:

"RESOLVED THAT the audited Financial Statements of the Company for the Financial year ended March 31, 2026, the report of the Auditors' thereon and the report of the Board of Directors for the Financial year ended March 31, 2026 be and are hereby received, considered and adopted."

2. **TO APPOINT MR. MUKESH MEHTA (DIN: 03187420) DIRECTOR WHO RETIRES BY ROTATION IN TERMS OF SECTION 152 OF THE COMPANIES ACT, 2013 AND BEING ELIGIBLE, OFFERS HIMSELF FOR RE-APPOINTMENT.**

To consider, and if thought fit, to pass, with or without modification(s), the following resolution, as an Ordinary resolution:

"**RESOLVED THAT** pursuant to the provisions of Section 152 and all other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Appointment and Qualifications of Directors) Rules, 2014, as amended from time to time ("Act"), Mr. Mukesh Mehta (DIN: 03187420) who retire by rotation at this meeting and being eligible has offered himself for re-appointment, be and is hereby re-appointed as a Whole Time Director of the Company, liable to retire by rotation."

SPECIAL BUSINESS:

3. **APPOINTMENT OF SECRETARIAL AUDITOR AND FIX THEIR REMUNERATION**

To appoint M/s Vishakha Agrawal & Associates, Practicing Company Secretaries, Indore, as Secretarial Auditor of the Company and to fix their remuneration in this regard to consider and if thought fit, to pass the following resolution as an Ordinary Resolution**.**

"RESOLVED THAT pursuant to Section 204 of the Companies Act, 2013, Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, Regulation 24A of the SEBI (LODR) Regulations, 2015 (as amended), and other applicable provisions, consent of the members be and is hereby accorded for the appointment of M/s Vishakha Agrawal & Associates, Practicing Company Secretaries, as the Secretarial Auditors of the Company to conduct Secretarial Audit for a term of five (5) consecutive years, commencing from FY 2025-26 to FY 2030-31, at remuneration as may be determined by the Board of Directors in consultation with the Audit Committee.

RESOLVED FURTHER THAT the Board of Directors be and is hereby authorized to do all acts, deeds, matters, and things necessary or expedient for giving effect to this resolution."

4. **INCREASE IN LIMIT OF TOTAL SHAREHOLDING OF ALL REGISTERED FOREIGN PORTFOLIO INVESTORS (FPIS) / REGISTERED FOREIGN INSTITUTIONAL INVESTORS (FIIS) PUT TOGETHER UP TO 49% OF THE PAID-UP EQUITY SHARE CAPITAL OF THE COMPANY**

To consider and, if thought fit, to pass with or without modification the following resolution as a Special Resolution:

"RESOLVED THAT pursuant to the applicable provisions of Foreign Exchange Management Act, 1999, as amended ("FEMA"), Foreign Exchange Management (Non-debt Instruments) Rules, 2019, which came into force with effect from October 17, 2019, and the Consolidated FDI Policy Circular of 2017, as amended, the Companies Act, 2013, as amended, and the rules and regulations made thereunder (collectively referred to as the "Companies Act") and subject to all applicable approvals, permissions and sanctions of the Reserve Bank of India ("RBI"), the Ministry of Finance, the Ministry of Corporate Affairs, Government of India and other concerned authorities and subject to such conditions as may be prescribed by any of the said concerned authorities while granting such approvals, permissions or sanctions which may be agreed to by the board of directors of the Company ("Board"), the limit of investment by foreign portfolio investors in the equity shares of face value of ₹ 10 each of the Company, including, without limitation, by subscription in the initial public offering in accordance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or direct purchase or acquisition from the open market or otherwise, is increased to 49% of the paid-up equity share capital of the Company, provided however that the shareholding of each foreign portfolio investor in the Company shall not exceed limit as may be stipulated by RBI in each case, from time to time;

RESOLVED FURTHER THAT any Director of the Company and/or the Company Secretary of the Company, be and are hereby severally authorised to take such steps as may be necessary for obtaining approvals, statutory or otherwise, in relation to the above and to settle all matters arising out of and incidental thereto and to sign and to execute deeds, applications, documents and file returns with Registrar of Companies, as may be required, on behalf of the Company and generally to do all such acts, deeds, matters and things as may be necessary, proper, expedient or incidental for giving effect to the resolution."

By the order of the Board of Directors
For Bio Medica Laboratories Limited

	Sd/-	**Sd/-**
Place: Indore	**Pradeep Mehta**	**Mukesh Mehta**
Date: 02nd September, 2026	**Managing Director**	**Whole Time Director**

NOTES:-

a) The Explanatory Statement pursuant to section 102 (1) of the Companies Act, 2013 in respect of the Special Business under Item No. 3 and 4 as stated above in annexed hereto.

b) The Ministry of Corporate Affairs ("MCA") vide its circular dated April 8, 2020, April 13, 2020, May 5, 2020,December 8, 2021, May 5, 2022, December 28, 2022and September 25, 2023 (collectively referred to as "MCA Circulars"), and Securities & Exchange Board of India (SEBI) vide its Circular No. SEBI/HO/ CFD/PoD-2/P/CIR/2023/4 dated January 5, 2023 read with Circular No. SEBI/HO/CFD/CMD2/CIR/P/2022/62 dated May 13, 2022, Circular No SEBI/HO/CFD/CMD1/CIR/F/2020/11 dated January 15, 2021 and Circular No. SEBI/HO/CFD/CMD1/CIR/F/2020/79 dated May 12, 2020 (collectively referred to as "SEBI Circulars") permitted convening the Annual General Meeting ("AGM") through Video Conferencing ("VC") or Other Audio Visual Means ("OAVM"), without physical presence of the members at a common venue. In accordance with the MCA and SEBI Circulars, provisions of the Companies Act, 2013 ("the Act") and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), this 11th AGM is being held through VC/OAVM, which does not require physical presence of members at a common venue. The deemed venue for the 11th AGM shall be the Registered Office of the Company.

c) Since this General Meeting is held through VC/OAVM the physical attendance of members is dispensed with and no proxies would be accepted by the Company pursuant to the relevant MCA Circulars.

d) No attendance slip/route map has been sent along with this Notice of the Meeting as the meeting is held through Audio Visual means.

e) The attendance through VC/OAVM is restricted and hence members will be allowed on first come first serve basis. However, attendance of Members holding more than 2% of the shares of the Company, and Directors and Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee, the Stakeholders Relationship Committee and Auditors will not be restricted on first come first serve basis.

f) Members attending the Meeting through VC/OAVM will be counted for the purposes of reckoning of Quorum under Section 103 of the Companies Act, 2013.

g) In line with the MCA Circulars and the SEBI Circular, the Notice calling the AGM has been uploaded on the website of the Company at www.biomedica.co.in. The Notice can also be accessed from the website of the Stock Exchange i.e. NSE Limited at www.nseindia.com.

h) Members are requested to notify immediately changes, if any, in their registered addresses to the Company's Registrar and Share Transfer Agents Skyline Financial Services Private Limited Address: D-153 A, 1st Floor, Okhla Industrial Area, Phase – I, New Delhi-110020. Members are also requested to furnish their Bank details to the company's Share Transfer Agents immediately for printing the same on the dividend warrants/Cheques to prevent fraudulent encashment of the instruments.

i) Members are also requested to furnish their Bank details to the company's Share Transfer Agents immediately for printing the same on the dividend warrants/Cheques to prevent fraudulent encashment of the instruments.

j) Members holding shares in physical form are requested to consider converting their holding to dematerialized form to eliminate all risks associated with physical shares and for ease of portfolio management. Members can contact the Company for assistance in this regard. Members who hold shares in dematerialized form are requested to bring their Client ID and DP ID numbers for easy identification of attendance at the meeting and number of shares held by them.

k) Members holding shares in physical form in identical order of names in more than one folio are requested to send to the Company, the details of such folios together with the share certificates for consolidating their holdings in one folio. A consolidated share certificate will be returned to such Members after making requisite changes thereon.

l) The Ministry of Corporate Affairs ("MCA") has taken a "Green Initiative in the Corporate Governance" by allowing paperless compliances by Companies and has issued a circular on April 21, 2011 stating that the service of document by a Company can be made through electronic mode.

m) In compliance with the provisions of Section 108 of the Companies Act, 2013 and the Rules framed there under and the SEBI (LODR) Regulation 2015, the Members are provided with the facility to cast their vote electronically, through the e-voting services provided by Central Depository Services (India) Limited (CDSL), on all the resolutions set forth in this Notice. Resolution(s) passed by Members through remote e-voting/ e-voting is deemed to have been passed as if they have been passed at the AGM.

n) CS Vishakha Agrawal of Vishakha Agrawal & Associates., Practicing Company Secretaries (Membership No. 39298) has been appointed as the Scrutinizer to scrutinize the voting and remote evoting process (including the Ballot Form received from the Members who do not have access to the evoting process) in a fair and transparent manner.

o) A member may participate in the general meeting even after exercising his right to vote through remote e-voting but shall not be allowed to vote again.

p) The chairman shall, at the general meeting at the end of discussion on the resolution on which voting is to be held, allow voting with assistance of scrutinizer, by using an e-voting system for all the members who are present at the general meeting but have not cast their votes by availing the remote e-voting facilities.

q) If a company opts to provide the same electronic system as used during the remote e-voting during the general meeting, the said facility shall be in operation till all the resolutions are considered and voted upon in the meeting and may be used for voting by the member attending the meeting and who have not exercised their vote through remote e- voting.

r) The Equity Shares of the Company are listed on following Stock Exchanges in India: National Stock Exchange Limited Exchange Plaza Plot No. C/1, G Block Bandra Kurla Complex Bandra (E) Mumbai – 400051, Mumbai, Maharashtra.

s) The Company has designated an exclusive E-Mail ID bmlpl2014@gmail.com called for redressal of Members' complaint/grievances. In case you have any queries/complaints or grievances, then please write to us bmlpl2014@gmail.com .

t) Members can avail facility of nomination in respect of shares held by them in physical form pursuant to the provisions of Section 72 of the Companies Act, 2013. Members desired to avail of this facility may send their nomination in the prescribed Form No. SH-13 duly filled into the office of Registrar and Share Transfer Agent of the Company Skyline Financial Services Private Limited, Address: D-153 A, 1st Floor, Okhla Industrial Area, Phase – I, New Delhi-110020. Members holding shares in electronic mode may contact their respective Depository Participants for availing this facility.

NSDL e-Voting System – For e-voting and Joining Virtual meetings.

1. Pursuant to the General Circular No. 09/2024 dated September 19, 2024, issued by the Ministry of Corporate Affairs (MCA) and circular issued by SEBI vide circular no. SEBI/ HO/ CFD/ CFDPoD-2/ P/ CIR/ 2024/ 133 dated October 3, 2024 ("SEBI Circular") and other applicable circulars and notifications issued (including any statutory modifications or re-enactment thereof for the time being in force and as amended from time to time, companies are allowed to hold EGM/AGM through Video Conferencing (VC) or other audio visual means (OAVM), without the physical presence of members at a common venue. In compliance with the said Circulars, EGM/AGM shall be conducted through VC / OAVM.

2. Pursuant to the Circular No. 14/2020 dated April 08, 2020, issued by the Ministry of Corporate Affairs, the facility to appoint proxy to attend and cast vote for the members is not available for this EGM/AGM. However, the Body Corporates are entitled to appoint authorised representatives to attend the EGM/AGM through VC/OAVM and participate there at and cast their votes through e-voting.

3. The Members can join the EGM/AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the EGM/AGM through VC/OAVM

will be made available for 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the EGM/AGM without restriction on account of first come first served basis.

4. The attendance of the Members attending the EGM/AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.

5. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) the Secretarial Standard on General Meet ings (SS-2) issued by the ICSI and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and the Circulars issued by the Ministry of Corporate Affairs from time to time the Company is providing facility of remote e-Voting to its Members in respect of the business to be transacted at the EGM/AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a member using remote e-Voting system as well as e-voting on the date of the EGM/AGM will be provided by NSDL.

6. In line with the Ministry of Corporate Affairs (MCA) Circular No. 17/2020 dated April 13, 2020, the Notice calling the EGM/AGM has been uploaded on the website of the Company at www.biomedica.co.in. The Notice can also be accessed from the websites of the Stock Exchanges i.e. National Stock Exchange of India Limited at www.nseindia.com respectively and the EGM/AGM Notice is also available on the website of NSDL (agency for providing the Remote e-Voting facility) i.e. www.evoting.nsdl.com.

7. EGM/AGM has been convened through VC/OAVM in compliance with applicable provisions of the Companies Act, 2013 read with MCA Circular issued from time to time

THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING AND JOINING GENERAL MEETING ARE AS UNDER:-

The remote e-voting period begins on Friday, 25th September, 2026, and ends on Sunday, 27th September, 2026. The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the record date (cut-off date) i.e. Tuesday, 22nd September, 2026, may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being, Tuesday, 22nd September, 2026.

How do I vote electronically using NSDL e-Voting system?

The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:

Step 1: Access to NSDL e-Voting system

A) Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	**Login Method**
Individual Shareholders holding securities in demat mode with NSDL.	1. For OTP based login you can click on https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID,8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 2. Existing **IDeAS** user can visit the e-Services website of NSDL Viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the "**Beneficial Owner"** icon under **"Login"** which is available under **'IDeAS'** section , this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on **"Access to e-Voting"** under e-Voting services and you will be able to see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 3. If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select **"Register Online for IDeAS Portal"** or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 4. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available

	under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 5. Shareholders/Members can also download NSDL Mobile App "**NSDL Speede**" facility by scanning the QR code mentioned below for seamless voting experience.
Individual Shareholders holding securities in demat mode with CDSL	1. Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi /Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & New System Myeasi Tab and then user your existing my easi username & password. 2. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly. 3. If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option. 4. Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will

	authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.
Individual Shareholders (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	**Helpdesk details**
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.com or call at 022 - 4886 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800-21-09911

B) Login Method for e-Voting and joining virtual meeting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

<u>How to Log-in to NSDL e-Voting website?</u>

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.
   Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at https://eservices.nsdl.com/ with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.
4. Your User ID details are given below :

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	**Your User ID is:**
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12****** then your user ID is IN300***12******.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12************** then your user ID is 12**************
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

5. Password details for shareholders other than Individual shareholders are given below:
   a) If you are already registered for e-Voting, then you can user your existing password to login and cast your vote.

   b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.

c) How to retrieve your 'initial password'?

(i) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.

(ii) If your email ID is not registered, please follow steps mentioned below in **process for those shareholders whose email ids are not registered.**

6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:
   a) Click on "**Forgot User Details/Password**?"(If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
   b) **Physical User Reset Password**?" (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
   c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.com mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
   d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.

7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.
8. Now, you will have to click on "Login" button.
9. After you click on the "Login" button, Home page of e-Voting will open.

Step 2: Cast your vote electronically and join General Meeting on NSDL e-Voting system.

How to cast your vote electronically and join General Meeting on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle and General Meeting is in active status.

2. Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on "VC/OAVM" link placed under "Join Meeting".

3. Now you are ready for e-Voting as the Voting page opens.

4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.

5. Upon confirmation, the message "Vote cast successfully" will be displayed.

6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.

7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for shareholders

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to csvishakhagrawal@gmail.com with a copy marked to evoting@nsdl.com. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "Upload Board Resolution / Authority Letter" displayed under "e-Voting" tab in their login.

2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.

3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on.: 022 - 4886 7000 or send a request to Shubham Manethiya at evoting@nsdl.com

Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to bmlpl2014@gmail.com.

2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to bmlpl2014@gmail.com . If you are an Individual shareholders holding securities in demat mode, you are requested to refer to the login method explained at **step 1 (A**) i.e. **Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode**.

3. Alternatively shareholder/members may send a request to evoting@nsdl.com for procuring user id and password for e-voting by providing above mentioned documents.

4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

THE INSTRUCTIONS FOR MEMBERS FOR e-VOTING ON THE DAY OF THE EGM/AGM ARE AS UNDER:-

1. The procedure for e-Voting on the day of the EGM/AGM is same as the instructions mentioned above for remote e-voting.
2. Only those Members/ shareholders, who will be present in the EGM/AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the EGM/AGM.
3. Members who have voted through Remote e-Voting will be eligible to attend the EGM/AGM. However, they will not be eligible to vote at the EGM/AGM.
4. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the EGM/AGM shall be the same person mentioned for Remote e-voting.

INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE EGM/AGM THROUGH VC/OAVM ARE AS UNDER:

1. Member will be provided with a facility to attend the EGM/AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for **Access to NSDL e-Voting system**. After successful login, you can see link of "VC/OAVM" placed under **"Join meeting"** menu against company name. You are requested to click on VC/OAVM link placed under Join Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.

2. Members are encouraged to join the Meeting through Laptops for better experience.

3. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.

4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.Shareholders who would like to express their views/have questions may send their questions in advance mentioning their name demat account number/folio number, email id, mobile number at bmlpl2014@gmail.com. The same will be replied by the company suitably.

5. Shareholders who would like to express their views/ask questions during the meeting may register themselves as a speaker by sending their request in advance atleast **2 days prior to**

meeting mentioning their name, demat account number/folio number, email id, mobile number at (company email id). The shareholders who do not wish to speak during the AGM but have queries may send their queries in advance **2 days prior to meeting** mentioning their name, demat account number/folio number, email id, mobile number at (company email id). These queries will be replied to by the company suitably by email.

6. Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.

ANNEXURE –I
TO ITEM NO.2

Relevant details, in terms of Regulation 36(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standards-2 of General Meetings in respect of Director proposed for appointment/reappointment at 11th Annual General Meeting are as follows:

Name of the Director	Mr. Mukesh Mehta
DIN	03187420
Nationality	Indian
Date of first appointment on the Board	August 14, 2015
Qualifications	Graduation
Expertise in specific Functional Areas	Mr. Mukesh Mehta (DIN: 03187420) has experience in the field of Accounts and Finance and has experience in the field of Management.
Terms and Conditions of Re-appointment	Whole Time Director Liable to retire by rotation.
Number of shares held in the Company as at 31.03.2026	44,44,816
List of Directorships held in other companies	NIL
Relationship between Directors and KMP of the Company	Mukesh Mehta is a related party to Director Mr. Pradeep Mehta

EXPLANATORY STATEMENT

[Pursuant to Section 102(1) of the Companies Act, 2013 & Regulation 36(3) of SEBI (LODR) Regulations, 2015]

Statement with respect to items under Special Business covered in the Notice of Meeting are given below:

ITEM NO: 3

Pursuant to provisions of Section 204 of the Companies Act, 2013, and relevant rules thereunder, read with Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations, 2015”), every listed company is required to annex with its Board’s Report, a secretarial audit report, issued by a Practicing Company Secretary. Further SEBI vide its notification dated December 12, 2024, amended the SEBI Listing Regulations, 2015. The amended regulations require companies to obtain shareholders’ approval for appointment of Secretarial Auditors, in addition to approval by the Board of Directors. Further, such Secretarial Auditor must be a peer reviewed company secretary and should not have incurred any of the disqualifications as specified by SEBI. In light of the aforesaid, the Board of Directors of the Company, pursuant to the recommendations of the Audit Committee, has recommended appointment of M/s Vishakha Agrawal & Associates, a firm of Practicing Company Secretaries, Indore, as the Secretarial Auditors of the Company for a term of five consecutive financial years for the FY 2025-26 to FY 2030-31. The Board of Directors in consultation with the Audit Committee may alter or vary the terms and conditions of appointment, including remuneration, in such manner and to such extent as may be mutually agreed with the Secretarial Auditors.

A brief profile of Mrs. Vishakha Agrawal, including her qualification, experience and expertise, is provided as Annexure-II of this Notice.

None of the Directors and Key Managerial Personnel of the Company and their relatives, are concerned or interested, financially or otherwise, in this resolution. The Board recommends the Ordinary Resolution set out at item number 3 of the notice for approval by the members.

ITEM NO: 4

In terms of the Foreign Exchange Management Act, 1999, as amended, the Foreign Exchange Management (Non-debt Instruments) Rules, 2019 (the “FEMA Rules”), the Master Direction – Foreign Investment in India issued by RBI through Master Direction No. 11/2017-18 and the Consolidated Policy Circular of 2017, as amended (together with the FEMA Rules, the “FEMA Laws”), the foreign portfolio investors registered with the Securities and Exchange Board of India (“SEBI”) can acquire and hold up to an aggregate limit of 24% of the paid up equity share capital of a listed Indian company. Further, in terms of the FEMA Rules, the FPI limit will automatically increase to the applicable sectoral limit with effect from April 1, 2020, which can be decreased to a lower limit, as prescribed under the FEMA Rules, by a special resolution to that effect by the shareholders prior to March 31, 2020. Considering the proposal of intending to get the shares of the Company listed, the board of directors of the Company (“Board”) has, at its meeting held on August 13, 2025 (“Board Resolution”), proposed, subject to the approval of the shareholders by way of a special resolution, to increase the foreign investment limit to 49% of the paid up equity share capital of the Company.

None of the directors or the key managerial personnel, of the Company or the relatives of the aforementioned persons are interested in the said resolution.

The Board recommends the resolutions set out at Item No. 6 of the accompanying Notice for your approval as a **Special Resolution.**

ANNEXURE- II

Sr. No.	Disclosure Requirement	Details
1	**Reason for change viz. appointment, ~~reappointment~~, ~~resignation~~, ~~removal~~, ~~death~~ or ~~otherwise~~**	M/s. Vishakha Agarwal & Associates Practicing Company Secretaries, Indore as the Secretarial Auditors of the Company.
2	**Date of appointment & term of appointment**	Appointment in the Board Meeting held on 02nd September, 2026, for a period of five consecutive years from FY 2025-26 to FY 2030-31, subject to the approval of shareholders of the Company at the ensuing Annual General Meeting.
3	**Brief Profile (In case of appointment)**	M/s. Vishakha Agrawal & Associates, Practicing Company Secretaries is established by Vishakha Agrawal, a Practicing Company Secretary having vast experience in providing services in Company Law, Securities Laws, Secretarial Audit etc. along with other specializations.
4	**Disclosure of Relationship between Directors {in case of appointment of Director)**	Not Applicable

By the order of the Board of Directors
For Bio Medica Laboratories Limited

	Sd/-	**Sd/-**
Place: Indore	**Pradeep Mehta**	**Mukesh Mehta**
Date: 02nd September, 2026	**Managing Director**	**Whole Time Director**

DIRECTORS' REPORT

To,
The Members,
Bio Medica Laboratories Limited,
(Formerly Known as Bio Medica Laboratories Private Limited)

Our Directors have pleasure in presenting the Eleventh 11^{th} Annual Report on the business and operations of your Company together with the audited accounts for the financial year ended 31^{st} March 2026.

1. **Financial Summary/ Performance of the Company:** **(Rs. In Lakhs)**

PARTICULARS	**STANDALONE**		**CONSOLIDATED**	
	For the financial year ended March 31, 2026	**For the financial year ended March 31, 2025**	**For the financial year ended March 31, 2026**	**For the financial year ended March 31, 2025**
Revenue from Operation	3829.66	3831.97	4308.99	3831.97
Other Income	13.39	0.53	2.32	0.53
Total Revenue	**3843.04**	**3832.50**	4311.31	3832.50
Total Expenses excluding Finance Cost	**2083.82**	**2398.73**	**2460.28**	**2398.73**
Finance Cost	189.81	119.51	225.62	119.51
Total Expenses	**2273.63**	**2518.24**	**2685.90**	**2518.24**
Profit before exceptional and extraordinary items and tax	**1569.41**	**1314.27**	**1625.41**	**1314.27**
Exceptional Item	-	-	-	-
Profit before Tax	**1569.41**	**1314.27**	**1625.41**	**1314.27**
Less: Current Tax	417.18	(343.52)	423.33	(343.52)
Less: Deferred Tax	(10.61)	9.17	17.45	(9.17)
Less: Short/ Excess of previous year Income Tax	(4.11)	(9.51)	(4.11)	(9.51)
Profit after Tax	**1166.95**	**970.41**	**1188.74**	**970.41**
Less: Minority Interest – Share of Profit/Loss	0	0	(10.68)	0
Profit/ Loss for the Year	1166.95	970.41	1178.06	970.41
Earning Per Share(EPS)				
Basic	12.71	10.57	12.95	10.57
Diluted	12.71	10.57	12.95	10.57

2. WORKING PERFORMANCE REVIEW:

Standalone:

During the year under review, the Company has earned revenue from operation of **Rs. 3829.66 Lacs** as against the previous year's revenue from operation of **Rs. 3831.97 Lacs**. The Company incurred Net Profit amounting **Rs. 1166.95 Lacs** as against Net Profit of **Rs. 970.41 Lacs** in the previous year.

Consolidated:

During the year under review, the Company has earned consolidated revenue from operation of **Rs. 4308.99 Lacs** as against the previous year's revenue from operation of **Rs. 3831.97 Lacs.** The Company incurred consolidated Net Profit amounting **Rs. 1188.74 Lacs** as against Net Profit of **Rs. 970.41 Lacs** in the previous year.

3. LISTING OF SECURITIES:

The Equity Shares of the Company were listed on the **SME Platform of NSE Limited w.e.f. May 29, 2026.**

4. TRANSFER TO RESERVE:

During the year the company has not proposed to transfer any amount to the General Reserve.

5. SHARE CAPITAL

The issued, subscribed, paid up equity capital as on March 31, 2026 was Rs. 9,18,00,010. The Authorized Capital of Company is Rs. 16,00,00,000 as on 31st March, 2026. Further, the company has not issued shares with differential voting rights nor granted stock options nor sweat equity.

Initial Public Offer:

The Company made an Initial Public Offer (IPO) of **37,72,000 Equity Shares** having a face value of ₹10 each at an issue price of ₹139 per Equity Share (including a share premium of ₹129 per Equity Share). The IPO comprised an Offer for Sale (OFS) of **3,77,000 Equity Shares** by the Promoters and a Fresh Issue of **33,95,000 Equity Shares** by the Company.

The Board of Directors, at its meeting held on August 8, 2025, approved the Draft Red Herring Prospectus (DRHP). Subsequently, the Board approved the proposal to undertake the IPO on April 25, 2026, which was thereafter approved by the Members of the Company at the Extraordinary General Meeting held on April 30, 2026.

Further, the Board approved the Red Herring Prospectus (RHP) on May 13, 2026, and the Prospectus on May 26, 2026, for filing with the Registrar of Companies and other regulatory authorities in connection with the IPO. The Company also received the listing approval from NSE

Emerge on **May 27th, 2026**, pursuant to which the Equity Shares of the Company were listed on the NSE Emerge SME Platform dated **May 29th 2026** with paid-up share capital of **₹12,57,50,010**.

6. **DIVIDEND:**

Your directors have considered it financially prudent in the long-term interest of the Company to reinvest the profits in the business of the Company to build a strong reserve base and grow the business of the Company. No final dividend has therefore been recommended for the year ended March 31, 2026.

7. **CORPORATE GOVERNANCE AND MANAGEMENT DISCUSSION & ANALYSIS REPORTS:**

The Corporate Governance and Management Discussion & Analysis Report, which form an integral part of this Report, are set out as separate "Annexure-III", together with the Certificate from the auditors of the Company regarding compliance with the requirements of Corporate Governance as stipulated in SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

8. **MATERIAL CHANGES AND COMMITMENTS AFFECTING THE FINANCIAL POSITION OF THE COMPANY**

Following are the material changes and commitments affecting the financial position of the Company occurred between the end of the financial year and the date of this report:

1. On 23rd July 2026, the Company has taken the approval of shareholders vide postal ballot remote E-voting to add new sub-clause 3(ii) thereby altering existing object clause of the Memorandum of Association of the Company to enable it to diversify its business by entering into entirely new business line of dealing in essential oils, aromatic oils, herbal extracts, fragrances, perfumery compounds and allied botanical products.

2. During the year, the Board of Directors, at its meeting held on **27th July 2026**, approved the proposal for the sale/disinvestment of the Company's entire investment of 5,100 equity shares (51% stake) in **Vitamax Healthcare Private Limited**, subject to the approval of the Members and other applicable statutory, regulatory and contractual approvals. Upon completion of the transaction, Vitamax Healthcare Private Limited shall cease to be a subsidiary of the Company. On **27th August 2026**, the Company has taken the approval of shareholders vide postal ballot remote e-voting.

9. **PERFORMANCE AND FINANCIAL POSITION OF ASSOCIATE COMPANIES**

As per Companies Act, 2013 and as on 31st March, 2026, the Company has one Subsidiary Company Vitamax Healthcare Private Limited (CIN: U24230MP2008PTC020939). During the year, Vitamax Healthcare Private Limited has earned a revenue of 624.71/- Lakhs with a net loss of 26.99 Lakhs. Further the Company has no Associate Company u/s 2(6) during the year under review.

10. INDIAN ACCOUNTING STANDARDS (IND AS):-

The Ministry of Corporate Affairs (MCA) vide its notification in the Official Gazette dated February 16, 2015, notified the Indian Accounting Standard (Ind AS) and Ind AS has replaced the existing Indian GAAP prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014. The Company has adopted Indian Accounting Standards ("Ind AS") from April 01, 2017 (transition date to Ind AS is April 01, 2016) and the financial Statements have been prepared in accordance with recognition and measurement principal of Indian Accounting Standards ("Ind AS") as prescribed under the Companies (Indian Accounting Standards) Rules, 2015, as specified in section 133 of the Companies Act, 2013.

The Annual Accounts for the year ended 31st March, 2026 have also been prepared in accordance with Indian Accounting Standard (Ind AS).

11. ANNUAL RETURN

The Extract of Annual Return as required under section 92(3) of the Companies Act, 2013 in Form MGT-9 is available on website of the Company i.e. www.biomedica.co.in.

12. DIRECTORS' RESPONSIBILITY STATEMENT :

Pursuant to Section 134 (5) of the Companies Act, 2013, the Board of Directors, to the best of their knowledge and ability, confirm that:
In the preparation of the annual accounts for the year ended March 31, 2026, the applicable accounting standards read with requirements set out under Schedule III to the Act, have been followed and there are no material departures from the same;

a) The Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at March 31, 2026 and of the profit of the Company for the year ended on that date.

b) The Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

c) The Directors have prepared the annual accounts on a going concern basis;

d) The Directors have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and are operating effectively; and

e) The Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

13. INTERNAL FINANCIAL CONTROLS AND THEIR ADEQUACY / INTERNAL FINANCIAL CONTROLS:

The directors has laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of financial statements.

The Company has an Internal Control System, commensurate with the size, scale and complexity of its operations. The scope and authority of the Internal Auditor is defined in the Internal Audit Manual. To maintain its objectivity and independence, the Internal Auditor reports to the Chairman of the Audit Committee of the Board. The Internal Auditor monitors and evaluates the efficacy and adequacy of internal control system in the Company, its compliance with operating systems, accounting procedures and policies at all locations of the Company. Based on the report of Internal Auditor, process owners undertake corrective action in their respective areas and thereby strengthen the controls. Significant audit observations and recommendations along with corrective actions thereon are presented to the Audit Committee of the Board.

14. CORPORATE SOCIAL RESPONSIBILITY INITIATIVES:

The Net profit of the company being in excess of Rs. 5 Crores in the preceding financial years, the provisions relating to Corporate Social Responsibility as contained in section 135 of the Companies Act, 2013 and rules made thereunder, are applicable to the Company, and your board wants to inform that your company is committed to develop the society at its best in the world.

The brief outline of the Corporate Social Responsibility (CSR) Policy of the Company and the initiatives undertaken by the Company on CSR activities during the year are set out in "Annexure-I" of this report.

15. DIRECTORS AND KEY MANAGERIAL PERSON

During the Year under review, the following changes have taken place in the Directors & KMPs of the Company. In compliance with the provisions of Section 149, 152 read with Schedule IV and all other applicable provisions of the Companies Act, 2013 and Companies (Appointment and Qualification of Directors) Rules, 2014 (including any Statutory modification(s) or re-enactment thereof for the time being in force) and Regulation 17 of SEBI (LODR) Regulation 2015, the composition of Board of Director and Key Managerial Personnel are as follows:

S. No.	Key Managerial Person Name	DIN/ PAN	Designation	Date of Appointment	Date of Cessation
1.	Pradeep Mehta	07254802	Managing Director	14.08.2015	-
2.	Mukesh Mehta	03187420	Whole-time Director	14.08.2015	-
3.	Saurabh Mahajan	10771559	Non-Executive Director	07.09.2024	-

4.	Divya Khandelwal	08444385	Independent Director	28.10.2024	-
5.	Sumeet Bansal	10822898	Independent Director	28.10.2024	-
6.	Santosh Kale	-	Chief Financial Officer	28.10.2024	-
7.	Khushi Gupta	-	Company Secretary	14.08.2026	-
8.	Pratiksha Bhandari	-	Company Secretary	03.04.2026	13.08.2026
9.	Rahul Kumar	-	Company Secretary	22.07.2026	01.04.2026

16. NATURE OF BUSINESS OF THE COMPANY

The Company, is engaged in the business of manufacturing, marketing, trading, import and export of pharmaceutical products, medicines, bulk drugs, chemicals and allied healthcare products including antibiotic, Ayurvedic, Allopathic and Homeopathic products, and also operates hospitals, clinics, diagnostic centres, laboratories and other healthcare facilities, including medical research and related healthcare services.

The company has altered the main object clause of the Memorandum of association of the Company Company to enable it to diversify its business by entering into entirely new business line of dealing in essential oils, aromatic oils, herbal extracts, fragrances, perfumery compounds and allied botanical products vide Postal ballot dated 23rd July 2026.

The management is committed to strengthening the Company’s operational efficiency, expanding its business activities, and ensuring sustainable growth while maintaining regulatory compliance and safeguarding stakeholders’ interests.

17. DECLARATION BY INDEPENDENT DIRECTORS:

Your Company has received declarations from all the Independent Directors confirming that they meet the criteria of independence as prescribed under the provisions of the Companies Act, 2013 read with the Schedules and Rules issued there under as well as Regulation 16(1)(b) of Listing Regulations (including any statutory modification(s) or re-enactment(s) for the time being in force).

18. MEETINGS OF THE BOARD OF DIRECTORS:

The following Meetings of the Board of Directors were held during the Financial Year 2025-26:

S. No.	Date of Meeting	Board Strength	No. of Directors Present	% of Attendance
1.	10/06/2025	5	5	100%
2.	09/07/2025	5	5	100%
3.	21/07/2025	5	5	100%
4.	04/08/2025	5	5	100%
5.	05/08/2025	5	5	100%
6.	08/08/2025	5	5	100%

7.	01/09/2025	5	5	100%
8.	19/09/2025	5	5	100%
9.	25/09/2025	5	5	100%
10.	06/10/2025	5	5	100%
11.	27/10/2025	5	5	100%
12.	01/12/2025	5	5	100%
13.	05/12/2025	5	5	100%
14.	24/12/2025	5	5	100%
15.	26/12/2025	5	5	100%
16.	27/12/2025	5	5	100%
17.	15/01/2026	5	5	100%
18.	06/02/2026	5	5	100%

19. FORMAL ANNUAL EVALUATION:

Pursuant to the provisions of the Companies Act, 2013 and other applicable legal provisions, if any, annual performance evaluation of Board was carried out by Independent Directors in their separate meeting. Further, evaluation of the committees was carried out by the Board. The performance evaluation of all the Directors was carried out individually by the Nomination and Remuneration Committee and in addition to it, performance evaluation of executive directors was also carried out by the Independent Directors at their separate meeting.

20. BOARD EVALUATION

Pursuant to the provisions of the Companies Act, 2013 read with the rules issued there under, Regulation 17(10) of the Listing Regulations and the circular issued by SEBI dated 5th January, 2017 with respect to Guidance Note on Board Evaluation, the evaluation of the annual performance of the Directors/Board/Committees was carried out for the financial year 2025-26.

The board of directors has carried out an annual evaluation of its own performance, Board committees and individual directors pursuant to the provisions of the Act and the corporate governance requirements as prescribed by Securities and Exchange Board of India ("SEBI") under SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015. The performance of the Board was evaluated by the Board after seeking inputs from all the directors on the basis of the criteria such as the Board composition and structure, effectiveness of board processes, information and functioning, etc.

The performance of the committees was evaluated by the board after seeking inputs from the committee members on the basis of the criteria such as the composition of committees, effectiveness of committee meetings, etc. The Board and the Nomination and Remuneration Committee ("NRC") reviewed the performance of the individual directors on the basis of the criteria such as the contribution of the individual director to the Board and committee meetings. In addition, the Chairman was also evaluated on the key aspects of his role.

In a separate meeting of Independent Directors, performance of Non-Independent directors, performance of the board as a whole and performance of the Chairman was evaluated, taking into account the views of executive directors and non-executive directors. The same was discussed in the board meeting that followed the meeting of the Independent Directors, at which the performance of the Board, its committees and individual directors was also discussed.

21. FAMILIARIZATION PROGRAMME FOR INDEPENDENT DIRECTORS

The Directors will be introduced to all the Board members and the senior management personnel such as Chief Financial Officer, Company Secretary and various Department heads individually to know their roles in the organization and to understand the information which they may seek from them while performing their duties as a director and meeting may be arranged for the Independent Directors with aforesaid officials to better understand the business and operation of the Company.

As a part of continuous updating and familiarization with the Company, every Independent Director will be taken for visits to the factory or manufacturing units and other branch of the company where the officials of the various departments apprise them of the operational and sustainability aspects of the plants to enable them to have full understanding on the activities of the Company and initiatives taken on safety, quality etc. The Company may also circulate news and articles related to the industry from time to time and may provide specific regulatory updates.

22. AUDITOR:

M/s. Vijay K. Jain & Associates, Chartered Accountants (FRN: 006719C) were appointed as Statutory Auditors of the company in the AGM held on 30.09.2025 to hold office for a period of 5 years till the conclusion of 15th Annual General Meeting of the Company to be in the calendar year 2030 .

Further, the Company has received a written Certificate of eligibility cum Consent letter to the effect that their re-appointment, is in accordance with the conditions prescribed in section 139 and 141 of the Companies Act 2013 and rules made thereunder. Members are requested to consider their re-appointment.

AUDITOR'S REPORT:

The Board has appointed, M/s.Vijay K. Jain & Associates to conduct the Statutory Audit for the year 2025-26. There are no qualifications or adverse remarks in the Auditors' Report which require any clarification/explanation. The Notes on financial statements are self-explanatory, and needs no further explanation. Further the Auditors' Report for the financial year ended 31st March, 2026 is annexed herewith for your kind perusal and information.

23. SECRETARIAL AUDITOR'S REPORT:

In terms of Section 204(1) of Companies Act, 2013, read with Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Company has appointed M/s Vishakha Agrawal & Associates, Practising Company Secretaries, Indore as the Secretarial auditor of the

Company for the financial year ending 31st March, 2026.

The Secretarial Audit Report submitted by Mrs. Vishakha Agrawal of M/s Vishakha Agrawal & Associates, Practising Company Secretaries in prescribed format in MR-3 to the shareholders of the Company is annexed to this Report as **"Annexure-A".**

24. BUSINESS RISK MANAGEMENT:

The Management has implemented business risk management policy. At present the company has not identified any element of risk which may threaten the existence of the company. The Company has Risk Management Policy to report genuine concerns or grievances of directors and employees and to deal with instance of fraud and mismanagement, if any.

25. CONSERVATION OF ENERGY:

Company ensures that the operations of the company are conducted in the manner whereby optimum utilization and maximum possible savings of energy is achieved.

No specific investment has been made in reduction in energy consumption equipment.

As the impact of measures taken for conservation and optimum utilization of energy are not quantitative, its impact on cost cannot be stated accurately.

No steps have been taken for by the company for utilizing alternate sources of energy.

The Information relating to conservation of energy, technology absorption, foreign exchange earnings and outgo under Section 134(3) (m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 is enclosed as "Annexure-II" and forms part to this report.

26. TECHNOLOGY ABSORPTION:

Company's operations are conducted by using in-house know how and no outside technology is being used for operating activities. Therefore, there is no outside technology absorption in the company. The Company has not incurred expenditure on research and development activities during the year.

27. FOREIGN EXCHANGE EARNINGS AND OUTGO:

The Information relating to conservation of energy, technology absorption, foreign exchange earnings and outgo under Section 134(3) (m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 is enclosed as "Annexure-II" and forms part to this report.

28. PARTICULARS OF EMPLOYEES:

Section 197 of companies act, 2013 read with rule 5 (2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 in respect of employees of the Company, are not applicable to company as no employee of company is in receipt of remuneration exceeding the limit as mentioned in relevant provision.

29. BOARD COMMITTEE:

Pursuant to Section 178 of the Companies Act, 2013, Company had constituted the following Board Committees:

1. Audit Committee;
2. Nomination and Remuneration Committee; and
3. Stakeholders Relationship Committee;

The composition of all Committees has been stated under Corporate Governance Report forming an integral part of Annual Report.

30. PARTICULARS OF LOANS, GUARANTEES OR/AND INVESTMENTS:

Particulars of loans given, investments made, guarantees given and securities provided along with the purpose for which the loan or guarantee or security is proposed to be utilized by the recipient are provided in the Financial Statement.

31. DISCLOSURE REQUIREMENTS:

- As per the Provisions of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 entered into with the stock exchanges, corporate governance report with auditors' certificate there on and management discussion and analysis are attached, which form part of this report.
- Details of the familiarization program of the independent directors are available on the website of the Company https://biomedica.co.in/ .
- The Company has formulated and published a Whistle Blower Policy to provide Vigil Mechanism for employees including directors of the Company to report genuine concerns. The provisions of this policy are in line with the provisions of the Section 177(9) of the Act. The whistle blowing Policy is available on the company's website at https://biomedica.co.in/ .

32. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, AND REDRESSAL) ACT, 2013

Our Company is committed to provide the healthy environment to all its employees, the company has in place a Prevention of the Sexual Harassment Policy and an Internal complaints redressal mechanism as per the requirements of Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

There was no complaint received from any employee during the financial year 2025-26, hence no complaints are outstanding as on 31.03.2026.

33. RELATED PARTY TRANSACTIONS:

The transaction with related parties (related to business) falls under the scope of Section 188(1) of the Companies Act 2013, Information on transactions with related parties pursuant to section 134

(3) (h) of the Act read with rule 8(2) of Companies (Accounts) Rules, 2014 are given in **"Annexure III" in Form AOC-2** and same forms part of this report.

34. FIXED DEPOSITS/ DEPOSITS:

During the year under review your Company has not accepted or invited any fixed deposits from the public and there were no outstanding fixed deposits from the public as on the Balance Sheet date.

Our Company has not accepted deposit from the public falling with in the ambit of Section 73 of the Companies Act, 2013 along with Companies (Acceptance of Deposits) rules, 2014.

35. DISCLOSURE UNDER SECTION *164 (2):*

None of the Directors of your Company are disqualified from being appointed as Directors as specified under Section 164(2) of the Companies Act, 2013.

36. SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS:

During the financial year 2025-26, there were no significant material orders passed by the Regulators or Courts or Tribunals which would impact the going concern status of your Company and its future operations.

37. AUDIT COMMITTEE:

The Audit Committee Comprises of Two (02) Non-Executive Independent Director and One (01) Executive Non-Independent Director:

- Mr. Sumeet Bansal
- Ms. Divya Khandelwal
- Mr. Pradeep Mehta

All recommendations made by the Audit Committee were accepted by the Board.

The Committee inter alia reviews Internal Control Systems and reports of Internal Auditors and compliance of various regulations. The Committee also reviews at length the Financial Statements before they are placed before the Board of Directors of the company.

38. STAKEHOLDERS RELATIONSHIP COMMITTEE:

Stakeholders' relations have been cordial during the year, as a part of compliance, your Company has Stakeholders Relationship Committee to consider and resolve the grievances of security holders of your Company. There were no grievances pending as on 31st March, 2026. A confirmation to this effect has been received from your Company's Registrar and Share Transfer Agent.

39. NOMINATION, REMUNERATION AND EVALUATION POLICY:

The Board has on recommendation of the Nomination and Remuneration Committee has framed a policy for selection and appointment of Directors, Senior Management and their remuneration and the evaluation. The Nomination and Remuneration Policy is forming part of Director's Report as **"Annexure 4".**

40. PARTICIPATION IN THE GREEN INITIATIVE:

Our Company continues to wholeheartedly participate in the Green Initiative undertaken by the Ministry of Corporate Affairs (MCA) for correspondences by Corporate to its Members through electronic mode. All the Members are requested to join the said program by sending their preferred e-mail addresses to their Depository Participant.

41. CODE OF FAIR DISCLOSURE OF UNPUBLISHED PRICE SENSITIVE INFORMATION AND CODE OF CONDUCT UNDER SEBI (PROHIBITION OF INSIDER TRADING) REGULATIONS, 2015

Pursuant to Regulation 8 of SEBI (Prohibition of Insider Trading) Regulations, 2015 the Board to Directors has formulated and adopted the "Code of Practices and Procedures for fair Disclosure of Unpublished Price Sensitive Information" (Code of Fair Disclosure) of the Company.

The Board has also formulated and adopted "Code of Conduct for Prohibition of Insider Trading" (Code of Conduct) of the company as prescribed under Regulation 9 of the said Regulation.

42. ACKNOWLEDGEMENTS:

The Board of Directors of your Company acknowledges their sincere appreciation for the support extended by the statutory authorities, the stock exchanges, advisors, shareholders and staff of the Company for the valuable assistance, support and co-operation extended to the Company and continuous support and faith reposed in the Company.

By the order of the Board of Directors
For Bio Medica Laboratories Limited

	Sd/-	**Sd/-**
Place: Indore	**Pradeep Mehta**	**Mukesh Mehta**
Date: 02nd September, 2026	**Managing Director**	**Whole Time Director**

[Annexure -I]

Annual Report on CSR Activities

1. **Brief outline on CSR Policy of the Company.**

   Our company being a socially responsible organization have secured its commitment towards community and have taken up challenges to stand alongside community. We continued with our endeavors to transform lives through structured CSR interventions and creating maximum value for all our stakeholders. We focus on our social and environmental responsibilities to fulfill the needs and expectations of the communities around us.

   Our CSR Policy aims to provide a dedicated approach to community development in the areas of improving healthcare infrastructure including preventive healthcare, supporting primary education, preserving Indian art and culture, removing malnutrition, rural development, and contribute to the sustainable development of society and environment sustainability, and to make our planet a better place for future generations.

2. **Composition of CSR Committee:**

   Pursuant to the provisions of Section 135(9) of the Companies Act, 2013 and rules made thereunder, where the amount to be spent by a company in CSR does not exceed fifty lakh rupees, the requirement to constitute CSR Committee shall not be applicable.

   The Board of Directors of the Company are committed to discharge the functions to be undertaken by a CSR Committee.

3. Provide the web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the board are disclosed on the website of the company https://biomedica.co.in/.

4. Provide the details of Impact assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social Responsibility Policy) Rules, 2014, if applicable (attach the report). N.A.

5. Details of the amount available for set off in pursuance of sub-rule (3) of rule 7 of the Companies (Corporate Social Responsibility Policy) Rules, 2014 and amount required for set off for the financial year, if any: **NIL**

Sl. No.	Financial Year	Amount available for set-off from preceding financial years (in Rs)	Amount required to be set-off for the financial year, if any (in Rs)

1	N.A.	N.A.	N.A.
	Total		

6. Average net profit of the company as per section 135(5) - **Rs. 5,83,01,158.33**

7. (a) Two percent of average net profit of the company as per section 135(5) - **Rs. 11.66,023.17**

(b) Surplus arising out of the CSR projects or programmes or activities of the previous financial years. NIL

(c) Amount required to be set off for the financial year, if any NIL

(d) Total CSR obligation for the financial year (7a+7b-7c). - **Rs. 11,66,023.17**

8. (a) CSR amount spent or unspent for the financial year:

Total Amount Spent for the Financial Year (in Rs.)	**Amount Unspent (in Rs.)**				
	Total Amount transferred to Unspent CSR Account as per section 135(6)		**Amount transferred to any fund specified under Schedule VII as per second proviso to section 135(5)**		
	Amount	**Date of transfer**	**Name of the Fund**	**Amount**	**Date of transfer**
11,70,000	**-**	**-**	**-**	**-**	**-**

(b) Details of CSR amount spent against ongoing projects for the financial year: **N.A.**

(1)	**(2)**	**(3)**	**(4)**		**(5)**	**(6)**	**(7)**	**(8)**	**(9)**	**(10)**	
Sl. No.	**Name of the Project**	**Item from the list of activities in Schedule VII to the Act**	**Location of the project.**		**Project duration**	**Amount allocated for the project (in Rs.)**	**Amount spent in the current financial Year (in Rs.)**	**Amount transferred to Unspent CSR Account for the project as per Section 135(6) (in Rs.)**	**Mode of Implementation – Direct (Yes/ No)**	**Mode of Implementation - Through Implementing Agency**	
			State	**District**						**Name**	**CSR Registration number**

	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
	Total										

(c) Details of CSR amount spent against **other than ongoing projects** for the financial year:

(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	
Sl. No.	**CSR Project of activity identified**	**Sector in which the project is covered**	**Project or Programs Local Area or other specify the state and district where the projects or programmes were undertaken**	**Amount spent for the project (in Rs.)**	**Date of Payment**	**Mode of implementation - Direct (Yes/No)**	**Mode of implementation - Through implementing agency**	
							Name	**CSR registration number**
1.	Promotion of Education	Vocational training for reaching to unreached rural development, community mobilization and Livelihood Promotion Activities	Gujarat	11,70,000/-	28/03/2026	Yes	Angel Charitable Trust	CSR00073876
	Total			11,70,000/-				

9. (a) Details of Unspent CSR amount for the preceding three financial years: **N.A.**

(b) Details of CSR amount spent in the financial year for ongoing projects of the preceding financial year(s): **N.A.**

10. In case of creation or acquisition of capital asset, furnish the details relating to the asset so created or acquired through CSR spent in the financial year **N.A.**

(asset-wise details).

(a) Date of creation or acquisition of the capital asset(s).

(b) Amount of CSR spent for creation or acquisition of capital asset.

(c) Details of the entity or public authority or beneficiary under whose name such capital asset is registered, their address etc.

(d) Provide details of the capital asset(s) created or acquired (including complete address and location of the capital asset).

11. Specify the reason(s), if the company has failed to spend two per cent of the average net profit as per section 135(5). **N.A.**

By the order of the Board of Directors
For Bio Medica Laboratories Limited

	Sd/-	**Sd/-**
Place: Indore	**Pradeep Mehta**	**Mukesh Mehta**
Date: 02nd September, 2026	**Managing Director**	**Whole Time Director**

Annexure- II

Information as per Section 134(3)(m) of the Companies Act, 2013 read with the Companies (Accounts) Rules, 2014 and forming part of the Directors' Report for the year ended March 31, 2026.

A.	**Conservation of Energy**		
	(i)	the steps taken or impact on conservation of energy	N.A
	(ii)	the steps taken by the company for utilising alternate sources of energy:	N.A
	(iii)	the capital investment on energy conservation equipments:	N.A
B.	**Technology absorption**		
	(i)	the efforts made towards technology absorption:	N.A
	(ii)	the benefit derived like product improvement, cost reduction, product development or import substitution:	N.A
	(iii)	in case of imported technology (imported during the last three years reckoned from the beginning of the financial year)	N.A
		a) the details of technology imported;	N.A
		b) the year of import;	N.A
		c) whether the technology been fully absorbed	N.A
		d) if not fully absorbed, area where absorption has not taken place, and the reasons thereof; and	N.A
		e) the expenditure incurred on Research and Development	N.A
		Note: Since your Company has not involved in manufactuirng operations, the requirements pertaining to disclosure of particulars relating to conservation of energy, research & development and technology absorption, as prescribed under the Companies (Accounts) Rules, 2014 are not applicable.	
C.	**Foreign Exchange Earning and outgo**		

	The company does not have any export sale, hence the respective point is not applicable.

Particulars	**Financial Year ended 31st March, 2026**	**Financial Year ended 31st March, 2025**
Foreign Exchange Earned	39.33 Lacs	Nil
Foreign Exchange used	$ 20617.17	$ 21100.63

By the order of the Board of Directors
For Bio Medica Laboratories Limited

	Sd/-	**Sd/-**
Place: Indore	**Pradeep Mehta**	**Mukesh Mehta**
Date: 02nd September, 2026	**Managing Director**	**Whole Time Director**

Annexure-III

FORM AOC-2

[Pursuant to clause (h) of sub section (3) of section 134 of the Act and Rule 8 (2) of the Companies (Accounts) Rules, 2014]

Form for disclosure of particulars of contracts/arrangements entered into by the Company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arm's length transactions under third proviso thereto.

1. **Details of contracts or arrangements or transactions not at Arm's length basis:**

S.No.	Name of the Related Party	Nature of Relation	Nature of Transaction	Value of transaction during the reporting period	Opening balance	Closing Balance
-	-	-	-	-	-	-
-	-	-	-	-	-	-

2. **Details of contracts or arrangements or transactions at Arm's length basis:**

S.No.	Name of the Related Party	Nature of Relation	Nature of Transaction	Value of transaction during the reporting period	Opening balance	Closing Balance
1.	Anju Mehta	Director's Wife	Salary	3,30,000	55,000	55,000
2.	Garima Mehta	Director's Wife	Salary	3,30,000	55,000	55,000
3.	Tara Mehta	Director's Mother	Salary	**398512.74**	**59500**	**20987.26**
4.	Lokesh Jain	Director's Father	Salary	**630000**	**99000**	**99000**
5.	Bio Medica Parenterals	Sister Concern	**Rent**	**62212**	**405716.20**	**403504.20**

6.	Vitamax Healthcare Private Limited	Sister Concern	**Loan**	**50149063**	**31557639**	**35387745**
7.	Vitamax Healthcare Private Limited	Sister Concern	**Sale / Purchase**	**3640594**	**864232**	**874151**

Note: The details of all related party transactions as per Indian Accounting Standard 24 have been disclosed in Notes to Accounts of Financial Statements.

Definition of the term 'Material Contracts or Arrangements or Transactions' is taken as per Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

By the order of the Board of Directors
For Bio Medica Laboratories Limited

	Sd/-	**Sd/-**
Place: Indore	**Pradeep Mehta**	**Mukesh Mehta**
Date: 02nd September, 2026	**Managing Director**	**Whole Time Director**

FORM NO. MR-3
SECRETARIAL AUDIT REPORT
[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule 9 of the Companies (Appointment and Remuneration of Personnel) Rules, 2014]

To,
The Members
Bio Medica Laboratories Limited
(Earlier known as Bio Medica Laboratories Private Limited)
CIN: U20293MP2015PLC034576
Plot No. 11B-11C, Sector-E, Sanwer Road
Industrial Area, Industrial Estate, Indore (M.P.) - 452015

FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2026

We have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by. While taking review after the completion of financial year, Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts / statutory compliances and expressing our opinion thereon.

Management's Responsibility
The Management of the Company is completely responsible for preparation and maintenance of Secretarial records and for developing proper systems to ensure compliance with the provisions of applicable laws, rules and regulations.

Auditor's Responsibility:
Our responsibility is to express an opinion on existence of adequate Board Process and Compliance Management System, commensurate to the size of the company, based on these secretarial records as shown to us during the said audit and also based on the information furnished to us by the officers and agents of the company during the said audit.

We have followed the audit practices and processes as were appropriate to the best of our understanding to obtain reasonable assurance about the correctness of the contents of the secretarial records. The verification was done on the test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed, provide a reasonable basis for our opinion.

Wherever required, we have obtained the management representation about the compliance of the laws, rules, regulations and happening of events, etc.

Our report is neither an assurance as to future viability of the Company nor of the efficacy or effectiveness or accuracy with which the management has conducted the affairs of the company.

Based on the information and/or details received on verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents, KMPs, Directors and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the Company has, during the audit period covering the financial year ended on 31st March, 2026 generally complied with the statutory provisions listed hereunder and also that the Company generally has proper Board-processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed (within / *beyond* the due date with the applicable additional fees) and other records maintained by the Company for the financial year ended on 31st March, 2026 according to the provisions of:

(i) The Companies Act, 2013 ("the Act") and the rules made thereunder;

(ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;

(iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;

(iv) Foreign Exchange Management Act,1999 and the Rules and Regulation made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings; **(Not applicable to the company during the audit period)**

(v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):

a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992 and Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.

c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009.

d) The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999 and The Securities And Exchange Board of India (Share Based Employees Benefits) Regulations 2014. **(Not applicable to the Company during Audit Period)**

e) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008. **(Not applicable to the Company during Audit Period)**

f) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client. **(Not applicable as the Company is not registered as a Registrar to an Issue or Share Transfer Agent)**.

g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009. **(Not applicable to the Company during the Audit Period)**

h) Securities and Exchange Board of India (Buy Back of Securities) Regulations, 2009. **(Not applicable to the Company during the Audit Period)**

As per the certificate received from the Managing Director, the company, has complied with all the laws and regulations governing the company's behavior as a Public Listed Company, has been following due processes enabling the Company to comply by all the legal requirements applicable to a Public Listed Company and has adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We have also examined compliance with the applicable clauses of the following:

i) Secretarial Standards issued by The Institute of Company Secretaries of India.
ii) Compliance of the applicable Clauses of the Listing Agreement entered into by the Company with the Bombay Stock Exchange Limited.

During the period under review the Company has generally complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc.

We further report that:

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. There were changes in the composition of the Board of Directors during the period under review.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

Majority decision is carried through and recorded in the minutes.

We further report that no audit has been conducted on compliance with finance and taxation laws as the same are subject to review and audit by Statutory Auditor and Internal Auditor to the Company and their observations, if any, shall hold for the purpose of the Audit Report.

We further report that there is scope to improve the systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

For Vishakha Agrawal & Associates
Practising Company Secretaries

CS Vishakha Agrawal
(Proprietor)
ACS: 39298 CP No. 15088
P.R. No. 2575/2022
UDIN: A039298H001355131

Place: Indore
Date: 03/09/2026

Note: This report is to be read with our letter of even date which is annexed as ‘ANNEXURE A’ and forms an integral part of this report.

ANNEXURE A

To,
The Members
Bio Medica Laboratories Limited
(Earlier known as Bio Medica Laboratories Private Limited)
CIN: U20293MP2015PLC034576
Plot No. 11B-11C, Sector-E, Sanwer Road
Industrial Area, Industrial Estate, Indore (M.P.) - 452015

Our report of even date is to be read along with this letter.

1. Maintenance of Secretarial record is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.

2. We have followed the audit practices and process as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices we followed provide a reasonable basis for our opinion.

3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company and have relied on the report of statutory auditors on direct and indirect taxes. Wherever required, we have obtained the management representation about the compliance of laws, rules and regulations and happening of events etc.

4. The compliance of the provisions of Corporate and other applicable laws, Rules, Regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.

5. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For Vishakha Agrawal & Associates
Practising Company Secretaries

CS Vishakha Agrawal
(Proprietor)
ACS: 39298 CP No. 15088
P.R. No. 2575/2022
UDIN: A039298H001355131

Place: Indore
Date: 03/09/2026

CORPORATE GOVERNANCE REPORT

(In compliance with Regulation 34(3) read with Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

1. CORPORATE GOVERNANCE: PHILOSOPHY

Corporate Governance is the creation and enhancement of long-term sustainable value for our stakeholders, comprising regulators, employees, customers, vendors, investors, and the society at large, through ethically driven business practices. Effective corporate governance practices constitute the strong foundation on which successful commercial enterprises are built to last. Strong leadership and effective corporate governance practices have been the Company' shall mark inherited from its culture and ethos. At Bio Medica Laboratories Limited, it is imperative that our Company's affairs are managed in a fair and transparent manner.

We ensure that we evolve and follow not just the stated corporate governance guidelines, but also the best practices. We consider it our inherent responsibility to protect the rights of our shareholders and disclose timely, adequate and accurate information regarding our financials and performance, as well as the leadership and governance of the Company.

The Company's philosophy of Corporate Governance aims to maximize long-term stakeholders value. It is a combination of many factors to achieve the objectives of transparency, full disclosure, a system of checks and balances between the Shareholders, Directors, Auditors and the Management. Integrity and transparency are key to our corporate governance practices and performance, and ensure that Company gain and retain the trust of our stakeholders at all times.

The Board is responsible for and committed to sound principles of Corporate Governance in the Company. The Board plays a crucial role in overseeing how the management serves the short and long-term interests of shareholders and other stakeholders. This belief is reflected in our governance practices, under which we strive to maintain an effective, informed and independent Board. We keep our governance practices under continuous review and benchmark ourselves to best practices across the globe.

The Company is a SME listed Company hence it is exempt from Regulations 17 to 27 read with Schedule V and clauses (b) to (i) and (t) of Regulation 46(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') as applicable, with regard to corporate governance.

The Company has been complying with the Corporate Governance requirements, as stipulated under Regulation 34(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with Stock Exchange.

2. CODE OF CONDUCT

The Company has a strong legacy of fair, transparent and ethical governance practices. The Company has adopted a Code of Conduct for its employees including the Managing Director and the Executive Directors. In addition, the Company has adopted a Code of Conduct for its Board Members, The Code of Conduct for regulating & Monitoring Trading by the Insiders and the Code of Practices and Procedures Fair Disclosure of Unpublished Price Sensitive Information, are available on the Company's website at https://biomedica.co.in/ .The company has received confirmation from the Senior Management Personnel regarding compliance of code of conduct during the period under the review.

3. BOARD OF DIRECTORS

Our Company is a professionally managed company functioning under the overall supervision of the Board. The Board has ultimate responsibility for the development of strategy, management, general affairs, direction, performance and long-term success of business as a whole. The Chairman leads the Board and is responsible for its overall effectiveness. The Chairman sets the Board Agenda, ensures the Directors receive accurate, timely and clear information, promotes and facilitates constructive relationships and effective contribution of all Executive and Non-Executive Directors, and promotes a culture of openness and debate. The Independent Directors provide constructive challenge, strategic guidance, and specialist advice and hold management to account. We believe that an active, well-informed and independent Board is necessary to ensure the highest standards of corporate governance.

The Board of Directors, along with its committees, provides leadership and guidance to the management and directs and supervises the performance of the Company, thereby enhancing stakeholders' value.

A. COMPOSITION OF BOARD:

The Board of your Company comprises highly experienced persons of repute, eminence and has a good and diverse mix of Executive and Non-Executive Directors with majority of the Board members comprising Independent Directors including Independent Women Directors. The Board composition is in conformity with the applicable provisions of Companies Act, 2013 (the Act) and Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) as amended from time to time.

The Board composition of your Company as on 31st March, 2026 comprises of Five (5) directors out of which Two (2) Independent Directors, One (1) Non-Executive Non Independent Directors, One (1) Executive Whole-Time Director and One (1) Executive Director designated as Managing Director.

The composition of the Board represents an optimal mix of professionalism, knowledge and experience and enables the Board to discharge its responsibilities and provide effective leadership to the business. The Board as part of its succession planning exercise periodically reviews its composition to ensure that the same is closely aligned with the strategy and long- term needs of the Company.

The number of Directorship(s), Committee Membership(s), and Chairmanship of all the Directors is within respective limits prescribed under the Act and Listing Regulations as amended from time to time. The Managing Director does not serve as an Independent Director in any Listed Company.

Further as mandated Regulation 26(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, none of the directors on the Board is a member of more than 10 (ten) committee or hold offices as a Chairman of more than 5 (five) Committees (Committee being Audit Committee and Stakeholder Relationship Committee as per Regulation 26 (1) (b) of SEBI (Listing Obligation and Disclosure Requirement Regulation, 2015) across all the public companies in which he/she is a Director. The necessary disclosures regarding the committee composition have been made to all the directors.

None of the Directors on the Board:

- holds directorships in more than ten public companies;
- serves as Director or as independent directors in more than seven listed entities; and
- who are the Executive Directors serve as independent directors in more than three listed entities.

The detailed composition and category of the Directors as on 31.03.2026 is as follows:

Name & DIN of the Director	DIN	Designation	Category
Mr. Pradeep Mehta	07254802	Managing Director	Promoter
Mr. Mukesh Mehta	03187420	Whole Time Director	Promoter
Ms. Surabhi Mahajan	10771559	Non- Executive Non-Independent Director	Professional
Ms. Divya Khandelwal	08444385	Independent Director	Independent
Mr. Sumeet Bansal	10822898	Independent Director	Independent

B. DETAILS OF ATTENDANCE OF DIRECTORS AT THE BOARD MEETING & LAST AGM

Sr. No	Name of the Directors	Category of Directorship	No. of Board Meetings Attended	Attendance at last AGM	Number of Directorships in Listed Companies including this listed company	Committee Membership and Chairmanship in other Public Ltd. Co. including this listed company	Shareholding in the Company (as at March 31, 2026)	No. of shares held (as at March 31, 2026)
1.	Mr. Pradeep Mehta	Managing Director	18	Yes	1	Membership-1 Chairmanship-1	48.42	44,44,725
2.	Mr. Mukesh Mehta	Whole Time Director	18	Yes	1	Membership-2 Chairmanship-0	48.42	44,44,816
3.	Ms. Surabhi Mahajan	Non-Executive Non-Independent Director	18	Yes	1	Membership-2 Chairmanship-0	NIL	NIL

4.	Ms. Divya Khandelwal	Independent Director	18	Yes	1	Membership-2 Chairmanship-1	NIL	NIL
5.	Mr. Sumeet Bansal	Independent Director	18	Yes	1	Membership-1 Chairmanship-2	NIL	NIL

C. BOARD MEETING

The Board meets at regular intervals to discuss and decide on Company/business policy and strategy and other matters. However, in case of business exigencies/ urgencies resolutions are passed through circulation or additional meetings are conducted.

During the financial year 2025-26, the members of the Board met 18 (Eighteen) times to review, discuss and decide about the business of the Company.

The dates on which the said meetings were held are as follows:

S. No.	Date of Meeting	Total No of Directors as on date of meeting	Attendance	
			No. of Directors attended	% of Attendance
1.	10/06/2025	5	5	100%
2.	09/07/2025	5	5	100%
3.	21/07/2025	5	5	100%
4.	04/08/2025	5	5	100%
5.	05/08/2025	5	5	100%
6.	08/08/2025	5	5	100%
7.	01/09/2025	5	5	100%
8.	19/09/2025	5	5	100%
9.	25/09/2025	5	5	100%
10.	06/10/2025	5	5	100%
11.	27/10/2025	5	5	100%
12.	01/12/2025	5	5	100%
13.	05/12/2025	5	5	100%
14.	24/12/2025	5	5	100%
15.	26/12/2025	5	5	100%
16.	27/12/2025	5	5	100%
17.	15/01/2026	5	5	100%
18.	06/02/2026	5	5	100%

The necessary quorum was present at all the Board Meetings. The maximum gap between any two Board meetings held during the year was not more than one hundred and twenty days.

D. APPOINTMENT AND TENURE

A Particulars and brief profile of Director retiring by rotation and also seeking re-appointment have been given in the notice for convening the Annual General Meeting.

The Directors of the Company are appointed/re- appointed by the Board on the recommendation of the Nomination and Remuneration Committee and approval of the Shareholders through means of Postal Ballot. In accordance with the Articles of Association of the Company and provisions of the Act, all the Directors, except the Managing Director and Independent Directors, of the Company, are liable to retire by rotation at the Annual General Meeting (AGM) each year and, if eligible, offer their candidature for re-appointment. The Board of Directors on the Board have been appointed as per the provisions of the Act and serve in accordance with the terms of employment with the Company.

Necessary disclosures regarding Committee positions in other public companies as on March 31, 2026 have been made by the Directors.

E. BOARD MEMBERSHIP CRITERIA AND LIST OF CORE SKILLS/ EXPERTISE/ COMPETENCIES IDENTIFIED IN THE CONTEXT OF THE BUSINESS:

The Board of Directors are collectively responsible for selection of a member on the Board. The Nomination and Remuneration Committee of the Company follows a defined criteria for identifying, screening, recruiting and recommending candidates for election as a Director on the Board. The criteria for appointment to the Board include:

- composition of the Board, which is commensurate with the size of the Company, its portfolio, geographical spread and its status as a Listed Company;
- desired age and diversity on the Board;
- size of the Board with optimal balance of skills and experience and balance of Executive and Non-Executive
- Directors consistent with the requirements of law;
- professional qualifications, expertise and experience in specific area of relevance to the Company;
- balance of skills and expertise in view of the objectives and activities of the Company;
- avoidance of any present or potential conflict of interest
- availability of time and other commitments for proper performance of duties;
- personal characteristics being in line with the Company’s values, such as integrity, responsibility, respect and pioneering mindset.

F. DISCLOSURE OF RELATIONSHIP OF DIRECTOR

None of the Directors of the Company has any pecuniary relationship with the Company. The Company has not issued any convertible instruments; hence, disclosure in this respect is not applicable. Except as disclosed below, none of the KMP of the Company are related to each other as per section 2(77) of the Companies Act, 2013:

1. Mr. Pradeep Mehta - Managing Director, Brother of Mr. Mukesh Mehta
2. Mr. Mukesh Mehta - Whole Time Director, Brother of Mr. Pradeep Mehta

G. INDEPENDENT DIRECTOR

All the Independent Directors are Non-Executive Directors as defined under Regulation 16(1)(b) of the SEBI Listing Regulations read with Section 149(6) of the Act along with rules framed thereunder. In terms of Regulation 25(8) of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with Section 149 of the Companies Act, 2013, the Independent Directors have confirmed that they are not aware of any circumstance or situation which exists or may be reasonably anticipated that could impair or impact their ability to discharge their duties. Based on the declarations received from the Independent Directors, the Board of Directors has confirmed that they meet the criteria of independence as mentioned under Regulation 16(1)(b) of the SEBI Listing Regulations and that they are independent of the management. The maximum tenure of the Independent Director is in compliance with the Act.

Further, the Independent Directors have included their names in the data bank of Independent Directors maintained with the Indian Institute of Corporate Affairs in terms of Section 150 of the Act read with Rule 6 of the Companies (Appointment and Qualification of Directors) Rules, 2014.

i. Terms and conditions of appointment of Independent Directors

The Company currently has 2 Non-Executive Independent Directors. All Independent Directors of the Company have been appointed as per the provisions of the Act and the SEBI Listing Regulations. Formal letters of appointment have been issued to Independent Directors. As required by Regulation 46 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, the terms and conditions of their appointment are disclosed on the Company's website at https://biomedica.co.in

In the opinion of the Board, the Independent Directors fulfill the conditions of independence specified in the Act and the SEBI Listing Regulations and are independent of the management.

ii. Separate Meeting of Independent Directors

In terms of Regulation 25 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Independent Directors of the Company shall meet once in a year to review the performance of Non-Independent Directors, the Board as a whole, review the performance of the Chairman of the Company and assessed the quality, quantity and timelines of flow of information between the Company Management and the Board.

The Independent Directors of the Company had met during the year on 06th February, 2026, without the presence of Non- Independent Director and members of management, to review the performance of Non-Independent Directors and the Board as whole, review the performance of the Chairman of the Company and has assessed the quality, quantity and timelines of flow of information between the Company Management and the Board.

The Independent Directors inter alia discuss the issues arising out of the Committee Meetings and Board discussion including the quality, quantity and timely flow of information between the Company Management and the Board that is necessary for the Board to effectively and reasonably perform its duties. In addition to these formal meetings, interactions outside the Board Meetings also take place between the Chairman and Independent Directors.

The Meeting was attended by all the Independent Director as on that date.

iii. Familiarization programmes for the Independent Director

Your Company has formulated Familiarization Programme for all the Independent Directors in accordance with Regulation 25 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Schedule IV of the Companies act, 2013 which provides that the Company shall familiarize the Independent Directors with the Company, their roles, rights, responsibilities in the Company, nature of industry in which the Company operates, business model of the Company etc. through various programs for the purpose of contributing significantly towards the growth of the Company.

They are given full opportunity to interact with senior Management personnel and are provided with all the documents required and/ or sought by them to have a good understanding of the Company, its business model and various operations and the industry of which it is a part.

H. INFORMATION PRESENTED AT MEETINGS

The Board business generally includes consideration of important corporate actions and events including:
a) Quarterly and annual result announcements;
b) Oversight of the performance of the business;
c) Board succession planning;
d) Review of the functioning of the Committees and
e) Other strategic, transactional and governance matters as required under the Companies Act, 2013, Listing Regulations and other applicable legislations.

I. INFORMATION SUPPLIED TO THE BOARD

The Board has complete access to all information with the Company; inter alia, the information as required under the SEBI (Listing Obligations and Disclosure Requirement) Regulation, 2015 is regularly provided to the Board as a part of the Board Meeting agenda well in advance of the Board meetings along with comprehensive background information on the items in the agenda to enable the Board to arrive at appropriate decisions. In addition, the Board is kept informed of all major events, including information listed under Part A of Schedule II to the SEBI Listing Regulations.

Based on the agenda, members of the senior leadership are invited to attend the Board Meetings, which brings in requisite accountability and provides developmental inputs.

J. COMPLIANCE REPORTS OF ALL APPLICABLE LAWS TO THE COMPANY

The periodical reports submitted by the Internal Auditors and by the concerned executives of the Company with regard to compliance of all laws applicable to the Company including steps taken by the Company to rectify instances of non-compliances, if any, are reviewed by the Board at regular intervals.

K. EVALUATION OF PERFORMANCE OF THE BOARD, ITS COMMITTEES AND INDIVIDUAL DIRECTORS

As required under Section 134 (3) (p) of the Companies Act, 2013, and regulation 17 (10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors has carried out an annual evaluation of its own performance and that of its Committees and individual Directors.

Evaluation of the Board and its Committees is based on various aspects of their functioning, such as adequacy of the constitution and composition of the Board and its Committees, matters addressed in the meetings, processes followed at the meeting, Board's focus, regulatory compliances and Corporate Governance, etc., are in place. Similarly, for evaluation of individual Director's performance, various parameters like Director‘s profile, contribution in Board and Committee meetings, execution and performance of specific duties, obligations, regulatory compliances and governance, etc., are considered.

Further, the performance of the Board, its Committees and individual directors was evaluated by the board after seeking inputs from all Directors. The performance of the committees was evaluated by the Board after seeking inputs from the committee members.

As required under Regulation 17(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Board assessed the performance of the Independent Directors, individually and collectively as per the criteria laid down and on an overall assessment, the performance of independent directors was found noteworthy. The Board has therefore recommended the continuances of the Independent Directors on the Board of the Company. The Board has evaluated the performance of the independent directors on the parameters such as Qualification, knowledge, experience, initiate, attendance, concerns for the stakeholders, leadership, team work attributes, effective interaction, willing to speak up, high governance standard, integrity, relationship with management, Independent views and judgement. Further, the Board and each of the Directors had evaluated the performance of each individual director on the basis of above criterion.

The Board of Directors assessed the performance of the Board as whole and committees of the Company based on the parameters which amongst other included structure of the Board, including qualification, expectance and competency of the Directors, diversity of the Board and process of appointment; Meeting of the Board, including regularity and frequency, agenda, discussion and dissent, recording of the minutes, functions of the Board, including strategy and performance valuation, corporate culture and value, evaluation of risks, succession plan, focus on the shareholders' value creation, effectiveness of Board process, governance and compliance and meaning full communication, high governance standard, knowledge of business, openness discussion/integrity and information and functioning and quality of relationship between the Board and management.

The nomination and remuneration Committee & Audit Committee has also reviewed and considered the collective feedback of the whole of evaluation process. The Directors were satisfied with the evaluation results which reflected the overall management and effectiveness of the Board and its Committees.

4. COMMITTEES OF THE BOARD

The Board Committees play a crucial role in the Governance Structure of the Company and have been constituted to deal with specific areas/activities as mandated by applicable regulations, which concern the Company and need a closer review. The Board Committees are set up under the formal approval of the Board to carry out clearly defined roles which are considered to be performed by Members of the Board, as part of good governance practices. The Chairperson of the respective Committee informs the Board about the summary of the discussions held in the Committee Meetings. The minutes of the Meeting of all Committees are placed before the Board for review. The Board Committees can request special invitees to join the Meeting, as appropriate.

As on 31st March, 2026, the Board has constituted the following Committees:



The Board Committees play a crucial role in the governance structure of the Company and have been constituted to deal with specific areas of concern for the company.

The Board is responsible for constituting, assigning, co-opting, and fixing the terms of reference of various committees. Details on the role and composition of these committees, including the number of meetings held during the financial year and the related attendance are provided below.

- **Audit Committee**

The Audit Committee of the Company is constituted in line with the provisions of Regulation 18 of the SEBI (Listing Obligations and Disclosure Requirement) Regulation, 2015 entered into with the Stock Exchange(s) read with Section 177 of the Companies Act, 2013 ("Act").

a) Terms of Reference of Audit Committee

The Committee is governed by the terms of reference which are in line with the regulatory requirements mandated by the Act and Listing Regulations.

As a measure of good Corporate Governance and to provide assistance to the Board of Directors in fulfilling their responsibilities, the Audit Committee was constituted. Majority of the members of the Audit Committee are Independent Directors and have rich experience in the financial/legal sector.

The Audit Committee ensures that it has reviewed each area that it is required to review under its terms of reference and under applicable legislations or by way of good practice. This periodic review ensures that all areas within the scope of the Committee are reviewed.

The terms of reference of Audit Committee are as per Regulation 18 of SEBI (Listing Obligations and Disclosure Requirement) Regulation, 2015 executed with the Stock Exchange(s), read with Section 177 of the Companies Act, 2013 and includes such other functions as may be assigned to it by the Board from time to time. The composition of the Audit Committee also adheres to the provisions of Section 177 of the Companies Act, 2013.

Activities of the Committee during the year	**Frequency**
Overseeing the Company's financial reporting process and disclosure of financial information to ensure that the financial statements are correct, sufficient and credible	▲ \ ■
Reviewing and examining with Management the quarterly and annual financial results and the Limited Review/Auditor's Report thereon before submission to the Board for approval	▲ \ ■
Reviewing management discussion and analysis of financial condition and results of operations	▲
Recommending the appointment, remuneration and terms of appointment of Statutory Auditors of the Company and approval for payment of any other services	●
Reviewing and monitoring the Statutory Auditor's independence and performance and effectiveness of audit process	■
Reviewing, approving or subsequently modifying any Related Party Transactions in accordance with the Related Party Transaction Policy of the Company	▲
Reviewing the adequacy of internal audit function and the findings of any internal investigations by the internal auditors	▲
Reviewing management letters/letters of internal control weaknesses issued by the Statutory Auditors	▲
Evaluating internal financial controls and risk management systems	▲
Verifying that the systems for internal controls for compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015 are adequate and are operating effectively	▲
Reviewing the functioning of the Code of Business Principles and Vigil Mechanism	▲
Scrutiny of Inter-corporate loans and investments.	▲
Discussion with the Statutory Auditors, before the Audit commences, about the nature and scope of Audit as well as post audit discussions to ascertain any area(s) of concern.	■
Carrying out any other function as mentioned in terms of reference of the Audit Committee.	■

The main functions of the Audit Committee, inter-alia, include:

Role(s)/Terms of reference of Audit Committee are:

Annually=
Quarterly =
Periodically =

All the items listed in Section 177 of the Act and Regulation 18(3) read with Part C of Schedule II of the SEBI (Listing Obligation and Disclosure Requirements) Regulation are covered in terms of reference of the Audit Committee, directly or indirectly.

Further, pursuant to Regulation 18(2) (c) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, the Audit Committee is empowered to investigate any activity within its terms of reference, seek information it requires from any employee, obtain outside legal or other independent professional advice and secure attendance of outsiders with relevant expertise, if considered necessary.

Apart from the above, the Audit Committee also exercises the role and powers entrusted upon it by the Board of Directors from time to time.

b) Composition of Audit Committee

Name	**Category of Directorship**	**Designation in Audit Committee**	**No. of Meetings Attended**
Mr. Sumeet Bansal	Independent Director	Chairperson	4
Ms. Divya Khandelwal	Independent Director	Member	4
Mr. Pradeep Mehta	Managing Director	Member	4

c) **Meetings of Audit Committee**

During the financial year 2025-2026, 8 (Eight) meetings of Audit Committee were held:

Date	**Total Number of Directors in the Committee as on date of the meeting**	**Number of Directors Present (All directors including Independent director)**	**No. of Independent Directors attending the meeting***
10/06/2025	3	3	2
09/07/2025	3	3	2
14/07/2025	3	3	2
25/09/2025	3	3	2
24/12/2025	3	3	2
25/12/2025	3	3	2
27/12/2025	3	3	2
15/01/2026	3	3	2

- **Nomination & Remuneration Committee**

The Nomination and Remuneration Committee ("NRC") function in accordance with Section 178 of the Companies Act, 2013, read with rules framed thereunder and Regulation 19 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

The NRC is responsible for evaluating the balance skills, experience, independence, diversity and knowledge on the Board and for drawing up selection criteria, ongoing succession planning and for both internal and external appointment including Managing Director.

Further, the Committee is also responsible for formulating policies as to remuneration, performance evaluation, Board diversity, etc. in line with the Act and the SEBI Listing Regulations.

a. Key terms of reference of the committee are:

The roles and responsibilities of the Committee covers the area as specified in the Listing Regulations, Companies Act,2013 and other applicable laws, if any, besides other role and powers entrusted upon it by the Board of Directors from time to time. The roles and responsibilities of the Committee include the following:

Activities of the Committee during the year	Frequency
Determine/recommend the criteria for appointment of Directors, Members of Management Committee and Key Managerial Personnel	●
Identify candidates who are qualified to become Directors and who may be appointed as the member of the Committees, or as a Key Managerial Personnel	●
Evaluate the balance of skills, knowledge and experience on the Board and prepare a description of the role and capabilities required for Independent Director(s)	●
Review and determine all elements of remuneration package of all the Executive Directors, i.e. salary, benefits, bonuses, stock options, pension, etc.	●
Ensure succession planning (including the development of a diverse pipeline for succession) to the Board and the leadership development plans to enhance such succession planning	●
Recommend to the Board, all remunerations, in whatever form, payable to Senior Management	■
Review, appraise and approve such other matter(s) as the board may recommend to it	■

Periodically =●
Annually =■

b. Composition of Nomination & Remuneration Committee:

Name	Category of Directorship	Designation in Committee
Ms. Divya Khandelwal	Independent Director	Chairperson
Mr. Sumeet Bansal	Independent Director	Member
Ms. Surabhi Mahajan	Non- Executive Director	Member

2 meeting of the Committee were held during the year under the review and the same were attended by all the members of Committee.

Dates & number of meetings of Nomination and Remuneration Committee held during the year under member's attendance thereon:

Date	Total Number of Directors in the Committee as on date of the meeting	Number of Directors Present (All directors including Independent director)	No. of Independent Directors attending the meeting
21/07/2025	3	3	2
01/09/2025	3	3	2

c. Performance evaluation criteria for independent directors

The performance evaluation criteria for independent directors is determined by the Nomination and Remuneration Committee. An indicative list of factors on which evaluation was carried out includes participation and contribution by a director, commitment, effective deployment of knowledge and expertise, commitment to his/her role towards the company and various stakeholders, willingness to devote time and efforts towards his/her role, high ethical standards, adherence to applicable codes and policies, effective participation and application of objective independent judgment during meetings, integrity and maintenance of confidentiality and independence of behaviour and judgment. etc.

On the basis of performance evaluation of Independent Directors, it is determined whether to extend or continue their term of appointment, whenever their respective term expires.

d. Policy on Board Diversity

Pursuant to the provisions of the Companies Act, 2013 and under SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 the Nomination and Remuneration Committee (NRC) of the Company provides a framework for ensuring diversity of the Board members based on factors, such as gender, age, qualifications, professional experience, expertise, skills and ability to add value to the business.

The Policy shall confirm with the following two principles for achieving diversity on its Board:

(a) Decisions pertaining to recruitment, promotion and remuneration of the directors will be based on their performance and competence; an

(b) For embracing diversity and being inclusive, best practices to ensure fairness and equality shall be adopted and there shall be zero tolerance for unlawful discrimination and harassment of any sort whatsoever.

In order to ensure a balanced composition of executive, non-executive and independent directors on the Board, the Company shall consider candidates from a wide variety of background

- **Stakeholders' Relationship Committee**

In compliance with the provisions of Section 178 of the Companies Act, 2013 read with Regulation 20 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, the stakeholder Relationship Committee (SRC) looks into various aspects of interest of stakeholders.

The role of Stakeholders' Relationship Committee includes resolving the grievances of Shareholders, ensuring expeditious share transfer process in line with the proceedings of the Share Transfer Committee, evaluating performance and service standards of the Registrar and Share Transfer Agent (RTA) of the Company.

The Committee has periodic interactions with the representatives of the RTA of the Company. Over the last few years, SEBI, the capital market regulator has issued guidelines and undertaken a number of measures for raising industry standards for RTA to facilitate effective shareholder service. In order to ensure compliance with various guidelines and measures issued by SEBI to improve investor services, the Committee invites the representatives of the RTA to join the Committee Meeting for sharing an update on the steps and actions taken by them. The Committee also invites Shareholders for interactions during the meeting to get a direct feedback on investor service.

The Committee ensures cordial investor relation and oversees the mechanism for redressal of investor's grievances. The term of references shall inter alia include:

- ❖ Resolving the grievances of the security holders of the entity including complaints related to transfer/ transmission of shares, non-receipt of annual report, non-receipt of declared dividends, issue of new/duplicate certificates, general meetings etc.;
- ❖ Review of measures taken for effective exercise of voting rights by shareholders of the Company;
- ❖ Review of adherence to the service standards adopted by the Company in respect of various services being rendered by the Registrar & Share Transfer Agent;
- ❖ Review of the various measures and initiatives taken by the Company for reducing the quantum of unclaimed dividends and ensuring timely receipt of dividend warrants/ annual reports/statutory notices by the shareholders of the company.
- ❖ Initiatives for registration of e-mail IDs, PAN & Bank mandates and demat of shares;
- ❖ Review shareholding distribution;
- ❖ Review movement in shareholding pattern;
- ❖ Comparative details on demat and physical holding.
- ❖ Monitor expeditious redressal of Investors' grievances;
- ❖ Consider all matters related to all security holders of the Company

- In addition, the Committee looks into other issues including status of dematerialization/ re-materialization of shares, transfer/transmission as well as systems and procedures followed to track investor complaints and suggest measures for improvement from time to time.
- During the year 2025-26, the Committee met on 06th February, 2026**.** The Committee also looks into redressal of shareholder's/investors complaints.

a) Composition of Stakeholders' Relationship Committee:

Name	Category of Directorship	Designation
Mr. Sumeet Bansal	Independent Director	Chairperson
Ms. Divya Khandelwal	Independent Director	Member
Mr. Mukesh Mehta	Whole Time Director	Member

b) Initial Public Offer Committee

The Initial Public Offer Committee has been formed by the Board of Directors, at the meeting held on March 5, 2025.

Composition of Initial Public Offer Committee:

Name	Category of Directorship	Designation
Mr. Pradeep Mehta	Managing Director	Chairperson
Mr. Mukesh Mehta	Whole Time Director	Member
Ms. Surabhi Mahajan	Non- Executive Director	Member

c) Name and designation of Compliance Officer

Ms. Pratiksha Bhandari
Company Secretary & Compliance Officer
Email: companysecretary@biomedica.co.in
(Appointed w.e.f. 03.04.2026 and Resigned w.e.f. 13.08.2026)

Ms. Khushi Gupta
Company Secretary & Compliance Officer
Email: companysecretary@biomedica.co.in
(Appointed w.e.f. 14.08.2026)

d) Status of Investor Complaint

Status of Investor Compliant as on March 31, 2026 as reported under Regulation 13(3) of the SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015 is as under:

Compliant pending as on April 01, 2025	Nil
Received during the year	Nil
Resolved during the year	Nil

Pending as on March 31, 2026	Nil

5. Senior Management:

Rahul Kumar resigned from the position of Company Secretary of the Company with effect from 1st April, 2026.

Ms. Pratiksha Bhandari was appointed as the Company Secretary of the Company on 3rd April, 2026 and resigned w.e.f. 13th August, 2026.

Further, Ms. Khushi Gupta is appointed as a Company Secretary of the Company w.e.f. 14th August, 2026.

Other than the above there has been no change in the senior management personnel excluding the Board of Director of the Company.

6. Remuneration Policy:

Pursuant to the provisions of the Companies Act, 2013 and under the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, the remuneration policy is framed and adopted.

Remuneration policy of the Company is designed to create a high-performance culture. It enables the Company to attract, retain and motivate employees to achieve results. Our business model promotes customer centricity and requires employee mobility to address project needs.

The remuneration policy supports such mobility through pay models that are compliant to local regulations. In each country where the Company operates, the remuneration structure is tailored to the regulations, practices and benchmarks prevalent in the IT industry.

The Board of Directors, on the recommendation of the Nomination and Remuneration Committee, decides the commission payable to the Managing Director and the Executive Directors out of the profits for the financial year and within the ceilings prescribed under the Act, based on the Board evaluation process considering the criteria such as the performance of the Company as well as that of the Managing Director and each Executive Director.

The Broad objectives of the Policy are:

i. To lay down criteria for identifying persons who are qualified to become Directors and who may be appointed in senior management of the Company in accordance with the criteria laid down;

ii. To lay down criteria for determining qualification, positive attributes and Independence of a Director;

iii. To lay down criteria relating to remuneration of directors, key managerial personnel and other employees;

iv. To retain, motivate and promote exceptional talent and to ensure long term sustainability of the talented managerial persons and create competitive advantage;

v. To promote and welcome diversity, equal opportunities and gender mix in the Board composition with due recognition and weightage to the skills, experience and business acumen of the directorship candidatures.

Particulars of Directors' Remuneration during the financial year 2025-26:

The details of remuneration paid to the Directors during the year ended March 31, 2026 are given below:

Directors	Salary	Perquisites	Sitting Fees	Total
Pradeep Mehta	10,93,951	-	-	10,93,951
Mukesh Mehta	11,98,012	-	-	11,98,012
Santosh Kale	1,36,500	-	-	1,36,500
Rahul Kumar	2,40,000	-	-	2,40,000
Total	**26,68,463**	-	-	**26,68,463**

Remuneration of the Executive Directors consists of a fixed component and a variable performance incentive. The Nomination and Remuneration Committee makes annual appraisal of the performance of the Executive Directors based on a detailed performance evaluation, and recommends the remuneration payable to them, within the parameters approved by the shareholders, to the Board for their approval.

Further, the Non-Executive Directors and Independent Directors are not entitled to any stock options.

7. **General Body Meetings:**

The concise details of Annual General Meetings held during the previous three years are as under:

a) **Annual General Meetings:**

AGM	Year	Date, Day and Time	Venue
10th	**2024-25**	30th September, 2025	Registered Office of the Company at Plot No. 11B-11C, Sector-E, Sanwer Road, Industrial Area, Indore-452015 (MP).
9th	**2023-24**	30th September, 2024	Registered Office of the Company at Plot No. 254, Sector-F, Sanwer Road, Industrial Area, Indore-452015 (MP).
8th	**2022-23**	30th September, 2023	Registered Office of the Company at Plot No. 254, Sector-F, Sanwer Road, Industrial Area, Indore-452015 (MP).

8. Means of Communication

- **Financial Results**: The half-yearly/annual financial results are published within the timeline stipulated under SEBI Listing Regulations. The results are uploaded on NSE portal within stipulated time period. The financial results of the Company are published in widely circulated national dailies such as The Economic Times, English newspaper and Swadesh, Hindi newspaper.

  They are also available on the website of the Company at https://biomedica.co.in/.

- **Newspapers wherein results normally published:** The financial results of the Company are published in widely circulated national dailies such as The Economic Times English newspaper and Swadesh, Hindi newspaper

- **Any website, where displayed:** The results of the Company are displayed on the Company's website: https://biomedica.co.in/.

- **Company Website:** Comprehensive information about the Company, its business and operations can be reviewed on the Company's website https://biomedica.co.in/. The "**Investor Relation" and "Shareholder Desk**" sections on the website give the information about results, annual reports, Shareholding Pattern.

9. General Shareholder Information:

a) Annual General Meeting (Date, Time & Venue)	Monday, 28th September, 2026. Through Video Conferencing/ Other Audio-Visual Mode Deemed venue- Registered Office of the Company situated at Registered Office of the Company at Plot No. 11B-11C, Sector-E, Sanwer Road, Industrial Area, Indore - 452015 (MP).
b) Financial Year	1st April 2025 to 31st March 2026
c) Financial Calendar 2025-26 (Tentative & Subject to Change)	NA
d) Date of Book Closure	23rd September, 2026 to 28th September, 2026
e) Dividend Record (Last three years)	Financial Year 2024-2025 - NIL Financial Year 2023-2024- NIL Financial Year 2022-2023- NIL
f) Dividend Payment date for FY 2025-26	Your Company has not declared dividend

g) Listing on Stock Exchanges	Shares of the Company are listed on SME Board of NSE Limited w.e.f. 29th May, 2026. **NSE:** Department of Corporate Affairs, Exchange Plaza, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (E), Mumbai-400051, Maharashtra, India.
h) Scrip Code	NA
i) ISIN NO.	INE1BKA01015

Registrar & Transfer Agents (both for Electronic & Physical Segment)

As per Regulation 7 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 Every Listed Entity is required to appoint Share transfer agent. Accordingly,

Skyline Financial Services Private Limited shall continue to act as the Registrar and Share Transfer Agent of the Company.

Skyline Financial Services Private Limited

Address: D-153 A, 1st Floor, Okhla Industrial Area, Phase - I, New Delhi-110020.

Share Transfer Systems

In terms of Regulation 40(1) of SEBI Listing Regulations, as amended from time to time, transfer, transmission and transposition of securities shall be effected only in dematerialized form.

Pursuant to SEBI Circular dated January 25, 2022, the listed companies shall issue the securities in dematerialized form only, for processing any service requests from shareholders viz., issue of duplicate share certificates, endorsement, transmission, transposition, etc. After processing the service request, a letter of confirmation will be issued to the shareholders and shall be valid for a period of 120 days, within which the shareholder shall make a request to the Depository Participant for dematerializing those shares. If the shareholders fail to submit the dematerialisation request within 120 days, then the Company shall credit those shares in the Suspense Escrow Demat account held by the Company. Shareholders can claim these shares transferred to Suspense Escrow Demat account on submission of necessary documentation.

Shareholding Pattern of the Company as on March 31, 2026:

Please note that the Company was listed on 29th May, 2026. Therefore, Company was not obliged to file the Shareholding Pattern prior to the listing. Further, prior to IPO following was the Shareholding pattern:

Category	No. of Shares	%
Promoters	88,89,909	96.84%
Public	2,90,092	3.16%
Total	91,80,001	**100.00**

Post IPO, the Shareholding Pattern of the company is as mentioned below:

Category	No. of Shares	%
Promoters	85,12,909	67.70%
Public	40,62,092	32.30%
Total	1,25,75,001	**100.00**

j) Reconciliation of Share Capital audit

Reconciliation of Share Capital Audit is conducted on quarterly basis by a Qualified Practicing Company Secretary to reconcile the total admitted capital with National Securities Depository Limited (NSDL) and Central Depository Service Limited (CDSL) with the total issued and listed Capital. The Reports are placed before the Board of Directors for its perusal and are submitted to the concerned Stock Exchanges where the shares of the Company are listed for trading. The said report confirms that the total issued and listed capital is in agreement with the total number of shares in physical form and the total number of dematerialized shares held with NSDL and CDSL.

k) Dematerialization of Shares

The Company's shares are available for dematerialisation on both the depositories viz. National Securties Depository Ltd. (NSDL) and Central Depository Service Ltd. (CDSL).

The Company's entire shareholding is in dematerialised form.

Dematerialisation of shares as on 31st March 2026:

Particular Dematerialization	Number of Shares	Percentage (%)
NSDL	9180001	100
CSDL	-	-
Physical:	-	-
Total:	**9180001**	**100**

l) Outstanding global depository receipts or American depository receipts or warrants or any convertible instruments, conversion date and likely impact on equity;

The Company has not issued any GDRs/ADRs/Warrants or any convertible instruments in the past and hence, as on March 31, 2026, the Company does not have any outstanding GDRs/ADRs/Warrants or any convertible instruments.

m) Address for Correspondence – Plot No. 11B-11C, Sector-E, Sanwer Road, Industrial Area, Indore - 452015 (MP).

n) Commodity Price Risk or Foreign Exchange Risk and Hedging Activities:

The Company does not deal in commodities and hence the disclosure pursuant to SEBI Circular dated November 15, 2018 is not required to be given.

o) Credit Rating:

The Company has not availed any credit Rating facility during the year. The Company does not have any fixed deposit programme nor has any proposal involving mobilization of funds in India or abroad.

p) Other Disclosures

S.No	Particulars	Statutes	Details
a)	**Disclosure of Related Party Transactions**	Regulation 23 of SEBI (LODR) Regulations, 2015	The details of Related Party Transaction are mentioned in AOC-2 in annexure.
b)	**Details of Compliances/ Non compliances by the Company with applicable Laws**	Schedule V (C) 10(b) to the SEBI Listing Regulations	Company is in compliance with the applicable Laws, Regulations and Rules.
c)	**Establishment of Vigil Mechanism/Whistle Blower Mechanism**	Regulation 22 of SEBI Listing Regulations	A Vigil Mechanism/Whistle Blower policy as recommended by the Audit Committee has been adopted by the Board of Directors of the Company. The policy provides a formal mechanism for all employees of the Company to approach the Chairman of the Audit Committee of the Company and no personnel has been denied access to the audit committee and make protective disclosures about the unethical behavior, actual or suspected fraud, or violation of the Company's Code of Conduct. The disclosures reported are addressed in the manner and within the time frames prescribed in the policy. Under the policy, each employee has an assured access to the Ethics Chairman of the Audit Committee.
d)	**Details of Compliance with mandatory requirements and adoption of the non-mandatory requirements of this clause**		The Company has complied with all the applicable mandatory requirements as specified in the SEBI(Listing Obligation and Disclosure Requirements) Regulation, 2015 and the non-mandatory have been adopted to the extent and in the manner as stated under the appropriate headings detailed elsewhere in this report.
e)	**Web link where policy for determining**	Regulation 24 of SEBI (LODR) 2015	The policy for determination of material Subsidiary is stated below: https://biomedica.co.in/

	material subsidiaries is disclosed		
f)	**Proceeds from the public issue/rights issue/preferential issues etc**		Company during the financial year 2025-26, has not raised proceeds from public issue, rights issue or preferential issue.
g)	**Certificate from Company Secretary in Practice regarding disqualification of Directors**		The certificate from Practicing Company Secretary issued as per requirements of Listing Regulations, confirming that none of the Directors in the Board of the Company have been debarred or disqualified from being appointed or continuing as Director of Companies by SEBI/ Ministry of Corporate Affairs or any such statutory authority is attached to this Report. The requisite certificate is annexed as **Annexure- A.**
h)	**Disclosure under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2018**	Section 134 of the Act, read with Rule 8 of the Companies (Accounts) Rules, 2014	1. Number of complaints filed during the financial year: NIL 2. Number of complaints disposed of during the financial year: NIL 3. Number of complaints pending as on end of the financial year: NIL

q) Other Disclosures

a) There were no instances where the Board had not accepted any recommendation of any committee during the financial year.

b) Fees to Statutory Auditors

Total fees for all services paid by the listed entity to the statutory auditor are mentioned in Notes to Accounts.

c) Disclosure on compliance with Corporate Governance Requirements specified in Listing Regulations:

The Company has complied with the requirements of Part C (corporate governance report) of sub-paras (2) to (10) of Schedule V of the Listing Regulations.

d) Adoption of Mandatory and discretionary requirements of the Corporate Governance as specified in the Listing Regulation 17 to 27 and Regulation 34(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

The Company is a SME Listed Company. Therefore, compliance with Corporate Governance as specified in the Listing Regulation 17 to 27 and Regulation 34(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 is not mandatory for the Company.

e) **Details of material subsidiaries of the listed entity; including the date and place of incorporation and the name and date of appointment of the statutory auditors of such subsidiaries:** Company does not have any material Subsidiary. However, Company has one subsidiary company named Vitamax Healthcare Private Limited during the year under the review.

Date of Acquisition: 25^{th} September, 2025

f) **Disclosure of loan and advances in the nature of loan to firms/ companies in which directors are interested by name and amount:** During the year Company has Advance to subsidiary Company of 167.96 Lakhs.

g) **Disclosure of Accounting Treatment**

The Ministry of Corporate Affairs (MCA), vide its notification in the official gazette dated February 16, 2015, notified the Indian Accounting Standards (IND AS) applicable to certain classes of Companies. INDAS has replaced the existing Indian GAAP prescribed under section133 of the Companies (Accounts) Rules, 2014.
The Company has adopted Indian Accounting Standards ("Ind AS") from April 01, 2017 (transition date to IND AS is April 01,2016) and the financial Statements have been prepared in accordance with recognition and measurement principal of Indian Accounting Standards ("IND AS") as prescribed under the Companies (Indian Accounting Standards) Rules, 2015, as specified in section 133 of the Companies Act, 2013. The Annual Accounts for the year ended March 31, 2026 have been prepared in accordance to Indian Accounting Standard (IND AS).
There is no explanation required to be given by the management, as per Regulation 34(3) read Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

h) **Management & Discussion Analysis Report:**

The comprehensive Management & Discussion Analysis Report has been enclosed with this report.

i) **Affirmed compliance with the code of conduct of board of directors and senior management**

The Company has a well-defined policy framework which lays down procedures to be followed by the employees for ethical professional conduct. The code of conduct has been laid down for all the board members and senior management of the Company.
The Board of Directors has adopted the Code of Conduct applicable to Directors and to Senior Management Personnel of the Company.
The Company has obtained declarations from all its Directors and Senior Management Personnel affirming their compliances with the applicable Code of Conduct. The declaration by

the Chief Executive Officer under Schedule V sub-clause (D)of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 affirming compliance of the Code of Conduct by all members of the Board and the Senior Management Personnel for the year ended 31st March, 2026 is attached to this Corporate Report. The declaration received has been attached as **Annexure –B** to this report.

j) Compliance Certificate from Practicing Company Secretary on Corporate Governance

As required under **Schedule V sub-clause (E)**and Regulation 34 (3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Certificate from Practicing Company Secretary is annexed and forms part of this Annual Report as **Annexure -C**

k) Disclosure regarding appointment/re-appointment of directors

Brief Details as required under Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Secretarial Standard-2 on the General Meeting in respect of the Director seeking reappointment at Annual General Meeting is annexed and forms integral part of the notice of the Annual General Meeting. The director has furnished the requisite consent/declaration(s) for his reappointment.

l) Code for Prevention of Insider Trading Practices

In compliance with SEBI's regulations on Prevention of Insider Trading, the Company has instituted a comprehensive Code of Conduct for its Directors and Designated Employees. The code lays down guidelines which advise them on procedure to be followed and disclosures to be made while dealing with shares of the Company and cautioning them of consequences of violations.

Based on the recent amendments in the SEBI (Prevention of Insider Trading Regulations), 2015, the company has revised the "Code of Conduct for Prevention of Insider Trading" of the Company. Company Secretary is the Compliance Officer for the purpose of this code. During the year, there has been due compliance with the code by the Company and all insiders and requisite disclosures were made to the Stock Exchanges from time to time.

The Company has now adopted the new amended SEBI's (Prevention of Insider Trading) Regulations, 2015 duly approved by the Board of Directors at its meeting in term of which the Code of Practices Procedure for fair disclosure unpublished price sensitive information and the Code of Internal procedure and conduct for regulation, monitor and report of trading in the Securities for the designated employees and the connected persons have been adopted.

m) Risk Management

The Company has adopted a Risk Management Policy. It has laid down the procedures to inform the Board members about potential risks, their assessment and control. These procedures are periodically reviewed to ensure that the executive management controls risks by means of properly defined framework of policies and strategies.

The Company also has a system of Internal Audit and the Internal Auditors report directly to the Audit Committee of the Company.

The Company has complied with all the mandatory requirements stipulated under the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The Company has also adopted non-mandatory requirements to the extent and in the manner as stated under the appropriate headings detailed elsewhere in this report.

n) Disclosure on demat Suspense Account/unclaimed Suspense Account

As per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the listed entity shall disclose the details with respect to Demat Suspense Account/Unclaimed Suspense Account in its annual report, as long as there are shares in the unclaimed suspense account. There are no shares of the Company which lying in the demat suspense Account and Unclaimed Suspense Account.

o) The SEBI (Listing Obligations & Disclosure Requirements), Regulations, 2015, vide its Regulation 46(1) stipulated that the company should maintain a functional website containing the basic information about the company and to update the contents of the said website periodically. In pursuance to this clause, the Company updates its website with all relevant information as envisaged in the said regulation and as per the provision of the companies Act, 2013.

p) Green Initiative in the Corporate Governance by the Ministry of Corporate Affairs

The Ministry of Corporate Affairs ("MCA") has taken a "Green Initiative in the Corporate Governance" by allowing paperless compliances by companies and has issued circulars stating that the service of official documents by a company to its members can be made through electronic mode.

To support this green initiative of the Government in full measure, all the members are requested to register/update their email IDs with their depository participants, in case shares are held in electronic mode, to ensure that Annual Report and other documents reach them at their preferred email IDs and, where the shares are held in physical mode, members are requested to get their email IDs updated in the records of the company.

All the official documents including Annual Report of the Company is circulated to the Members of the Company through electronic mode.

q) SEBI Complaints Redress System (SCORES)

The Company processes the investors' complaints received by it through a computerized complaints redressal system. The salient features of this system are computerized database of all the inward receipts and action taken on them, online submission of Action Taken Reports (ATRs) along with supporting documents electronically in SCORES. The investors' can view online the current status of their complaints submitted through SEBI Complaints Redress System (SCORES).

r) Discretionary Requirements

As required under Regulation 27(1) read with Part –E of Schedule II the details of discretionary requirements are given below:

I. The Board

The Company has not set up any office for the Executive Chairman and no reimbursement of expenses is incurred in the performance of his duties.

II. Shareholders Rights

The half yearly financial un-audited results of the Company after being subjected to a Limited Review by the Statutory Auditors are published in newspapers and on the Company's website https://biomedica.co.in/.

These results are not sent to shareholders individually.

III. Unmodified Opinion(s) in Audit Report

The Auditor has issued an unqualified/unmodified opinion on the statutory financial statement of the Company.

IV. Reporting of Internal Auditor

The Internal Auditor reports directly to the Audit Committee.

s) Information disclosed under clause 5A of paragraph A of Part A of Schedule III of these regulations:

No such agreement has been entered by the listed entity that will impact the management or control of the listed entity or impose any restriction or create any liability upon the listed entity.

By the order of the Board of Directors
For Bio Medica Laboratories Limited

	Sd/-	**Sd/-**
Place: Indore	**Pradeep Mehta**	**Mukesh Mehta**
Date: 02nd September, 2026	**Managing Director**	**Whole Time Director**

Annexure –B

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

(Pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To
The Members
Bio Medica Laboratories Limited
(Formerly Known as Bio Medica Laboratories Private Limited)
CIN U20293MP2015PLC034576
Plot No. 11B-11C, Sector-E, Sanwer Road, Industrial Area,
Industrial Estate, Indore (M.P.) - 452015

We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of Bio Medica Laboratories Limited (Formerly Known as Bio Medica Laboratories Private Limited) , having **CIN U20293MP2015PLC034576** and having registered office at, Plot No. 11B-11C, Sector-E, Sanwer Road, Industrial Area, Industrial Estate, Indore, Madhya Pradesh, India, 452015 . (hereinafter referred to as 'the Company'), produced before us by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to us by the Company & its officers, We hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on 31stMarch, 2026 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India (SEBI)and Ministry of Corporate Affairs, or any such other Statutory Authority.

Details of the Directors

S. No	Name of Director	DIN No	Date of Appointment in Company*
1.	Mr. Pradeep Mehta	07254802	14/08/2025
2.	Mr. Mukesh Mehta	03187420	14/08/2025
3.	Ms. Surabhi Mahajan	10771559	07/09/2024
4.	Ms. Divya Khandelwal	08444385	28/10/2024
5.	Mr. Sumeet Bansal	10822898	28/10/2024

*the date of appointment is as per the MCA portal.

Ensuring the eligibility for the appointment/ continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For Vishakha Agrawal & Associates
Practising Company Secretaries

CS Vishakha Agrawal
(Proprietor)
ACS: 39298 CP No. 15088
P.R. No. 2575/2022
UDIN: A039298H001355118

Place: Indore
Date: 03/09/2026

Annexure -C

CERTIFICATE ON COMPLIANCE OF CORPORATE GOVERNANCE

To
The Members of
Bio Medica Laboratories Limited
(Formerly Known as Bio Medica Laboratories Private Limited)
CIN: U20293MP2015PLC034576
Plot No. 11B-11C, Sector-E, Sanwer Road, Industrial Area,
Industrial Estate, Indore, Madhya Pradesh, India, 452015

1. This report contains details of compliance of conditions of corporate governance by Bio Medica Laboratories Limited (Formerly Known as Bio Medica Laboratories Private Limited) ('the Company') for the year ended 31^{st} March, 2026 as stipulated in regulation 17-27, clause (b) to (i) of regulation 46 (2) and paragraphs C, D and E of Schedule V of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time ('Listing Regulations') pursuant to Listing Agreement of the Company with Stock Exchanges.

Management's Responsibility for compliance with the conditions of Listing Regulations

2. The compliance with the terms and conditions contained in the corporate governance is the responsibility of the Management of the Company including the preparation and maintenance of all relevant supporting records and documents.

Auditor's Responsibility

3. Our examination was limited to procedures and implementation thereof adopted by the Company for ensuring the compliance of the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

4. Pursuant to the requirements of the Listing Regulations, it is our responsibility to provide a reasonable assurance whether the Company has complied with the conditions of Corporate Governance as stipulated in Listing Regulations for the year ended 31^{st} March, 2026.

5. We conducted our examination in accordance with the Guidance Note on Corporate Governance Certificate issued by the Institute of Company Secretaries of India (ICSI).

Opinion

6. In our opinion, and to the best of our information and according to explanations given to us, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the above-mentioned Listing Regulations.

7. We state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the Company.

Restriction on use

8. The certificate is addressed and provided to the members of the Company solely for the purpose to enable the Company to comply with the requirement of the Listing Regulations and it should not be used by any other person or for any other purpose. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this certificate is shown or into whose hands it may come without our prior consent in writing.

For Vishakha Agrawal & Associates
Practising Company Secretaries

CS Vishakha Agrawal
(Proprietor)
ACS: 39298 CP No. 15088
P.R. No. 2575/2022
UDIN: A039298H001355129

Place: Indore
Date: 03rd September, 2026

COMPLIANCE CERTIFICATE TO THE BOARD PURSUANT TO REGULATION 17(8) OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To
Board of Directors
Bio Medica Laboratories Limited

I, the undersigned, in our respective capacities as Chief Financial Officer of Bio Medica Laboratories Limited (Formerly Known as Bio Medica Laboratories Private Limited) (the company), to the best of our Knowledge and belief certify for the financial year ended 31st March, 2026 that:

(a) I have reviewed the IND-AS financial statements and the cash flow statement for the year ended 31st March, 2026 and that to the best of our knowledge and belief.

(i) These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
(ii) These statements together present a true and fair view of the company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.

(b) I further state that to the best of our knowledge and belief, no transactions entered into by the company during the year which are fraudulent, illegal or violative of the company's code of conduct.

(c) I accept the responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of internal control systems of the company pertaining to financial reporting and we have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.

(d) I have indicated to the auditors and the Audit committee

(i) Significant changes in internal control over financial reporting during the year;
(ii) (ii) Significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
(iii) That no instances of significant fraud have come to our notice.

By the order of the Board of Directors
For Bio Medica Laboratories Limited

Sd/-
Santosh Kale
Chief Financial Officer

Place: Indore
Date: 02nd September, 2026

DECLARATION REGARDING COMPLIANCE BY BOARD MEMBERS AND SENIOR MANAGEMENT PERSONNEL WITH THE COMPANY'S CODE OF CONDUCT

This is to confirm that the Company has adopted a Code of Conduct for its employees including the Managing Director. The Code of Conduct as adopted is available on the Company's website. I confirm that the Company has in respect of the Financial Year ended March 31, 2026, received from the senior management team of the Company and the Members of the Board, a declaration of compliance with the code of conduct as applicable to them.

For the purpose of this declaration, Senior Management Team means the President, Sr. Vice Presidents and Vice President Cadre as on March 31, 2026.

By the order of the Board of Directors
For Bio Medica Laboratories Limited

	Sd/-	**Sd/-**
Place: Indore	**Pradeep Mehta**	**Mukesh Mehta**
Date: 02nd September, 2026	**Managing Director**	**Whole Time Director**

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

A. INDUSTRY STRUCTURE AND DEVELOPMENTS

Global Growth:

- India Growth was supported by consumption, public investment and services.
- Healthier balance sheets of households, corporates and banks supported economic activity.
- Strong domestic demand reduced India's dependence on external demand.
- Investment and infrastructure development remained important growth drivers.
- India’s growth prospects remain favourable, although external risks could affect exports and investment.
- Against this backdrop, India remained one of the fastest-growing major economies, with real GDP growth estimated at 7.8% in FY 2025–26

Inflation:

- Inflation moderated to historically low levels during FY 2025–26.
- Headline CPI inflation averaged 1.7% during April–December 2025, the lowest recorded for this period since the beginning of the CPI series.
- Lower food-price pressures helped bring down headline inflation.
- Improved agricultural supply conditions supported price stability.
- Softer inflation created greater room for supportive monetary policy.
- Some firming of inflation is possible going forward.
- Commodity prices, food supply shocks and global disruptions remain key risks to prices.

Risks & Policy Backdrop:

- Policy remained focused on balancing growth with macroeconomic stability.
- Government continued fiscal consolidation while maintaining public investment.
- GST rationalisation and deregulation were important policy measures.
- Simplification of compliance was aimed at improving the ease of doing business.
- Monetary conditions became more supportive as inflation moderated.
- Maintaining policy credibility and adequate economic buffers remains important amid global uncertainty.

B. INDIAN ECONOMY OVERVIEW (FY 2025–26)

- Real GDP growth: 7.8%, up from 6.5% in FY 2024–25.
- Real GVA growth: approximately 7.7%, reflecting broad-based economic expansion.
- Inflation: Average headline CPI inflation was 1.7% during April–December 2025, reflecting significant price moderation.
- Fiscal deficit: 4.4% of GDP in FY 2025–26 RE, maintaining the Government's fiscal-consolidation trajectory.
- Consumption: Private consumption remained an important contributor to growth, supported by lower inflation and improving household purchasing power.

C. EXTERNAL ENVIRONMENT & RISKS (FY 2025–26)

- The global economic environment remained challenging during FY 2025–26 due to slower growth, trade fragmentation and geopolitical uncertainty.

- Higher tariffs and protectionist policies increased uncertainty for global trade and created risks for export-oriented economies.
- A slowdown in major trading partners could affect India's merchandise exports and external demand.
- Geopolitical tensions continued to pose risks to global supply chains, energy security and international trade routes.
- Volatility in crude-oil and other commodity prices remained an important risk for India because of its dependence on imports.
- Changes in global interest rates and investor sentiment could lead to volatility in foreign capital flows and the exchange rate.

Key Table: FY 2025–26 Economic Summary

Economy/Region	FY 2025–26 GDP Growth (%)	Inflation (%)
World	**3.1**	**4.4**
Advanced Econ.	**1.8**	**2.6**
EM & Dev. Econ.	**3.9**	**4.9**
United States	**2.3**	**3.8**
Eurozone	**1.1**	**2.6**
China	**4.4**	**1.3**
India	**7.5**	**3.5**

D. CAUTIONARY STATEMENT

Statements in the Management Discussion and Analysis describing the Company's objectives, projections, estimates and expectations are "forward-looking statements" within the meaning of applicable securities laws and regulations. Actual results may differ materially from those expressed or implied. Important factors that could make a difference to the Company's operations include economic conditions affecting demand/supply and price conditions in the domestic and overseas markets in which the Company operates; changes in the Government regulations; tax laws and other statutes and incidental factors.

PHARMACEUTICAL INDUSTRY

INTRODUCTION:

India is the largest provider of generic drugs globally and is renowned for its affordable vaccines and high-quality medicines. Over the years, the Indian pharmaceutical industry has evolved into a vibrant sector, currently ranked third in pharmaceutical production by volume and 14th in terms of value. The industry has grown at a CAGR of 9.43% over the past nine years and contributes around 1.72% to India's GDP.

As of May 2025, India supplies 55-60% of UNICEF's vaccines, meets 99% of WHO's DPT vaccine demand, and provides 52% of BCG and 45% of measles vaccines. The domestic pharmaceutical ecosystem comprises around 3,000 drug companies and roughly 10,500 manufacturing units, supported by a large pool of skilled scientists and engineers. Over 80% of antiretroviral drugs used globally to combat AIDS are supplied by Indian firms, reinforcing India's reputation as the "pharmacy of the world."

According to Mordor Intelligence, the Indian pharmaceutical market stood at Rs. 4,97,000 crore (US$ 57.61 billion) in 2025, is estimated at Rs. 5,20,000 crore (US$ 60.32 billion) in 2026 and is expected to grow to Rs. 6,89,000 crore (US$ 79.74 billion) by 2031, at a CAGR of 5.74%.

MARKET SIZE:

The Indian hospital market was valued at US$ 98.98 billion in FY23 and is projected to grow at a CAGR of 8%, reaching US$ 193.59 billion by FY32. India is also among the top 12 destinations for biotechnology globally and ranks third in Asia Pacific, holding 3-5% of the global biotechnology industry.

The country's biosimilars market is estimated to grow at a CAGR of 22%, reaching US$ 12 billion by 2025, representing nearly 20% of India's total pharmaceutical market. As of November 2024, India is the third-largest producer of active pharmaceutical ingredients (APIs), contributing an 8% share of the global API industry. Over 500 different APIs are manufactured in India, which accounts for 57% of WHO-prequalified APIs.

The government has set ambitious targets for the medical devices industry, aiming to expand its valuation from Rs. 1,02,564 crore (US$ 12 billion) in 2023-24 to Rs. 4,27,350 crore (US$ 50 billion) by 2030. Domestic pharmaceutical consumption in FY24 was valued at Rs. 2,01,372 crore (US$ 23.5 billion).

Indian pharmaceutical companies hold a significant share in the prescription markets of the US and EU, with India hosting the largest number of FDA-approved manufacturing plants outside the US. Globally, India is a major supplier of generic medications, providing 20% of the worldwide supply by volume and fulfilling around 60% of global vaccination demand.



EXPORTS:

India's pharmaceutical exports recorded strong growth, rising 9.4% to Rs. 2.66 lakh crore (US$ 30.47 billion) in 2024-25, according to data released by the commerce ministry on February 21, 2026. This reflects India's expanding global footprint as a key supplier of medicines, with exports reaching over 200 markets and a significant share going to regulated regions like the US and Europe. Building on this momentum, the industry is targeting double-digit export growth by 2026-27, supported by ongoing government–industry collaboration, improved market access, and trade engagements with major global partners.

India's pharmaceuticals exports stood at Rs. 2.74 lakh crore (US$ 31.11 billion) in FY26, compared to Rs. 2.59 lakh crore (US$ 30.38 billion) in FY25.

India's medical technology industry is poised to reach exports of up to US$ 20 billion (Rs. 1,69,000) by FY30, according to the CII.

India is the 12th largest exporter of medical goods in the world. Indian drugs are exported to more than 200 countries in the world, with US being the key market. Generic drugs account for 20% of the global export in terms of volume, making the country the largest provider of generic medicines globally.

As of May 2025, India supplies 55-60% of UNICEF's vaccines, meets 99% of WHO's DPT vaccine demand, 52% of BCG vaccines and 45% of measles vaccines, while creating jobs across manufacturing and research.

RECENT INVESTMENTS/DEVELOPMENTS:

The Indian Pharmaceuticals industry plays a prominent role in the global pharmaceuticals industry. India ranks third worldwide for production by volume and 14th by value.

In this regard the sector has seen a lot of investments and developments in the recent past.

As per the Press Information Bureau release dated February 2, 2026, India is strengthening its pharmaceutical sector through the Biopharma SHAKTI initiative with an outlay of Rs. 10,000 crore (US$ 1.11 billion) over five years. The initiative focuses on boosting biologics and biosimilars manufacturing, expanding research and education via NIPER institutes, and developing over 1,000 clinical trial sites. These investments highlight India's shift towards innovation-led growth and reinforce its position as a global biopharma hub.

India's healthcare sector is projected to reach US$ 320 billion (Rs. 27,28,320 crore) by 2028, according to the latest report by Great Place to Work.

The pharmaceutical sector targets Rs. 11,08,380 crore (US$ 130 billion) by 2030, while biotechnology aims for Rs. 25,57,800 crore (US$ 300 billion) by the same year.

For the period 2020-21 to 2027-28, 26 Applicants for manufacturing of Medical Devices have been approved for 138 products under the PLI scheme with total financial outlay of US$ 411.01 million (Rs. 3,420 crore).

The Department of Pharmaceuticals will soon launch the Scheme for the Promotion of Research and Innovation in Pharma (PRIP) MedTech Sector. The scheme has been approved by the Union Cabinet for a period of five years starting from 2023-24 to 2027-28 with a total outlay of Rs. 5,000 crore (US$ 604.5 million).

Anglo French Drugs & Industries Limited (AFDIL), a 99-year-old organization in the pharmaceutical sector, announced that it has entered into the fertility space with the launch of the LYBER range.

GOVERNMENT INITIATIVES:

Some of the initiatives taken by the Government to promote the pharmaceutical sector in India are as follows:

Published on February 14, 2026, the Biopharma SHAKTI initiative announced in the Union Budget aims to boost India's pharmaceutical sector by promoting innovation-led growth. With a Rs. 10,000 crore (US$ 1.11 billion) fund, the scheme will support biologics, biosimilars, and R&D, alongside plans for a 1,000-site clinical trial network. The government is also reviewing support for late-stage (Phase III) trials, addressing funding gaps and strengthening India's position as a global hub for advanced pharma innovation and manufacturing.

Under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana, 16,912 Jan Aushadhi Kendras are operational as of June 30, 2025, with a target of 25,000 by March 2027, offering 2,110 medicines and 315 devices/consumables to promote affordable quality generic healthcare. Over the last 11 years, this scheme has saved citizens about Rs. 38,000 crore (US$ 4.43 billion), cutting household out-of-pocket health spending from 63% in FY15 to 39% in FY22.

As per Union Budget 2025-26:

- Rs. 1,400 crore (US$ 163 million) provided to support three mega bulk drug parks across states.
- Total pharma industry budget allocation raised to Rs. 5,268 crore (US$ 614 million).
- Medical device parks promotion budget raised to Rs. 1,460 crore (US$ 170 million).

PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 crore (US$ 838.16 million) during the tenure of the scheme from 2020-21 to 2029-30.

ROAD AHEAD:

The pharmaceutical industry in India is a significant part of the nation's foreign trade and offers lucrative potential for investors. Millions of people around the world receive affordable and inexpensive generic medications from India, which also runs a sizable number of plants that adhere to Good Manufacturing Practices (GMP) standards set by the World Health Organization (WHO) and the United States Food and Drug Administration (USFDA).

Medicine spending in India is projected to grow 9-12% over the next five years, leading India to become one of the top 10 countries in terms of medicine spending.

The National Health Protection Scheme, which aims to offer universal healthcare, the ageing population, the rise in chronic diseases, and other government programmes, including the opening of pharmacies that offer inexpensive generic medications, should all contribute to boost the Indian pharmaceutical industry.

Speedy introduction of generic drugs into the market has remained in focus and is expected to benefit the Indian pharmaceutical companies.

Going forward, India’s biopharma growth will depend on accelerating innovation-led manufacturing, strengthening global regulatory alignment, and deepening industry–academia collaboration to commercialise high-value biologics and biosimilars. Expanding clinical research capabilities and skilled talent pipelines, while ensuring faster approvals and IP protection, will be critical to attract global investments.

Additionally, scaling domestic infrastructure, reducing import dependence on critical inputs, and leveraging digital and biotech convergence (AI, genomics, precision medicine) can position India as a competitive global hub for advanced therapeutics and resilient pharmaceutical supply chains.

BIO MEDICA LABORATORIES LIMITED

CIN: U24230MP2015PLC034576

Registered Office: Plot No. 11B-11C, Sector-E, Sanwer Road, Industrial Area, Indore (MP) 452015

STANDALONE AUDITED FINANCIAL STATEMENTS

For the Financial Year Ended 31st March, 2026

Auditors:
M/s Vijay K Jain & Associates
Chartered Accountants
(Firm Registration No. 006719C)

Address: 307 Manas Bhawan Extn,
11 RNT Marg, Indore

VIJAY K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
Branches : UJJAIN | AGAR
H.O.: 307, Manas Bhawan Extn., & 315-316, Bharti Bhawan 11 R.N.T. Marg, Indore - 452 001 (M.P.)
Ph.: (0731) 2524215 | 4224215 | Cell : 97137 00582
E-mail : cavijayjain2011@yahoo.com

Independent Auditor's Report

To the Members of **BIO MEDICA LABORATORIES LIMITED**
(Formerly known as Bio Medica Laboratories Private Limited)

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the standalone financial statements of BIO MEDICA LABORATORIES LIMITED (Formerly known as Bio Medica Laboratories Private Limited) ("the Company"), which comprise the balance sheet as at 31st March 2026, and the statement of Profit and Loss and statement of cash flows for the year then ended, and notes to the standalone financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2026, its profit/loss and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information other than the financial statements and auditors' report thereon

The Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexures to Board's Report but does not include the standalone financial statements and our auditor's report thereon. Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report on in this regard.

VIJAY JAIN & ASSOCIATES
CA
INDORE
CHARTERED ACCOUNTANTS

VIJAY K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
Branches : UJJAIN | AGAR
H.O.: 307, Manas Bhawan Extn., & 315-316, Shert Bhawan 11, R.N.T. Marg, Indore - 452 001 (M.P.)
Ph.: (0731) 2524215 | 4224215 | Cell : 97137 00682
E-mail : cavijayjain2011@yahoo.com

Responsibilities of Management and Those Charged with Governance for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

• Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

• Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.

• Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

VIJAY K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
Branches : UJJAIN | AGAR
H.O.: 307, Manas Bhawan Extn., & 315-316, Bharti Bhawan
11 R.N.T. Marg, Indore - 452 001 (M.P.)
Ph.: (0731) 2524215 | 4224215 | Cell: 97137 00582
E-mail: cavijayjain2011@yahoo.com

• Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

• Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the 'Annexure A', a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

2. As required by Section 143 (3) of the Act, we report that:

   a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

   b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

   c) The Balance Sheet, the Statement of Profit and Loss and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.

   d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act and rules made thereunder.

CA INDIA
VIJAY K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
Branches : UJJAIN | AGAR
H.O.: 307, Manas Bhawan Extn., & 315-316, Bharti Bhawan 11 R.N.T. Marg, Indore - 452 001 (M.P.)
Ph.: (0731) 2524215 | 4224215 | Cell : 97137 00582
E-mail : cavijayjain2011@yahoo.com

e) On the basis of the written representations received from the directors as on 31st March, 2026 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.

f) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in 'Annexure B'.

g) With respect to the matter to be included in the Auditor's Report under section 197(16), In our opinion and according to the information and explanations given to us, the remuneration paid by the Company to its directors during the current year is in accordance with the provisions of section 197 of the Act. The remuneration paid to any director is not in excess of the limit laid down under section 197 of the Act. The Ministry of Corporate Affairs has not prescribed other details under section 197(16) which are required to be commented upon by us. (applicable in case of Public Company)

h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

i. The Company does not have any pending litigations which would impact its financial position.

ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

iv. (a) The management has represented that, to the best of it's knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(b) The management has represented, that, to the best of it's knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

VIJAY K. JAIN & ASSOCIATES INDORE CHARTERED ACCOUNTANTS

VIJAY K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
Branches : UJJAIN | AGAR
H.O.: 307, Manas Bhawan Extn., & 315-316, Bharti Bhawan
11 R.N.T. Marg, Indore - 452 001 (M.P.)
Ph.: (0731) 2524215 | 4224215 | Cell : 97137 00582
E-mail : cavijayjain2011@yahoo.com

(c) Based on such audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material mis-statement.

v. During the year no dividend has been declared the year by the company.

vi. Based on our examination which included test checks, the company has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of audit trail feature being tampered with.

For VIJAY K JAIN & ASSOCIATES
Chartered Accountants
Firm Registration No: 006719C

CA SUNNY JAIN
Partner
Membership No. 429107

Place: Indore
Date: 27.07.2026
UDIN: 26429107HUEJSK4996

VIJAY K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
Branches : UJJAIN | AGAR
H.O.: 307, Manas Bhawan Extn., & 315-316, Bharti Bhawan
11 R.N.T. Marg, Indore - 452 001 (M.P.)
Ph.: (0731) 2524215 | 4224215 | Cell : 97137 30582
E-mail : cavijayjain2011@yahoo.com

Annexure 'A'

The Annexure referred to in paragraph 1 of Our Report on "Other Legal and Regulatory Requirements".

We report that:

(i) (a) (A) The company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment;

(B) The company has maintained proper records showing full particulars of intangible assets;

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Property, Plant and Equipment have been physically verified by the management at reasonable intervals; no material discrepancies were noticed on such verification;

(c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of all the immovable properties (other than properties where the company is the lessee and the lease agreements are duly executed in favor of the lessee) disclosed in the financial statementsare held in the name of the company;

(d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the company has not revalued its Property, Plant and Equipment (including Right of Use assets) or intangible assets during the year. Accordingly, the reporting under Clause 3(i)(d) of the Order is not applicable to the Company.

(e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings have been initiated or are pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder.

(ii) (a) As explained to us & on the basis of the records examined by us, in our opinion, physical verification of inventory has been conducted at reasonable intervals by the management. In our opinion, the coverage and procedure of such verification by the management is appropriate. No discrepancy of 10% or more in the aggregate for each class of inventory were noticed on physical verification of stocks by the management as compared to book records.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the company has been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks or financial institutions on the basis of security of current assets during any point of time of the year. The quarterly returns or statements filed by the company with such banks or financial institutions are in agreement with the books of account of the Company.

VIJAY K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
Branches : UJJAIN | AGAR
H.O.: 307, Manas Bhawan Extn., & 315-316, Bharti Bhawan 11 R.N.T. Marg, Indore - 452 001 (M.P)
Ph.: (0731) 2524215 | 4224215 | Cell : 97137 00582
E-mail : cavijayjain2011@yahoo.com

(iii) According to the information and explanations given to us and on the basis of our examination of the records of the company during the year the company has made investment of ₹ 51,000.00 in equity shares of a subsidiary and granted loans to its subsidiary during the year.

a) According to the information and explanations given to us and on the basis of our examination of the records of the company, the company has granted loans to its subsidiary during the year. The company has not provided advances in the nature of loans, or stood guarantee, or provided security to any other entity;

(A) According to the information and explanations given to us and on the basis of our examination of the records of the company, the aggregate amount of loans granted during the year to its subsidiary was ₹2,50,49,000 and the balance outstanding as at the balance sheet date was Nil. The company has not provided any guarantees or security to subsidiaries, joint ventures and associates;

(B) According to the information and explanations given to us and on the basis of our examination of the records of the company, the company has not granted any loans or advances and guarantees or security to parties other than subsidiaries, joint ventures and associates.;

b) According to the information and explanations given to us and on the basis of our examination of the records of the company, the investments made and the terms and conditions of the loan granted to the subsidiary during the year are not prejudicial to the interest of the Company;

c) According to the information and explanations given to us and on the basis of our examination of the records of the company the schedule of repayment of principal and payment of interest has been stipulated and the repayments of principal and interest have been regular;

d) According to the information and explanations given to us and on the basis of our examination of the records of the company, there are no amounts overdue for more than ninety days in respect of the loan granted;

e) According to the information and explanations given to us and on the basis of our examination of the records of the company, no loan falling due during the year has been renewed or extended or fresh loan granted to settle the overdues of existing loans;

f) According to the information and explanations given to us and on the basis of our examination of the records of the company, company has not granted any loans or advances in the nature of loans either repayable on demand or without specifying any terms or period of repayment, accordingly, provisions of clause 3(iii)(f) of the Order are not applicable to the Company.

VIJAY K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
Branches : UJJAIN | AGAR
H.O.: 307, Manas Bhawan Extn., & 315-316, Bharti Bhawan
11 R.N.T. Marg, Indore - 452 001 (M.P.)
Ph.: (0731) 2524215 | 4224215 | Cell : 97137 00582
E-mail : cavijayjain2011@yahoo.com

(iv) In our opinion and according to the information and explanations given to us, provisions of section 186 of the Act in respect of investments made have been complied with by the Company. Further, in our opinion and according to the information and explanations given to us, there are no loans, guarantees, and securities given in respect of which provisions of section 185 and 186 of the Act are applicable. Accordingly, the requirement to report on clause 3(iv) of the Order is not applicable to that extent to the.

(v) The company has not accepted any deposits or amounts which are deemed to be deposits covered under sections 73 to 76 of the Companies Act, 2013. Accordingly, clause 3(v) of the Order is not applicable.

(vi) As per information & explanation given by the management, maintenance of cost records has not been specified by the Central Government under sub-section (1) of section 148 of the Companies Act.

(vii) (a) According to the information and explanations given to us and on the basis of our examination of the records of the company, the company is regular in depositing undisputed statutory dues including Goods and Services Tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues to the appropriate authorities. According to the information and explanation given to us there were no outstanding statutory dues as on 31st of March, 2026 for a period of more than six months from the date they became payable.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the company, there is no statutory dues referred to in sub-clause (a) that have not been deposited on account of any dispute except following : (if applicable) :

Name of the Statute	Nature of the Dues	Amount (Rs.)	Period to which the amount relates	Forum where Dispute is pending	Remarks, if Any
IGST Act 2017	Tax Interest Penalty	64,258/- 1,109/- 39,844/-	FY 2018-19	Commissioner Appeals	Case is under hearing
CGST Act 2017	Tax Penalty	92,161/- 19,308/-	FY 2018-19	Commissioner Appeals	Case is under hearing
SGST Act 2017	Tax Penalty	92,161/- 19,308/-	FY 2018-19	Commissioner Appeals	Case is under hearing

VIJAY K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS INDORE

VIJAY K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
Branches : UJJAIN | AGAR
H.O.: 307, Manas Bhawan Extn., & 315-316, Bhart Bhawan 11 R.N.T. Marg, Indore - 452 001 (M.P.)
Ph.: (0731) 2524215 | 4224215 Cell : 97137 00582
E-mail : cavijayjain2011@yahoo.com

(viii) According to the information and explanations given to us and on the basis of our examination of the records of the company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year.

(ix) (a) According to the information and explanations given to us and on the basis of our examination of the records of the company, the company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender;.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the company, the company has not been declared a willful defaulter by any bank or financial institution or other lender;

(c) According to the information and explanations given to us by the management, the Company has utilized the money obtained by way of term loans during the year for the purposes for which they were obtained;

(d) According to the information and explanations given to us and on an overall examination of the balance sheet of the Company, we report that no funds raised on short term basis have been used for long term purposes by the company.

(e) The Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures. Accordingly, clause 3(ix)(e) is not applicable;

(f) The Company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies (as defined under the Act) during the year ended 31 March 2026. Accordingly, clause 3(ix)(f) is not applicable;

(x) (a) The company has not raised any money by way of initial public offer or further public offer (including debt instruments) during the year. Accordingly, clause 3(x)(a) of the Order is not applicable.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the company has not made any preferential allotment or private placement of shares or convertible debentures (fully, partially or optionally convertible) during the year. Accordingly, clause 3(x)(b) of the Order is not applicable.

(xi) (a) Based on examination of the books and records of the Company and according to the information and explanations given to us , no fraud by the company or any fraud on the company has been noticed or reported during the course of audit.

K. JAIN & ASSOCIATES INDORE CHARTERED ACCOUNTANTS

VIJAY K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
Branches : UJJAIN | AGAR
H.O.: 307, Manas Bhawan Extn., & 315-316 Bharti Bhawan 11 R.N.T. Marg, Indore - 452 001 (M.P.)
Ph.: (0731) 2524215 | 4224215 | Cell : 97137 00582
E-mail : cavijayjain2011@yahoo.com

(b) According to the information and explanations given to us, no report under sub-section (12) of section 143 of the Companies Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government;

(c) According to the information and explanations given to us by the management, no whistle-blower complaints had been received by the company

(xii) The company is not a Nidhi Company. Accordingly, clause 3(xii)(a), 3(xii)(b) and 3(xii)(c) of the Order is not applicable.

(xiii) In our opinion and according to the information and explanations given to us, all transactions with the related parties are in compliance with sections 177 and 188 of Companies Act, where applicable and the details have been disclosed in the financial statements, as required by the applicable accounting standards;

(xiv) (a) Based on information and explanations provided to us and our audit procedures, the company has an internal audit system commensurate with the size and nature of its business;

(b) We have considered the internal audit reports of the Company issued till date for the period under audit.

(xv) In our opinion and according to the information and explanations given to us, the company has not entered into any non-cash transactions with directors or persons connected with him and hence, provisions of Section 192 of the Companies Act, 2013 are not applicable to the Company

(xvi) (a) In our Opinion and based on our examination, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934 (2 of 1934). Accordingly, clause 3(xvi)(a) of the Order is not applicable.

(b) In our Opinion and based on our examination, the Company has not conducted any Non-Banking Financial or Housing Finance activities without a valid Certificate of Registration (CoR) from the Reserve Bank of India as per the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(b) of the Order is not applicable. ,

(c) In our Opinion and based on our examination, the Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.

(d) According to the information and explanations given by the management, the Group does not have any CIC as part of the Group.

VIJAY K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
Branches : UJJAIN | AGAR

H.O.: 307, Manas Bhawan Extn., & 315-316, Bharti Bhawan
11 R.N.T. Marg, Indore - 452 001 (M.P.)
Ph.: (0731) 2524215 | 4224215 | Cell : 97137 00682
E-mail : cavijayjain2011@yahoo.com

(xvii) Based on our examination, the company has not incurred cash losses in the financial year and in the immediately preceding financial year.

(xviii) There has been no resignation of the statutory auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable.

(xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the company as and when they fall due.

(xx) Based on our examination, there is no unspent amount under section 135 accordingly, clauses 3(xx)(a) and 3(xx)(b) of the Order are not applicable.

For VIJAY K JAIN & ASSOCIATES
Chartered Accountants
Firm Registration No: 006719C

CA SUNNY JAIN
Partner
Membership No. 429107

Place: Indore
Date: 27.07.2026
UDIN: 26429107HUEJSK4996

VIJAY K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
Branches : UJJAIN | AGAR
H.O.: 307, Manas Bhawan Extn., & 315-316 Bhart Bhawan
11 R.N.T. Marg, Indore - 452 001 (M.P.)
Ph.: (0731) 2524215 | 4224215 | Cell : 97137 00582
E-mail : cavijayjain2011@yahoo.com

Annexure 'B'

Report on Internal Financial Controls with reference to financial statements

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of BIO MEDICA LABORATORIES LIMITED ("the Company") as of March 31st 2026, in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

VIJAY K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
Branches : UJJAIN | AGAR
H.O.: 307, Manas Bhawan Extn., & 315-316, Bharti Bhawan 11 R.N.T. Marg, Indore - 452 001 (M.P.)
Ph.: (0731) 2524215 | 4224215 | Cell : 97137 00582
E-mail : cavijayjain2011@yahoo.com

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that

1. pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
2. provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and
3. provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For VIJAY K JAIN & ASSOCIATES
Chartered Accountants
Firm Registration No: 006719C

CA SUNNY JAIN
Partner
Membership No. 429107

Place: Indore
Date: 27.07.2026
UDIN: 26429107HUEJSK4996

BIO MEDICA LABORATORIES LIMITED

(Formerly known as Bio Medica Laboratories Private Limited)

CIN : U24230MP2015PLC034576

Standalone Balance Sheet as at 31st March 2026

Amount (in ₹ Lakhs)

Particulars	Note No.	As at 31st March 2026	As at 31st March 2025
I. EQUITY AND LIABILITIES			
(1) Shareholder's funds			
(a) Share capital	3	918.00	918.00
(b) Reserves and surplus	4	1722.25	555.30
(c) Money received against share warrants		-	-
		2640.25	1473.30
(2) Share application money pending allotment	-	-	-
(3) Non-current liabilities			
(a) Long-term borrowings	5	1625.81	1008.49
(b) Deferred tax liabilities (Net)		-	-
(c) Other long term liabilities	6	62.00	31.00
(d) Long-term provisions	7	38.09	31.58
		1725.90	1071.07
(4) Current liabilities			
(a) Short-term borrowings	8	663.32	492.95
(b) Trade payables	9		
(A) total outstanding dues of micro enterprises and small enterprises; and		20.29	32.71
(B) total outstanding dues of creditors other than micro enterprises and small enterprises		237.70	395.05
(c) Other current liabilities	10	133.02	94.07
(d) Short-term provisions	11	325.36	310.97
		1379.68	1325.75
TOTAL		**5745.83**	**3870.13**
II. ASSETS			
(1) Non-current assets			
(a) Property, Plant and Equipment and Intangible assets	12		
(i) Property, Plant and Equipment		692.27	767.56
(ii) Intangible assets		-	-
(iii) Capital work-in-Progress		-	-
(iv) Intangible assets under development		-	-
(b) Non-current investments	13	0.51	-
(c) Deferred tax assets (net)	14	30.61	20.01
(d) Long-term loans and advances	15	171.97	4.00
(e) Other non-current assets	16	13.01	13.44
		908.37	805.01
(2) Current assets			
(a) Current investments	-	-	-
(b) Inventories	17	3330.55	1813.79
(c) Trade receivables	18	907.06	410.02
(d) Cash and cash equivalents	19	2.64	0.68
(e) Short-term loans and advances	20	461.62	752.52
(f) Other current assets	21	135.60	88.12
		4837.46	3065.12
TOTAL		**5745.83**	**3870.13**

Significant Accounting Policies & Notes To The Accounts 2

The accompanying notes are an integral part of the financial statements.

As per our report of even date
For VIJAY K JAIN & ASSOCIATES
Chartered Accountants
Firm Registration No: 006719C

CA SUNNY JAIN
Partner
Membership No. 429107
Place: Indore
Date: 27.07.2026

For and on behalf of the Board of Directors of Bio Medica Laboratories limited

Mukesh Mehta	**Pradeep Mehta**
Director	**Director**
DIN: 03187420	**DIN: 07254802**
Pratiksha Bhandari	**Santosh Kale**
Company Secretary	**CFO**
PAN: AQLPB2934M	**PAN:**

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Standalone Statement of Profit and loss for the year ended 31st March 2026

Amount (in ₹ Lakhs)

Particulars	Note No.	For the year ended 31st March 2026	For the year ended 31st March 2025
I. Revenue from operations	22	3829.66	3831.97
II. Other income	23	13.39	0.53
III. Total Income (I + II)		**3843.04**	**3832.50**
IV. Expenses			
Cost of materials consumed	24	1618.51	1914.63
Purchase of stock-in-trade	25	47.20	12.22
Changes in inventories of finished goods work-in-progress and stock in-trade	26	(142.78)	(17.37)
Employee benefit expenses	27	234.30	194.53
Finance costs	28	189.81	119.51
Depreciation and amortization expenses	29	91.53	100.54
Other expenses	30	235.07	194.18
Total expenses		**2273.63**	**2518.24**
V. Profit before exceptional and extraordinary items and tax (III - IV)		1569.41	1314.27
VI. Exceptional items		-	-
VII. Profit before extraordinary items and tax (V - VI)		**1569.41**	**1314.27**
VIII. Extraordinary items		-	-
IX. Profit before tax (VII - VIII)		**1569.41**	**1314.27**
X. Tax expense:			
(1) Current tax		417.18	(343.52)
(2) Deferred tax	31	(10.61)	9.17
(3) Short /(Excess) Previous Year Income Tax		(4.11)	(9.51)
XI. Profit (Loss) for the period from continuing operations (IX - X)		**1166.95**	**979.41**
XII. Profit / (loss) from discontinuing operations		-	-
XIII. Tax expense of discontinuing operations		-	-
XIV. Profit/(loss) from Discontinuing operations (after tax) (XII - XIII)		-	-
XV. Profit (Loss) for the period (XI + XIV)		**1166.95**	**979.41**
XVI. Earnings per equity share	32		
(1) Basic		12.71	10.57
(2) Diluted		12.71	10.57

Significant Accounting Policies & Notes To The Accounts 2

The accompanying notes are an integral part of the financial statements.

As per our report of even date
For VIJAY K JAIN & ASSOCIATES
Chartered Accountants
Firm Registration No: 006719C

CA SUNNY JAIN
Partner
Membership No. 429107
Place: Indore
Date: 27.07.2026

For and on behalf of the Board of Directors
of Bio Medica Laboratories limited

Mukesh Mehta
Director
DIN: 03187420

Pradeep Mehta
Director
DIN: 07254802

Pratiksha Bhandari
Company Secretary
PAN: ABLPB2934M

Santosh Kale
CFO
PAN:

BIO MEDICA LABORATORIES LIMITED

(Formerly known as Bio Medica Laboratories Private Limited)

CIN : U24230MP2015PLC034576

Standalone Cash Flow Statement for the year ended 31st March 2026

Amount (in ₹ Lakhs)

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
A. Cash Flow From Operating Activities		
Net Profit before tax and extraordinary items (as per Statement of Profit and Loss)	1569.41	1314.27
Adjustments for non Cash/ Non trade items:		
Depreciation & Amortization Expenses	91.53	100.54
Finance Cost	189.81	-
Extra Ordinary item (Prior period gratuity)	-	-
(Profit) / Loss on sale of asset	1.78	-
Operating profits before Working Capital Changes	**1852.53**	**1414.81**
Adjusted For:		
(Increase) / Decrease in trade receivables	(497.04)	(176.43)
Increase / (Decrease) in trade payables	(169.77)	225.26
(Increase) / Decrease in inventories	(1516.76)	(1077.10)
Increase / (Decrease) in other current liabilities	38.94	15.81
Increase / (Decrease) in other long term liabilities	31.00	31.00
Increase / (Decrease) in short term provisions	14.39	275.69
Increase / (Decrease) in long term provisions	6.50	-
(Increase) / Decrease in Short Term Loans & Advances	290.90	(736.32)
(Increase) / Decrease in Long Term Loans & Advances	(167.96)	-
(Increase) / Decrease in other current assets	(47.48)	(76.92)
(Increase) / Decrease in other non-current assets	0.43	(1.18)
Cash generated from Operations	**(164.32)**	**(104.39)**
Income Tax (Paid) / Refund	(413.07)	(353.03)
Net Cash flow from Operating Activities(A)	**(577.39)**	**(457.42)**
B. Cash Flow From Investing Activities		
Purchase of tangible assets	(88.16)	-
Proceeds from sales of tangible assets	12.05	-
Receipt of capital subsidy	58.10	4.62
Investment in subsidiary	(0.51)	-
Net Cash used in Investing Activities(B)	**(18.52)**	**4.62**
C. Cash Flow From Financing Activities		
Finance Cost	(189.81)	-
Increase in / (Repayment) of Short term Borrowings	170.36	324.23
Increase in / (Repayment) of Long term borrowings	617.33	128.22
Increase / (Decrease) in share capital	-	-
Net Cash used in Financing Activities(C)	**597.88**	**452.44**

BIO MEDICA LABORATORIES LIMITED

(Formerly known as Bio Medica Laboratories Private Limited)

CIN : U24230MP2015PLC034576

Standalone Cash Flow Statement for the year ended 31st March 2026

Amount (in ₹ Lakhs)

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
D. Net Increase / (Decrease) in Cash & Cash Equivalents(A+B+C)	**1.97**	**(0.36)**
E. Cash & Cash Equivalents at Beginning of period	0.68	1.03
F. Cash & Cash Equivalents at End of period	2.64	0.68
G. Net Increase / (Decrease) in Cash & Cash Equivalents(F-E)	**1.97**	**(0.36)**

Notes:

1. The Cash Flow Statement has been prepared by Indirect Method as per AS-3 issued by ICAI.
2. Figures of previous year have been rearranged / regrouped wherever necessary
3. Figures in brackets are outflow / deductions

SIGNIFICANT ACCOUNTING POLICIES & NOTES TO THE ACCOUNTS 2

The accompanying notes are an integral part of the financial statements.

As per our report of even date
For VIJAY K JAIN & ASSOCIATES
Chartered Accountants
Firm Registration No: 006719C

CA SUNNY JAIN
Partner
Membership No. 429107
Place: Indore
Date: 27.07.2026

For and on behalf of the Board of Directors
of Bio Medica Laboratories limited

Mukesh Mehta
Director
DIN: 03187420

Pradeep Mehta
Director
DIN: 07254862

Pratiksha Bhandari
Company Secretary
PAN: AQLPB2934M

Santosh Kale
CFO
PAN:

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Significant Accounting Policies and Notes to Standalone Financial statements for the year ended 31st March 2026

Note 3: Share Capital

Particulars	As at 31st March 2026	As at 31st March 2025
Authorised		
1,60,00,000 (31st March 2025: 1,60,00,000) Equity shares of INR 10.00 par value	1600.00	1600.00
Issued		
91,80,001 (31st March 2025: 91,80,001) Equity shares of INR 10.00 par value	918.00	918.00
Subscribed and paid up		
91,80,001 (31st March 2025: 91,80,001) Equity shares of INR 10.00 par value	918.00	918.00
Total	918.00	918.00

A. Reconciliation of the Shares outstanding at the beginning and at the end of the reporting period

Equity shares

	For the year ended 31st March 2026	For the year ended 31st March 2025
	No. of Shares	No. of Shares
At the beginning of the period	91,80,001	1,00,000
Issued during the Period	-	90,80,001
Redeemed or bought back during the period	-	-
Outstanding at end of the period	**91,80,001**	**91,80,001**

B. Right, Preferences and Restriction attached to shares

(i) The company has only one class of Equity having a par value Rs. 10.00 per share.

(ii) Each shareholder is eligible for one vote per share held.

(iii) The dividend proposed by board of directors is subject to the approval of the shareholders in ensuing Annual General Meeting, except in case of interim dividend.

(iv) During the year ended 31st March 2026, no dividend was declared by the company (31st March 2025: Nil)

(v) In the event of liquidation, the Equity shareholders are eligible to receive the remaining assets of the company after distribution of all preferential amounts, in proportion to their shareholding.

C. Details of shareholders holding more than 5% shares in the company

Name of Shareholders	As at 31st March 2026	
	No. of Shares	%
Pradeep Mehta	45,89,725	49.997%
Mukesh Mehta	45,89,816	49.998%
	91,79,541	**99.995%**

Name of Shareholders	As at 31st March 2025	
	No. of Shares	%
Pradeep Mehta	45,89,725	49.997%
Mukesh Mehta	45,89,816	49.998%
	91,79,541	**99.995%**

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Significant Accounting Policies and Notes to Standalone Financial statements for the year ended 31st March 2026

D. Details of shares held by Promoters

Equity Shares

Sr. No.	Promoter's name	As at 31st March 2026		
		Number of shares	% holding	% Change
1.	Pradeep Mehta	45,89,725	49.997%	0%
2.	Mukesh Mehta	45,89,816	49.998%	0%
Total		**91,79,541**	**99.995%**	

Sr. No.	Promoter's name	As at 31st March 2025		
		Number of shares	% holding	% Change
1.	Pradeep Mehta	45,89,725	49.997%	0%
2.	Mukesh Mehta	45,89,816	49.998%	0%
Total		**91,79,541**	**99.995%**	

E. Aggregate no. of shares allotted as fully paid up without payment of cash/in bonus and share bought back in last five years

Particulars	Aggregate No. Of Shares In Last 5 Years	
	Current Year	Previous Year
Equity Shares		
Fully paid up by way of bonus shares	90,80,110	90,80,110

Note 4: Reserves and Surplus

Particulars	As at 31st March 2026	As at 31st March 2025
Surplus		
Opening Balance	555.30	524.48
Add: Profit for the year	1166.95	970.41
Less: Issue of fully paid bonus shares	-	908.00
Less: Prior Period Gratuity	-	31.58
Closing Balance (b)	1722.25	555.30
Balance carried to balance sheet (a+b)	**1722.25**	**555.30**

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Significant Accounting Policies and Notes to Standalone Financial statements for the year ended 31st March 2026

Note 5: Long term borrowings

Particulars	As at 31st March 2026	As at 31st March 2025
(a) Term Loan		
From Banks		
Secured		
Kotak Mahindra Bank (5933CL0100000119)	35.27	54.13
Kotak Mahindra Bank (5933TL0100000400)	42.74	52.07
Kotak Mahindra Bank (5933TL0100000521)	81.40	98.62
Kotak Mahindra Bank (LAP-13622800)	49.06	59.01
Kotak Mahindra Bank (LAP-18312485)	82.75	91.65
Kotak Mahindra Bank (LAP-18400788)	107.02	117.06
Kotak Mahindra Bank (LAP-18782388)	130.81	155.95
Kotak Mahindra Bank (LAP-19028771)	222.66	237.39
Kotak Mahindra Bank (LAP-19461797)	225.41	-
Bank of India -Car Loan (409)	22.89	-
Bank of India -Car Loan (416)	44.75	
Subtotal	**1044.76**	**865.88**
(b) Loans and advances from related parties		
Unsecured		
Directors		
Mukesh Mehta	334.29	156.55
Pradeep Mehta	385.14	154.74
Related Parties		
Lokesh Jain	20.18	20.72
Subtotal	**739.61**	**332.00**
Less: Current maturities of long term debts [Disclosed under short term borrowings, Refer Note 8]	(158.56)	(189.40)
Net Amount	**1625.81**	**1008.49**

5A. Terms and Conditions of Borrowings

Name of Loan	ROI	No of EMIs	Amount of EMI
Kotak Mahindra Bank (5933CL0100000119)	8.30%	60	1.90
Kotak Mahindra Bank (5933TL0100000400)	9.80%	84	1.12
Kotak Mahindra Bank (5933TL0100000521)	8.05%	60	2.03
Kotak Mahindra Bank (LAP-13622800)	9.90%	120	1.35
Kotak Mahindra Bank (LAP-18312485)	8.00%	120	1.52
Kotak Mahindra Bank (LAP-18400788)	7.40%	120	1.77
Kotak Mahindra Bank (LAP-18782388)	9.10%	84	3.30
Kotak Mahindra Bank (LAP-19028771)	9.00%	144	2.85
Kotak Mahindra Bank (LAP-19461797)	9.35%	120	3.09
Bank of India -Car Loan (409)	11.00%	84	0.38
Bank of India -Car Loan (416)	11.00%	84	0.73

VIJAY K. JAIN & ASSOCIATES INDORE CHARTERED ACCOUNTANTS

BIO MEDICA LABORATORIES LTD. INDORE

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Significant Accounting Policies and Notes to Standalone Financial statements for the year ended 31st March 2026

Loans guaranteed by directors and others

Name of loan	Guaranteed By	Guarantee Amount
Kotak Mahindra Bank (5933CL0100000119)	Pradeep Mehta, Mukesh Mehta, Bio Medica Parentals	60.00
Kotak Mahindra Bank (5933TL0100000400)	Pradeep Mehta, Mukesh Mehta, Bio Medica Parentals	70.00
Kotak Mahindra Bank (5933TL01000000521)	Pradeep Mehta, Mukesh Mehta, Bio Medica Parentals	100.00
Kotak Mahindra Bank (LAP-13622800)	Pradeep Mehta, Mukesh Mehta, Bio Medica Parentals	102.50
Kotak Mahindra Bank (LAP-18312485)	Pradeep Mehta, Mukesh Mehta.	125.00
Kotak Mahindra Bank (LAP-18400788)	Pradeep Mehta, Mukesh Mehta, Bio Medica Parentals	150.00
Kotak Mahindra Bank (LAP-18762388)	Pradeep Mehta, Mukesh Mehta, Bio Medica Parentals	220.00
Kotak Mahindra Bank (LAP-19028771)	Pradeep Mehta, Mukesh Mehta, Bio Medica Parentals	250.00
Kotak Mahindra Bank (LAP-19461797)	Pradeep Mehta, Mukesh Mehta, Bio Medica Parentals	240.00
Bank of India -Car Loan (409)	Pradeep Mehta, Mukesh Mehta	24.30
Bank of India -Car Loan (416)	Pradeep Mehta, Mukesh Mehta	47.00
HDFC Bank Ltd. CC	Pradeep Mehta, Mukesh Mehta	495.00
Kotak Mahindra Bank O.D.	Pradeep Mehta, Mukesh Mehta, Bio Medica Parentals	500.00

Nature of security for secured borrowings

Name of loan	Nature of security
Kotak Mahindra Bank (5933CL0100000119)	First charge on plant and machinery and other fixed assets of the company (primary security) and equitable mortgage of factory land and building and factory land and building of promoter's partnership firm (Collateral security).
Kotak Mahindra Bank (5933TL0100000400)	
Kotak Mahindra Bank (5933TL01000000521)	
Kotak Mahindra Bank (LAP-13622800)	Equitable mortgage of factory land and building of promoter's partnership firm.
Kotak Mahindra Bank (LAP-18312485)	Equitable mortgage of factory land and building of company.
Kotak Mahindra Bank (LAP-18400788)	Equitable mortgage of factory land and building of company and factory land and building of promoter's partnership firm.
Kotak Mahindra Bank (LAP-18762388)	
Kotak Mahindra Bank (LAP-19028771)	
Kotak Mahindra Bank (LAP-19461797)	
Bank of India -Car Loan (409)	Earmarked Vehicle
Bank of India -Car Loan (416)	Earmarked Vehicle

5B. Unsecured Loans taken from directors

Unsecured loans have been taken from the directors at 10.00% rate of interest and there is no written agreement for repayment terms. Though the same are generally repayable on demand, but keeping in view the terms of bank loans i.e. "Unsecured loans not to be withdrawn during the currency of bank loan", the same is considered to be of long term nature and have been classified accordingly.

5C. Continuing default of repayment of Loans and interest

The company does not have any continuing defaults in repayment of loans and interest as at the reporting date.

Note 6: Other Long Term Liabilities

Particulers	As at 31st March 2026	As at 31st March 2025
Advance Against Property	62.00	31.00
Total	**62.00**	**31.00**

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Significant Accounting Policies and Notes to Standalone Financial statements for the year ended 31st March 2026

Note 7: Long-term provisions

Particulars	As at 31st March 2026	As at 31st March 2025
(a) Provision for employee benefits		
Provision for gratuity	38.09	31.58
Total	**38.09**	**31.58**

Note 8: Short-term borrowings

Particulars	As at 31st March 2026	As at 31st March 2025
(a) Loans repayable on demand		
From Banks		
Secured		
HDFC Bank Ltd. CC	331.17	-
Kotak Mahindra Bank O.D.	173.59	303.55
Subtotal	**504.76**	**303.55**
(b) Current maturities of long-term debt (Refer Note 5)	158.56	189.40
Subtotal	**158.56**	**189.40**
Total	**663.32**	**492.95**

8A. Terms and Conditions of Borrowings

(i) Cash Credit limit from HDFC bank and Kotak Mahindra Bank is secured against all current assets of the company and carries interest rate of 9%. The loan is repayable on demand. Loan is secured by collateral security of factory land and building of the company

(ii) Current maturities of long-term debt: Refer Note 5A and 5B for terms and conditions

8B. Continuing default of repayment of Loans and Interest

The company does not have any continuing defaults in repayment of loans and interest as at the reporting date.

Note 9: Trade Payables

Particulars	As at 31st March 2026	As at 31st March 2025
Total outstanding dues of micro enterprises and small enterprises [Refer Note 9(a) below]		
Trade payables	20.29	32.71
Subtotal	**20.29**	**32.71**
Total outstanding dues of creditors other than micro enterprises and small enterprises		
Others	237.70	395.05
Subtotal	**237.70**	**395.05**
Total	**257.99**	**427.76**

Note 9(a) : Disclosure Under Micro Small And Medium Enterprises Development Limited

Particulars	As at 31st March 2026	As at 31st March 2025
The principal amount and interest due thereon outstanding	-	-
The Principal amount paid beyond appointed dates	-	-
The Interest amount paid on delay payments	-	-
The Amount Interest Due and Payable (Principal already paid)	-	-
The Amount of Interest Accrued and unpaid	-	-

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Significant Accounting Policies and Notes to Standalone Financial statements for the year ended 31st March 2026

Note 9(b): Trade Payables Ageing Schedule

Particulars	Not due	Outstanding from due date of payment				Total
		Less than 1 year	1-2 years	2-3 years	More than 3 years	
As at 31st March 2026						
(i) MSME	-	20.29	-	-	-	20.29
(ii) Others	-	175.17	37.11	25.42	-	237.70
(iii) Disputed dues- MSME	-	-	-	-	-	-
(iv) Disputed dues- Others	-	-	-	-	-	-
Total	-	**195.46**	**37.11**	**25.42**	-	**257.99**
As at 31st March 2025						
(i) MSME	-	32.71	-	-	-	32.71
(ii) Others	-	395.05	-	-	-	395.05
(iii) Disputed dues- MSME	-	-	-	-	-	-
(iv) Disputed dues- Others	-	-	-	-	-	-
Total	-	**427.76**	-	-	-	**427.76**

Note 10: Other current liabilities

Particulars	As at 31st March 2026	As at 31st March 2025
(a) Statutory dues		
GST RCM Payable	0.02	0.02
TDS/TCS Payable	1.68	2.22
Professional Tax -Employee	-	0.18
Employee Provident Fund	0.61	0.16
ESIC	0.07	0.04
Subtotal	**2.38**	**2.61**
(b) Employee benefits payable		
Salary Payable	26.28	36.69
Director Remuneration	5.52	5.96
Bonus Payable	4.09	4.05
Subtotal	**35.88**	**46.70**
(b) Interest accrued and due on borrowings		
Interest payable (TL and LAP)	5.45	5.19
Subtotal	**5.45**	**5.19**
(c) Other payables		
Audit Fees	0.54	0.30
Electricity Payable	2.98	8.26
Telephone Exp. Payable	0.01	0.01
Creditors for expenses	24.88	31.00
Advance from Customers (Due for settlement within 12 months)	60.88	-
Subtotal	**89.30**	**39.58**
Total	**133.02**	**94.07**

VIJAY K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS INDORE

BIO MEDICA LABORATORIES LTD. INDORE

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Significant Accounting Policies and Notes to Standalone Financial statements for the year ended 31st March 2026

Note 11: Short-term provisions

Particulars	As at 31st March 2026	As at 31st March 2025
(a) Provision for employee benefits		
Gratuity	11.87	7.45
Subtotal	**11.87**	**7.45**
(b) Other Provisions		
Current Tax (refer note 11(a))	313.49	303.52
Subtotal	**313.49**	**303.52**
Total	**325.36**	**310.97**

Note 11(a): Current Tax

Particulars	As at 31st March 2026	As at 31st March 2025
Current Tax	417.18	343.52
Less: Advance Tax	(100.00)	(40.00)
Less: TDS/TCS	(3.70)	-
Total	**313.49**	**303.52**

Note 12: Property, Plant and Equipment and Intangible assets

Particulars	As at 31st March 2026	As at 31st March 2025
(i) Property, Plant and Equipment [Refer Note 12A]	692.27	767.56
(ii) Intangible assets	-	-
(iii) Capital work-in-Progress	-	-
Total	692.27	767.56

Note 13: Non current investments

Particulars	As at 31st March 2026	As at 31st March 2025
Non Trade Investments (Valued at cost unless stated otherwise)		
(a) Investments in Equity Instruments		
Unquoted		
Investments in Subsidiary	0.51	-
Total	0.51	-

Note 13(a)

Particulars	As at 31st March 2026	As at 31st March 2025
Aggregate amount of unquoted investments in subsidiary	0.51	-

Note 13(b) Investments in Equity Instruments unquoted non-trade

Name of Subsidiary	Share in Equity	
	As at 31st March 2026	As at 31st March 2025
Vitamax Healthcare Private Limited	51.00%	-
	51.00%	-

BIO MEDICA LABORATORIES LTD. INDORE

VIJAY K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS INDORE

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Significant Accounting Policies and Notes to Standalone Financial statements for the year ended 31st March 2026

Note 14: Deferred tax assets (net)

Particulars	As at 31st March 2026	As at 31st March 2025
Opening Balance	20.01	10.84
Deferred Tax Asset / (Liability) [Refer Note 32]	10.61	9.17
Total	**30.61**	**20.01**

Note 15: Long-term loans and advances

Particulars	As at 31st March 2026	As at 31st March 2025
(a) Capital advances		
Unsecured, considered good		
Advance for machinery	4.00	4.00
(b) Loans and advances to related parties		
Unsecured, considered good		
Advance to subsidiary Company	155.46	-
Loan to subsidiary Company	12.50	
Less: Allowance for bad and doubtful loans and advances	-	-
Total	**171.97**	**4.00**

Note 16: Other non-current assets

Particulars	As at 31st March 2026	As at 31st March 2025
(a) Security Deposits		
MPEB	6.75	7.45
National Stock Exchange	1.17	0.90
Natural Gas	5.10	5.10
Total	**13.01**	**13.44**

Note 17: Inventories

Particulars	As at 31st March 2026	As at 31st March 2025
(a) Raw Material [Valued at cost]	2620.44	1152.41
(b) Finished Goods [Valued at lower of cost or NRV]	215.09	113.00
(c) Work in Progress [Valued at cost]	76.74	36.04
(d) Others		
Packing Material [Valued at lower of cost or NRV]	418.28	512.33
Total	**3330.55**	**1813.79**

Note 18: Trade Receivables

Particulars	As at 31st March 2026	As at 31st March 2025
Secured, Considered good	-	-
Unsecured, Considered Good	907.06	410.02
Doubtful	-	-
Less: Allowance for bad and doubtful debts		
Total	**907.06**	**410.02**

BIO MEDICA LABORATORIES LTD. INDORE

INDORE

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Significant Accounting Policies and Notes to Standalone Financial statements for the year ended 31st March 2026

Note 18(a): Trade Receivables ageing schedule

Particulars	Not due	Outstanding from due date of payment					Total
		Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
As at 31st March 2026							
(i) Undisputed Trade receivables – considered good	-	842.77	34.60	-	29.68	-	907.06
(ii) Undisputed Trade Receivables – considered doubtful	-	-	-	-	-	-	-
(iii) Disputed Trade Receivables considered good	-	-	-	-	-	-	-
(iv) Disputed Trade Receivables considered doubtful	-	-	-	-	-	-	-
Total	**-**	**842.77**	**34.60**	**-**	**29.68**	**-**	**907.06**
As at 31st March 2025							
(i) Undisputed Trade receivables – considered good	-	403.39	6.63	-	-	-	410.02
(ii) Undisputed Trade Receivables – considered doubtful	-	-	-	-	-	-	-
(iii) Disputed Trade Receivables considered good	-	-	-	-	-	-	-
(iv) Disputed Trade Receivables considered doubtful	-	-	-	-	-	-	-
Total	**-**	**403.39**	**6.63**	**-**	**-**	**-**	**410.02**

Note 19: Cash and cash equivalents

Particulars	As at 31st March 2026	As at 31st March 2025
Balances with banks	0.03	0.03
Cheques, drafts on hand	-	-
Cash on hand	2.61	0.64
Total	**2.64**	**0.68**

Note 20: Short-term loans and advances

Particulars	As at 31st March 2026	As at 31st March 2025
(a) Others		
Unsecured, considered good		
Advance to Staff	4.37	6.35
Advance to parties	457.25	746.17
Subtotal	**461.62**	**752.52**
Less: Allowance for bad and doubtful loans and advances	-	-
Total	**461.62**	**752.52**

Note 21: Other current assets

Particulars	As at 31st March 2026	As at 31st March 2025
Prepaid Expenses	3.91	3.42
Prepaid IPO Expenses	41.75	12.90
TDS/TCS	0.58	1.42
GST Receivable	89.35	70.38
Total	**135.60**	**88.12**

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Significant Accounting Policies and Notes to Standalone Financial statements for the year ended 31st March 2026

Note 22: Revenue from operations

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
(a) Sale of products		
Domestic sales of manufactured medical products	3714.41	3806.43
Export Sales of manufactured medical products	39.33	-
Trading sales of medical products	63.92	13.09
Less: Goods in transit	-	-
Subtotal	**3817.66**	**3819.52**
(b) Other operating revenues		
Other operating income	12.00	12.45
Subtotal	**12.00**	**12.45**
Net revenue from operations	**3829.66**	**3831.97**

Note 23: Other income

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
(a) Interest income		
MPPKVVCL	0.40	-
Interest from Income Tax Refund	-	0.20
Interest from Party	12.50	-
Subtotal	**12.90**	**0.20**
(b) Other non-operating income		
Exchange Rate Differences	0.02	0.32
Custom Duty Drawback	0.47	-
Subtotal	**0.49**	**0.32**
Total	**13.39**	**0.53**

Note 24: Cost of materials consumed

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
Inventory at the begining		
Raw Materials	1152.41	100.34
Packing Materials	512.33	504.67
Subtotal	**1664.75**	**605.01**
Add: Purchase during the year		
Raw Materials	2460.06	2034.13
Packing Materials	532.43	940.24
Subtotal	**2992.49**	**2974.37**
Less: Inventory at the end		
Raw Material	2620.44	1152.41
Packing Materials	418.29	512.33
Subtotal	**3038.73**	**1664.75**

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Significant Accounting Policies and Notes to Standalone Financial statements for the year ended 31st March 2026

Cost of materials consumed		
Raw Material	992.03	982.06
Packing Materials	626.48	932.58
Subtotal	**1618.51**	**1914.63**
Total	**1618.51**	**1914.63**

Note 24(a): Value of import and indigenous material consumed

Particulars	Unit of Measurement	For the year ended 31st March 2026		For the year ended 31st March 2025	
		Value	% to total Consumption	Value	% to total Consumption
Raw Material					
Imported		-	-	-	-
Indigenous		1618.51	100.00%	1914.63	100.00%
Total		**1618.51**	**100.00%**	**1914.63**	**100.00%**

Note 25: Purchase of Stock in Trade

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
Trading Purchases	47.20	12.22
Total	**47.20**	**12.22**

Note 26: Changes in inventories of finished goods work-in-progress and stock in-trade

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
Inventory at the beginning of the year		
Work in Progress	36.04	34.65
Finished Goods	113.00	97.03
Subtotal	**149.04**	**131.68**
Inventory at the end of the year		
Work in Progress	76.74	36.04
Finished Goods	215.09	113.00
Subtotal	**291.82**	**149.04**
(Increase)/decrease in inventories		
Work in Progress	(40.69)	(1.40)
Finished Goods	(102.09)	(15.97)
Total	**(142.78)**	**(17.37)**

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Significant Accounting Policies and Notes to Standalone Financial statements for the year ended 31st March 2026

Note 27: Employee benefit expenses

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
Salaries and wages		
Direct wages (Manufacturing)	116.73	76.36
Bonus	4.09	12.83
Salary and wages	50.18	49.14
Director's remuneration	48.00	48.00
Gratuity	10.93	5.72
Subtotal	**229.92**	**192.05**
Contribution to provident and other funds		
ESIC	0.76	0.44
Employer Contribution EPF	3.31	1.82
Subtotal	**4.07**	**2.26**
Staff welfare expenses		
EPF Administration Charges	0.14	0.06
Staff welfare expenses	0.16	0.16
Subtotal	**0.31**	**0.22**
Total	**234.30**	**194.53**

Note 28: Finance costs

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
Interest expense		
Working Capital	36.56	24.21
Machinery Term Loan	93.83	80.76
Car Loan	2.57	-
Unsecured Loans	48.67	11.87
Subtotal	**181.63**	**116.84**
Other borrowing costs		
Loan renewal exp	8.18	2.67
Subtotal	**8.18**	**2.67**
Applicable (net gain) / loss on foreign currency transactions and translation	-	-
Subtotal	-	-
Total	**189.81**	**119.51**

Note 29: Depreciation and amortization expenses

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
Depreciation on tangible Assets	91.53	100.54
Depreciation on intangible Assets	-	-
Total	**91.53**	**100.54**

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Significant Accounting Policies and Notes to Standalone Financial statements for the year ended 31st March 2026

Note 30: Other expenses

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
Factory Expenses	9.69	2.64
Power and fuel	90.00	94.06
Repairs to machinery	2.62	2.66
Repairs to Building	2.23	2.88
Insurance	7.58	2.18
Rates and taxes, excluding, taxes on income	0.27	7.65
Interest Income Tax / TDS	32.57	15.91
Professional Tax	0.03	0.03
Property Tax	6.31	1.59
Statutory Audit Fees	0.60	0.50
Professional Fees	1.70	2.09
Carriage inward	8.72	10.98
Commission on Sales	12.28	2.00
Director Sitting Fees	4.20	1.20
Legal & Professional fees	8.72	30.30
Factory Rent and Maintenance	1.20	1.20
Vehicle Running	1.15	0.57
Corporate Social Responsibility	11.70	-
Miscellaneous expenses	29.88	14.96
Travelling Expenses	1.64	0.84
Loss on Sale of Plant and Machinery	1.76	-
Total	**235.07**	**194.18**

Note 31: Deferred tax

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
(a) Tax effect of items constituting deferred tax liability / asset		
On expenses allowed only on payment		
Provision for gratuity	10.93	5.72
(b) Difference on account of Depreciation		
Depreciation as per Companies Act	91.53	100.54
Depreciation as per Income Tax Act	60.31	69.83
Difference	31.22	30.71
Total timing difference	42.14	36.43
Deferred tax asset / (liability) @25.168%	**10.61**	**9.17**
Deferred tax debited / (credited) to profit and loss account	**10.61**	**9.17**

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (In ₹ Lakhs)

Significant Accounting Policies and Notes to Standalone Financial statements for the year ended 31st March 2026

Note 32: Earnings per share

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
<u>Basic EPS</u>		
Net profit / (loss) for the year from Total operations	1166.95	970.41
Less: Preference dividend and tax thereon	-	-
(a) Net profit / (loss) for the year attributable to the equity shareholders	1166.95	970.41
(b) Year end number of equity shares	91,80,001	91,80,001
Par value per share (INR)	10.00	10.00
Earnings per share from continuing operations - Basic (INR) (a/b)	**12.71**	**10.57**
<u>Diluted EPS **</u>		
Net profit / (loss) for the year from Total operations	1166.95	970.41
Less: Preference dividend and tax thereon	-	-
Net profit / (loss) for the year attributable to the equity shareholders	1166.95	970.41
Add: Interest expense and exchange fluctuation on convertible bonds (net)	-	-
(a) Profit / (loss) attributable to equity shareholders (on dilution)	1166.95	970.41
Year end number of equity shares	91,80,001	91,80,001
Add: Effect of Warrants, ESOPs and Convertible bonds which are dilutive	-	-
(b) Year end number of equity shares - for diluted EPS	91,80,001	91,80,001
Par value per share (INR)	10.00	10.00
Earnings per share - Diluted (a/b)	**12.71**	**10.57**

Note: The diluted earnings per share has been computed by dividing the net profit after tax available for equity shareholders by the weighted average number of equity shares, after giving dilutive effect of the outstanding warrants, stock options and convertible bonds for the respective periods. Since, the effect of the conversion of preference shares was anti-dilutive, it has been ignored.

Note: 12A

Property, plant and equipment and intangible assets

Amount (in ₹ Lakhs)

	Gross Block				Depreciation				Net Block	
Property, plant and equipment	**Opening Balance**	**Additions During the Year**	**Deletion During the Year**	**Closing Balance**	**Opening Balance**	**Provided During the year**	**Deletions/Adjustments during the year**	**Closing Balance**	**As at current year end**	**As at previous year end**
Buildings	565.67	3.73	–	569.41	128.74	41.55	–	170.30	399.11	436.93
Furniture and fixtures	16.42	0.80	–	17.22	11.16	1.57	–	12.72	4.50	5.26
Land	–	–	–	–	–	–	–	–	–	–
Office equipment	10.50	–		10.50	9.79	0.46	–	10.25	0.25	0.71
Plant and equipment	507.88	4.27	58.10	454.05	208.14	37.98	–	246.12	207.93	299.74
Plant and equipment (Held for Sale)	41.30	–	26.55	14.74	19.80	–	12.73	7.07	7.68	21.50
Vehicles	30.11	79.36	–	109.47	26.69	9.98	–	36.67	72.80	3.42
Property, plant and equipment (Sub-total)	**1171.89**	**88.16**	**84.65**	**1175.40**	**404.33**	**91.53**	**12.73**	**483.13**	**692.27**	**767.56**
GRAND TOTAL	**1171.89**	**88.16**	**84.65**	**1175.40**	**404.33**	**91.53**	**12.73**	**483.13**	**692.27**	**767.56**

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Significant Accounting Policies and Notes to Standalone Financial statements for the year ended 31st March 2026

Note No. : 01
Company Information

This financial statements of Bio Medica Laboratories Limited (Formerly known as Bio Medica Laboratories Private Limited) (hereinafter referred to as the "Company"), for the year ended March 31, 2026.
The company is a public company domiciled in India and is incorporated under the provisions of the Companies Act, 1956 ("the Act"). The registered office of the Company is located at Plot No. 11B-11C,Sctor-E, Sanwer Road , Industrial Area , Indore (MP).
The principal place of business of the Company is in India. The Company is in the business of manufacturing and selling of Medicals items such as Injection, Tablets etc.

Note No. : 02
Significant Accounting Policies
(1) Basis of accounting:-

These financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) including the Accounting Standards notified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and the relevant provisions of the Companies Act, 2013.
The financial statements have been prepared under the historical cost convention on accrual basis.
All the amounts included in the Financial Statements are presented in Indian Rupees ('Rupees' or 'Rs.' Or 'INR') and are rounded to the nearest Lakhs, except per share data and unless stated otherwise.

(2) Use of Estimates :-

The preparation of financial statements in conformity with Indian GAAP requires the management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the disclosure of contingent liabilities, at the end of the reporting period. Although these estimates are based on the management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

(3) Revenue Recognition: -

Revenue is recognised in accordance with the principles laid down in Accounting Standard (AS) 9 - Revenue Recognition, as notified under the Companies (Accounting Standards) Rules, 2021.
Revenue is only recognised to the extent that it is highly probable that a significant reversal will not occur. The specific revenue recognition criteria described below must also be met before revenue is recognized. Cash received before the sale of goods is recognised as a contract liability.

Sale of Goods

Revenue from sale of goods is recognized when all the significant risks and rewards of ownership of the goods have been passed to the buyer, there is no continuing managerial involvement with the goods, the amount of revenue can be reliably measured, and it is probable that economic benefits associated with the transaction will flow to the entity. Sales are presented net of GST collected on behalf of the Government, trade discounts and returns, as applicable.
In case where goods have been dispatched but the conditions for revenue recognition are not met as at the reporting date - particularly where delivery is in transit and the transfer of control or risk and rewards has not occurred - the sale is not recognised. Such goods are included under inventories as "Finished Goods in Transit", measured at cost in accordance with the company's inventory accounting policy.

Other Operating Revenue

Any revenue accruing during the normal course of business of the company other than by way of main business activity of selling of manufactured items is treated as other operating revenue.

Interest Income

Interest income is recognised on a time proportion basis taking into account the amount outstanding and the applicable interest rate. Interest income is included under the head "other income" in the statement of profit and loss account.

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Significant Accounting Policies and Notes to Standalone Financial statements for the year ended 31st March 2026

(4) Property, Plant & Equipment :-

Property, Plant & Equipment including intangible assets are stated at their original cost of acquisition including taxes, freight and other incidental expenses related to acquisition and installation of the concerned assets less depreciation till date.

Subsequent costs are capitalized on the carrying amount or recognized as a separate asset, as appropriate, only when future economic benefits associated with the item are probable to flow to the Company and cost of the item can be measured reliably. When significant parts of property, plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their specific useful lives. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All repair and maintenance are charged to statement of profit and loss during the reporting period in which they are incurred.

Advances paid towards the acquisition of property, plant and equipment outstanding at each balance sheet date is classified as capital advances under the non-current assets and the cost of assets not ready to use before such date are disclosed under 'Capital work in progress'.

The gain or loss arising on the disposal or retirement of an item of property, plant and equipment is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognized in the statement of profit and loss on the date of disposal or retirement.

Company has adopted cost model for all class of items of Property Plant and Equipment.

(5) Depreciation :-

Depreciation on Fixed Assets is provided to the extent of depreciable amount on the Written down Value (WDV) Method. Depreciation is provided based on useful life of the assets as prescribed in Schedule II to the Companies Act, 2013.

All fixed assets individually costing Rs. 5,000/- or less are fully depreciated in the year of installation/purchase.

Depreciation on assets acquired/sold during the year is recognized on a pro-rata basis to the statement of profit and loss till the date of acquisition/sale.
The carrying amount of assets is reviewed at each balance sheet date if there is any indication of impairment based on internal/external factors. An impairment loss is recognized wherever the carrying amount of an asset exceeds its recoverable amount. The recoverable amount is the greater of the assets, net selling price and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and risks specific to the asset.

After impairment, depreciation is provided on the revised carrying amount of the asset over its remaining useful life.

(6) Financial Instruments - Trade Reeivables: -

Provision is made for doubtful trade receivables based on a management estimate of expected credit loss, considering ageing, specific identification and past recovery trends.
The Company provides for doubtful debts as follows:
- 20% of the value of undisputed trade receivables considered doubtful.
- 50% of the value of disputed trade receivables considered doubtful based on management's assessment of recoverability.

These estimates are reviewed periodically and adjusted as needed based on actual recoverability.

(7) Segment Reporting: -
The company is operating in one segment only i.e. manufacturing and sale of medical items and hence no separate reportable segment.

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Significant Accounting Policies and Notes to Standalone Financial statements for the year ended 31st March 2026

(8) Investments: -

Investments, which are readily realizable and intended to be held for not more than one year from the date on which such investments are made, are classified as current investments. All other investments are classified as non-current investments.
On initial recognition, all investments are measured at cost. The cost comprises purchase price and directly attributable acquisition charges such as brokerage, fees and duties.
On disposal of an investment, the difference between its carrying amount and net disposal proceeds is charged or credited to the statement of profit and loss.

(9) Inventories :-

Raw materials are valued at cost, packing materials are valued at lower of cost and net realizable value. Cost of raw materials and packing materials are determined on First in First out (FIFO) basis.

Work-in-progress and finished goods are valued at lower of cost and net realizable value. Cost includes direct materials and labour and a proportion of manufacturing overheads based on normal operating capacity. Cost is determined on FIFO basis.

Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and estimated costs necessary to make the sale.

(10) Retirement Benefits :-

For defined benefit plans, the liability or asset recognized in the statement of assets and liabilities on the basis of actuarial valuation at each year-end. Separate actuarial valuation is carried out for each plan using the projected unit credit method. Actuarial gains and losses for are recognized in full in the period in which they occur in the statement of profit and loss.

The Company's contributions to defined contribution plans (provident fund) are recognized in statement of profit and loss when the employee renders related service. The Company has no further obligations under these plans beyond its periodic contributions.

VIJAY K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS INDORE

BIO MEDICA LABORATORIES LTD. INDORE

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Significant Accounting Policies and Notes to Standalone Financial statements for the year ended 31st March 2026

(11) Foreign Currency Transactions :-

Transactions arising in foreign currencies during the year are converted at the rates closely approximating the rates ruling on the transaction dates. Liabilities and receivables in foreign currency are restated at the year-end exchange rates. All exchange rate differences arising from conversion in terms of the above are included in the statement of profit and loss.

(12) Government Grants :-

Government grants received in the form of capital subsidy related to specific assets are deducted directly from the gross block of the respective asset. Depreciation is charged on the net amount, i.e., after reducing the gross block by the amount of subsidy received. In cases where the amount of subsidy exceeds the carrying amount of the asset, no depreciation is charged and the carrying amount of the asset is reduced to nil.

The subsidy is recognized when there is reasonable assurance that the entity will comply with the conditions attached to it and the grant will be received.

(13) Taxes on Income :-

Provision for current tax is made on the basis of estimated taxable income for the current accounting year in accordance with the Income Tax Act, 1961.

The deferred tax for timing differences between the book and tax profits for the year is accounted for, using the tax rates and laws that have been substantively enacted by the balance sheet date. Deferred tax assets or liability arising from timing differences are recognized to the extent there is virtual certainty with convincing evidence that these would be realized or payable in future. At each Balance Sheet date, the carrying amount of deferred tax or liability is reviewed.

(14) Provisions, Contingent Liabilities and Contingent Assets (AS-29) :-

Provisions are recognized only when there is a present obligation as a result of past events and when a reliable estimate of the amount of the obligation can be made.

Contingent Liabilities is disclosed in Notes to the account for:-
(i) Possible obligations which will be confirmed only by future events not wholly within the control of the company or
(ii) Present Obligations arising from past events where it is not probable that an outflow of resources will be required to settle the obligation or a reliable estimate of the amount of the obligation cannot be made.

Contingent assets are not recognized in the financial statement since this may result in the recognition of the income that may never be realized.

(15) Borrowing costs :-

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalised as part of the cost of the asset. All other borrowing costs are expensed in the period in the statement of profit and loss in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.

(16) Cash and Cash Equivalents :-

The Company considers all highly liquid financial instruments, which are readily convertible into known amount of cash that are subject to an insignificant risk of change in value and having original maturities of three months or less from the date of purchase, to be cash equivalents.

VIJAY K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS INDORE

BIO MEDICA LABORATORIES LTD. INDORE

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Significant Accounting Policies and Notes to Standalone Financial statements for the year ended 31st March 2026

(17) Presentation of financial statements :-

The Balance Sheet and the Statement of Profit and Loss are prepared and presented in the format prescribed in the Schedule III to the Companies Act, 2013 ("the Act"). The disclosure requirements with respect to items in the Balance Sheet and Statement of Profit and Loss, as prescribed in the Schedule III to the Act, are presented by way of notes forming part of accounts along with the other notes required to be disclosed under the notified Accounting Standards as applicable.

(18) Basis of classification of Current and Non-current assets and liabilities :-

Assets and liabilities are classified as either current or non-current as per company's normal operating cycle and other criteria's set out in Schedule III of the Companies Act, 2013. Based on nature of products and services and time between acquisition of assets for processing and their realization in cash and cash equivalents, 12 months period has been considered by the company as its normal operating cycle.

(19) Expenses :-

Expenses are accounted on accrual basis and provisions are made for all known expenses, losses, and liabilities.

(20) Prior period items :-

Income and expenses which arises in the current year as a result of errors or omission in the preparation of financial statements of one or more prior periods were shown as prior period adjustments during the year.

(21) Earning Per Shares :-

Basic earnings per share is computed by dividing the profit / (loss) after tax (including the post-tax effect of extraordinary items, if any) by the weighted average number of equity shares outstanding during the year. Diluted earnings per share is computed by dividing the profit / (loss) after tax (including the post-tax effect of extraordinary items, if any) as adjusted for dividend, interest and other charges to expense or income relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares. Potential equity shares are deemed to be dilutive only if their conversion to equity shares would decrease the net profit per share from continuing ordinary operations. Potential dilutive equity shares are deemed to be converted as at the beginning of the period, unless they have been issued at a later date. The dilutive potential equity shares are adjusted for the proceeds receivable had the shares been actually issued at fair value (i.e. average market value of the outstanding shares). Dilutive potential equity shares are determined independently for each period presented. The number of equity shares and potentially dilutive equity shares are adjusted for share splits / reverse share splits and bonus shares, as appropriate.

(22) General :-

Except wherever stated, accounting policies are consistent with the generally accepted accounting principles and have been consistently applied.
Previous year figures have been regrouped / reclassified, wherever necessary to conform to the current year presentation.

VIJAY K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS INDORE

BIO MEDICA LABORATORIES LTD. INDORE

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Note No. 33: Other additional information to standalone financial statements

(1) Classification of creditors as per MSMED Act

The classification of creditors as micro and small enterprise has been given for the parties from whom the confirmation has been received regarding their classification as per MSMED Act. The interest on delayed payment to such parties, if any, has been calculated and booked as payable.

(2) Payment to auditors

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
Audit fees (excluding GST)	0.60	0.50
Total	**0.60**	**0.50**

(3) Disclosure in respect of pursuance of AS-29

Details of provisions

Particulars	As at 31st March 2025	Created during the year	Utilised during year	Reversed during year	As at 31st March 2026
Proposed Dividend	-	-	-	-	-
Provision for Gratuity	39.03	10.93	-	-	49.96
Corporate Dividend Tax	-	-	-	-	-
Provision for Income Tax (Net)	303.52	313.49	303.52	-	313.49

(4) Statement of Management

The current assets, loans and advances are good and recoverable and are approximately of the values, if realized in the ordinary courses of business unless and to the extent stated otherwise in the Accounts. Provision for all known liabilities is adequate and not in excess of amount reasonably necessary.

(5) Provision for retirement benefits

Provision for retirement benefit has been made on the basis of report by M/s Kandoi & Co. Actuaries, dated 08/05/2026.
Gratuity is payable to all the eligible employees at the rate of 15 days salary (Basic + D. A.) for each completed year of service, subject to a payment ceiling of INR 2,000,000, in line with Payment of Gratuity Act, 1972.
The formula to calculate daily salary is 1/26 * monthly salary and vesting period is 5 years.
In line with Gratuity Act, service more than 6 months is considered as 1 year, so past service is calculated as rounded years of service.
Gratuity shall be payable to an employee on termination of employment due to superannuation, retirement or resignation after successful completion of the vesting period. The completion of vesting period is not applicable in the case where termination of employment is due to death, disability.

Gratuity Disclosure Statement as Per Accounting Standard 15 (Revised 2005)

	Current Period	Previous Period
Particulars		
Type of Benefit	Gratuity	Gratuity
Country	India	India
Reporting Currency	INR	INR
	Accounting Standard 15	Accounting Standard 15
Reporting Standard	(Revised 2005)	(Revised 2005)
Funding Status	Unfunded	Unfunded
Starting Period	01-Apr-25	01-Apr-24
Date of Reporting	31-Mar-26	31-Mar-25
Period of Reporting	12 Months	12 Months

BIO MEDICA LABORATORIES LTD. INDORE

VIJAY K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS INDORE

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Note No. 33: Other additional information to standalone financial statements

	Current Period	Previous Period
Assumptions (Opening Period)		
Expected Return on Plan Assets	N.A.	N.A.
Rate of Discounting	6.55% p.a.	7.18% p.a.
Rate of Salary Increase	8.00% p.a.	8.00% p.a.
Attrition Rate	Directors: 5% p.a.; Others: 20% p.a.	Directors: 5% p.a.; Others: 20% p.a.
Mortality Rate During Employment	Indian Assured Lives Mortality (2012-14) Ultimate	Indian Assured Lives Mortality (2012-14) Ultimate

Assumptions (Closing Period)		
Expected Return on Plan Assets	N.A.	N.A.
Rate of Discounting	7.14% p.a.	6.55% p.a.
Rate of Salary Increase	8.00% p.a.	8.00% p.a.
Attrition Rate	Directors: 5% p.a.; Others: 20% p.a.	Directors: 5% p.a.; Others: 20% p.a.
Mortality Rate During Employment	Indian Assured Lives Mortality (2012-14) Ultimate	Indian Assured Lives Mortality (2012-14) Ultimate

BIO MEDICA LABORATORIES LTD. INDORE

VIJAY K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS INDORE

BIO MEDICA LABORATORIES LIMITED

(Formerly known as Bio Medica Laboratories Private Limited)

CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Note No. 33: Other additional information to standalone financial statements

	Current Period	Previous Period
Table Showing Change in the Present Value of Defined Benefit Obligation		
Present Value of Benefit Obligation at the Beginning of the Period	39.03	33.31
Interest Cost	2.56	2.39
Current Service Cost	5.02	4.05
Past Service Cost - Non-Vested Benefit Incurred During the period	-	-
Past Service Cost - Vested Benefit Incurred During the Period	-	-
Liability Transferred In/ Acquisitions	-	-
(Liability Transferred Out/ Divestments)	-	-
(Benefit Paid Directly by the Employer)	-	-
(Benefit Paid From the Fund)	-	-
Actuarial (Gains)/Losses on Obligations - Due to Change in Demographic Assumptions	-	-
Actuarial (Gains)/Losses on Obligations - Due to Change in Financial Assumptions	(1.50)	1.41
Actuarial (Gains)/Losses on Obligations - Due to Experience Adjustment	4.85	(2.13)
Present Value of Benefit Obligation at the End of the Period	49.96	39.03

Table Showing Change in the Fair Value of Plan Assets		
Fair Value of Plan Assets at the Beginning of the Period	-	-
Expected Return on Plan Assets	-	-
Contributions by the Employer	-	-
Assets Transferred In/Acquisitions	-	-
(Assets Transferred Out/ Divestments)	-	-
(Benefit Paid from the Fund)	-	-
Actuarial Gains/(Losses) on Plan Assets - Due to Experience Adjustment	-	-
Fair Value of Plan Assets at the End of the Period	-	-

BIO MEDICA LABORATORIES LTD. INDORE

VIJAY K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS INDORE

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Note No. 33: Other additional information to standalone financial statements

	Current Period	Previous Period
Actual Return on Plan Assets		
Expected Return on Plan Assets	-	-
Actuarial Gains/(Losses) on Plan Assets - Due to	-	-
Experience Adjustment		
Actual Return on Plan Assets	-	-

Actuarial (Gains)/Losses Recognized in the Statement of Profit or Loss for Current Period		
Actuarial (Gains)/Losses on Obligation For the Period	3.35	(0.72)
Actuarial (Gains)/Losses on Plan Asset For the Period	-	-
Actuarial (Gains)/Losses Recognized in the Statement of Profit or Loss	3.35	(0.72)

Amount Recognized in the Balance Sheet		
(Present Value of Benefit Obligation at the end of the Period)	(49.96)	(39.03)
Fair Value of Plan Assets at the end of the Period	-	-
Funded Status (Surplus/ (Deficit))	(49.96)	(39.03)
Unrecognized Past Service Cost at the end of the Period	-	-
Net (Liability)/Asset Recognized in the Balance Sheet	(49.96)	(39.03)

Net Interest Cost for Current Period		
Present Value of Benefit Obligation at the Beginning	39.03	33.31
(Fair Value of Plan Assets at the Beginning)	-	-
Net Liability/(Asset) at the Beginning	39.03	33.31
Interest Cost	2.56	2.39
(Expected Return on Plan Assets)	-	-
Net Interest Cost for Current Period	2.56	2.39

Expenses Recognized in the Statement of Profit or Loss for Current Period		
Current Service Cost	5.02	4.05
Net Interest Cost	2.56	2.39
Actuarial (Gains)/Losses	3.35	(0.72)
Past Service Cost - Non-Vested Benefit Recognized	-	-
Past Service Cost - Vested Benefit Recognized	-	-
Expenses Recognized in the Statement of Profit or Loss	**10.93**	**5.72**

VIJAY K. JAIN & ASSOCIATES INDORE CHARTERED ACCOUNTANTS

BIO MEDICA LABORATORIES LTD. INDORE

BIO MEDICA LABORATORIES LIMITED

(Formerly known as Bio Medica Laboratories Private Limited)

CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Note No. 33: Other additional information to standalone financial statements

	Current Period	Previous Period
Balance Sheet Reconciliation		
Opening Net Liability	39.03	33.31
Expense Recognized in Statement of Profit or Loss	10.93	5.72
Net Liability/(Asset) Transfer In	-	-
Net (Liability)/Asset Transfer Out	-	-
(Benefit Paid Directly by the Employer)	-	-
(Employer's Contribution)	-	-
Closing Net Liability/(Asset) Recognized in the Balance Sheet	**49.96**	**39.03**

Current and Non-Current Liability		
Current Liability	9.49	5.84
Non-Current Liability	40.47	33.20
Net Liability/(Asset) Recognized in the Balance Sheet	**49.96**	**39.03**

Category of Assets		
Government of India Assets	-	-
State Government Securities	-	-
Special Deposits Scheme	-	-
Corporate Bonds	-	-
Cash And Cash Equivalents	-	-
Insurance fund	-	-
Other	-	-
Total	-	-

Experience Adjustment		
Actuarial (Gains)/Losses on Obligations - Due to Experience Adjustment	4.85	(2.13)
Actuarial Gains/(Losses) on Plan Assets - Due to Experience Adjustment	-	-

Expected Expenses to be Recognized in the Statement of Profit or Loss for Next Year		
Current Service Cost	6.31	4.79
Net Interest Cost	3.57	2.56
Past Service Cost - Non-Vested Benefit Recognized	-	-
Expecied Expenses Recognized in the Statement of Profit or Loss for Next Year#	9.88	7.35

Next year Actual Expense will also include Actuarial Gain/ loss as incurred in next year and/ or any past service cost which may arise.

BIO MEDICA LABORATORIES LTD. INDORE

VIJAY K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS INDORE

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Note No. 33: Other additional information to standalone financial statements

(6) Government Grant

During the year capital subsidy against investment in property, plant & equipment has been approved under "Madhya Pradesh MSME Protsahan Yojna 2021".

The same was reduced from the Gross Block of the respective assets against which it has been approved. Corresponding effect in WDV and depreciation during the year has also been considered and provided.

Out of the approved amount of Rs. 1,16,19,207/-, part amount of Rs. 29,04,799/- has been received during prior years and Rs. 58,09,598/- has been received during current year and the same has been accounted for.

(7) Impairment loss

During the year, there was no impairment loss in the value of fixed assets and hence no provision is required as per AS-28

(8) Related party disclosures

Names of related parties and description of relationship and nature of transactions

A. Key Managerial Personnel

Name	Relation
Mukesh Mehta	Whole time Director
Pradeep Mehta	Managing Director
Divya Khandelwal	Director
Sumeet bansal	Director
Surbhi Mahajan	Director
Santosh Kale	CFO
Kavita Thakur	Company Secretary

Nature of transactions	For the year ended 31st March 2026	For the year ended 31st March 2025
Director's Remuneration		
Mukesh Mehta	24.00	24.00
Pradeep Mehta	24.00	24.00
Interest		
Mukesh Mehta	23.19	6.62
Pradeep Mehta	23.09	2.84
Director's Sitting Fees		
Divya Khandelwal	1.20	0.60
Sumeet bansal	1.20	0.60
Surbhi Mahajan	1.80	-
Salary		
Santosh Kale	3.40	3.60
Kavita Thakur	1.80	-
Professional Fees		
Kavita Thakur	-	2.40
Bonus		
Santosh Kale	-	0.32

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Note No. 33: Other additional information to standalone financial statements

Loan from directors	As at 1st April 2025	Loan taken during the year	Repayments made during the year	Interest during the year	As at 31st March 2026
Mukesh Mehta	156.55	279.64	125.09	23.19	334.29
Pradeep Mehta	154.74	321.54	111.92	23.09	387.45

Loan from directors	As at 1st April 2024	Loan taken during the year	Repayments made during the year	Interest during the year	As at 31st March 2025
Mukesh Mehta	69.36	114.00	33.43	6.62	156.55
Pradeep Mehta	14.33	180.85	43.29	2.84	154.74

B. Other related parties and Enterprises in which in which KMP / relatives of KMP have significant influence

Name	Relation
Bio Medica Parentals	Sister Concern
Sears Phytochem Pvt Ltd	Sister Concern
Italia pharmaceuticals pvt. Ltd	Common Director
Tara Mehta	Relative of Director
Garima Mehta	Relative of Director
Anju Mehta	Relative of Director
Lokesh Jain	Relative of Director
Vitamax Healthcare Pvt. Ltd.	Subsidiary

Nature of transactions	For the year ended 31st March 2026	For the year ended 31st March 2025
Purchases		
Vitamax Healthcare Pvt. Ltd.	26.99	-
Sears Phytochem Pvt Ltd	-	5.18
Godown Maintenance Charges		
Bio Medica Parentals	1.20	1.20
Salary		
Tara Mehta	7.20	5.70
Garima Mehta	6.60	5.10
Anju Mehta	6.60	5.10
Lokesh Jain	12.60	11.10
Interest on Unsecured Loan		
Lokesh Jain	2.40	2.40
Sales		
Vitamax Healthcare Pvt. Ltd.	26.80	-
Italia pharmaceuticals pvt. Ltd	-	1.09
Interest received		
Vitamax Healthcare Pvt. Ltd.	12.50	-
Advance Paid		
Vitamax Healthcare Pvt. Ltd.	155.46	-
Loan Given		
Vitamax Healthcare Pvt. Ltd.	250.49	-
Loan received back		
Vitamax Healthcare Pvt. Ltd.	250.49	-

BIO MEDICA LABORATORIES LTD. INDORE

VIJAY K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS INDORE

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Note No. 33: Other additional information to standalone financial statements

Balance outstanding	As at 31st March 2026	As at 31st March 2025
Salary Payable		
Mukesh Mehta	2.22	2.24
Pradeep Mehta	3.30	1.34
Santosh Kale	0.76	0.52
Kavita Thakur	0.08	0.50
Tara Mehta	0.21	1.82
Garima Mehta	0.55	2.08
Anju Mehta	0.55	2.08
Lokesh Jain	0.99	2.45
Sitting Fees Payable		
Divya Khandelwal	0.08	0.20
Sumeet Bansal	0.08	0.20
Surbhi Mahajan	0.54	-
Unsecured Loan		
Lokesh Jain	20.18	20.72
Advance receivable		
Vitamax Healthcare Pvt. Ltd.	155.46	-
Loan to subsidiary company		
Vitamax Healthcare Pvt. Ltd.	12.50	-
Godown Maintenance Charges payable		
Bio Medica Parentals	4.04	3.91

(9) Value of imports on CIF basis

Value of Imports	Current Year	Previous Year
Raw Material	Nil	Nil
Finished Goods	Nil	Nil

(10) Foreign currency transactions

	Current Year	Previous Year
Expenditure in Foreign Currency		
For Import of packing materials	$ 20617.17	$ 21100.63
Earning in Foreign Exchange	Nil	Nil

(11) Additional Regulatory Information

(11.1) Title deeds of Immovable Property not held in name of the Company

Title deeds of all immovable properties are held in name of the company.

(11.2) Revaluation of Property Plant & Equipments

No revaluation of property, plant and equipment.

(11.3) Loans or advances in the nature of loans to promoters, directors, KMPs and related parties

No loans and advances in the nature of loans to promoters, directors, KMPs and related parties.

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Note No. 33: Other additional information to standalone financial statements

(11.4) Capital work in progress

There is no Capital work in progress in the company

(11.5) Intangible assets under development

The company do not have any intangible assets under development

(11.6) Details of Benami Property held

No proceeding has been initiated or pending against the company for holding any Benami property under the Benami Transactions (Prohibition) Act, 1988, as amended, and rules made thereunder.

(11.7) Borrowings from banks or financial institutions on the basis of security of current assets

Company has borrowings from banks on the basis of security of current and quarterly returns or statements of current assets filed by the Company with are in agreement with the books of accounts.

(11.8) Wilful Defaulter

Where a company is a declared wilful defaulter by any bank or financial Institution or other lender, following details shall be given.

Company has not been declared wilful defaulter by any bank or financial institution or other lender.

(11.9) Relationship with Struck off Companies

No relationship of company with any struck off companies.

(11.10) Registration of charges or satisfaction with Registrar of Companies

Where any charges or satisfaction yet to be registered with Registrar of Companies beyond the statutory period, details and reasons thereof

No charges or satisfaction yet to be registered with Registrar of Companies beyond the statutory period.

(11.11) Compliance with number of layers of companies

Not applicable during the year.

(11.12) Compliance with approved Scheme(s) of Arrangements

Effect of such Scheme of Arrangements have been accounted for in the books of account of the Company

Not applicable during the year.

(11.13) Corporate Social Responsibility (CSR)

Not applicable during the year.

(11.14) Undisclosed Income

No undisclosed income surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.

(11.15) Details of Crypto Currency or Virtual Currency

Not applicable during the year.

(11.16) Utilisation of Borrowed funds and share premium

(A) Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities .

(B) Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding that, the company shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

BIO MEDICA LABORATORIES LTD. INDORE

K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS INDORE

BIO MEDICA LABORATORIES LIMITED

(Formerly known as Bio Medica Laboratories Private Limited)

CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Note No. 33: Other additional information to standalone financial statements

(11.17) Ratios:

Ratio	C.Y. Ratio	P.Y. Ratio	% Change	Reason for variance
(a) Current Ratio Current Assets / Current Liabilities	3.51	2.31	51.65%	Due to increase in current assets
(b) Debt-Equity Ratio (Long Term Debt + Short Term Debt) / Shareholder equity	0.87	1.02	-14.92%	
(c) Debt Service Coverage Ratio Earning Before Interest, tax, Depreciation & Amortisation / (Total principal + Interest on Borrowings)	6.09	5.29	15.09%	
(d) Return on Equity Ratio (%) Earning After Interest, tax, Depreciation & Amortisation / Average Shareholder's Equity	56.74%	65.87%	-13.87%	
(e) Inventory turnover ratio Turnover / Average Inventory	1.49	2.11	-29.44%	Due to increase in inventory levels
(f)Trade Receivables turnover ratio Net Credit Sales / Average Trade Receivable	5.82	9.35	-37.80%	Due to increase in trade receivables level
(g) Trade payables turnover ratio Net Credit Purchase / Average Trade Payable	7.17	8.96	-19.92%	
(h) Net capital turnover ratio Total Sales / Average Working Capital	1.47	2.20	-33.01%	Due to increase in avg working capital
(i) Net profit ratio (%) Net Profit / Net Sales	40.98%	34.30%	19.49%	
(j) Return on Capital employed (%) Earning Before Interest & tax / Capital Employed	41.24%	57.77%	-28.62%	Due to increase in capital employed
(k) Return on investment (%) Profit after tax / Total equity	44.20%	65.87%	-32.90%	Due to increase in total equity

Signature to notes 1 to 33

Mukesh Mehta **Director** **DIN: 03187420**	**Pradeep Mehta** **Director** **DIN: 07254802**
Pratiksha Bhandari **Company Secretary** **PAN:** AQLPB2934M	**Santosh Kale** **CFO** **PAN:**

Place: Indore

Date: 27.07.2026

BIO MEDICA LABORATORIES LTD. INDORE

INDORE CHARTERED ACCOUNTANTS

BIO MEDICA LABORATORIES LIMITED

CIN: U24230MP2015PLC034576

Registered Office: Plot No. 11B-11C, Sector-E, Sanwer Road, Industrial Area, Indore (MP) 452015

CONSOLIDATED AUDITED FINANCIAL STATEMENTS

For the Financial Year Ended 31st March, 2026

Auditors:
M/s Vijay K Jain & Associates
Chartered Accountants
(Firm Registration No. 006719C)

Address: 307 Manas Bhawan Extn,
11 RNT Marg, Indore

VIJAY K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
Branches : UJJAIN | AGAR
H.O.: 307, Manas Bhawan Extn., & 315-316, Bharti Bhawan
11 R.N.T. Marg, Indore - 452 001 (M.P.)
Ph.: (0731) 2524215 | 4224215 | Cell : 97137 00582
E-mail : cavijayjain2011@yahoo.com

Independent Auditor's Report

To the Members of **BIO MEDICA LABORATORIES LIMITED**
(Formerly known as Bio Medica Laboratories Private Limited)

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the consolidated financial statements of BIO MEDICA LABORATORIES LIMITED (Formerly known as Bio Medica Laboratories Private Limited) ("the Company"), which comprise the balance sheet as at 31st March 2026, and the statement of Profit and Loss and statement of cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2026, its profit/loss and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information other than the financial statements and auditors' report thereon

The Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexures to Board's Report but does not include the financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report on in this regard.

VIJAY K. JAIN & ASSOCIATES
INDORE
CHARTERED ACCOUNTANTS

VIJAY K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
Branches : UJJAIN | AGAR
H.O.: 307, Manas Bhawan Extn., & 315-316, Bharti Bhawan
11 R.N.T. Marg, Indore - 452 001 (M.P.)
Ph.: (0731) 2524215 | 4224215 | Cell : 97137 00682
E-mail : cavijayjain2011@yahoo.com

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these consolidated financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

• Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

• Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.

• Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

VIJAY K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
Branches : UJJAIN | AGAR
H.O.: 307, Manas Bhawan Extn., & 315-316, Bharti Bhawan
11 R.N.T. Marg, Indore - 452 001 (M.P.)
Ph.: (0731) 2524215 | 4224215 | Cell : 97137 00582
E-mail : cavijayjain2011@yahoo.com

• Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

• Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the consolidated financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the consolidated financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the consolidated financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the 'Annexure A', a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

2. As required by Section 143 (3) of the Act, we report that:

   a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

   b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

   c) The Balance Sheet, the Statement of Profit and Loss and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.

   d) In our opinion, the aforesaid consolidated financial statements comply with the Accounting Standards specified under Section 133 of the Act and rules made thereunder.

VIJAY K. JAIN & ASSOCIATES
CA
INDORE
CHARTERED ACCOUNTANTS

VIJAY K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
Branches : UJJAIN | AGAR
H.O.: 307, Manas Bhawan Extn., & 315-316, Bharti Bhawan
11 R.N.T. Marg, Indore - 452 001 (M.P.)
Ph.: (0731) 2524215 | 4224215 | Cell : 97137 00582
E-mail : cavijayjain2011@yahoo.com

e) On the basis of the written representations received from the directors as on 31st March, 2026 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.

f) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in 'Annexure B'.

g) With respect to the matter to be included in the Auditor's Report under section 197(16). In our opinion and according to the information and explanations given to us, the remuneration paid by the Company to its directors during the current year is in accordance with the provisions of section 197 of the Act. The remuneration paid to any director is not in excess of the limit laid down under section 197 of the Act. The Ministry of Corporate Affairs has not prescribed other details under section 197(16) which are required to be commented upon by us. (applicable in case of Public Company)

h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

i. The Company does not have any pending litigations which would impact its financial position.

ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

iv. (a) The management has represented that, to the best of it's knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(b) The management has represented, that, to the best of it's knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

VIJAY K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
Branches : UJJAIN | AGAR

H.O.: 307, Manas Bhawan Extn., & 315-316, Bharti Bhawan
11 R.N.T. Marg, Indore - 452 001 (M.P.)
Ph.: (0731) 2524215 | 4224215 | Cell : 97137 00582
E-mail : cavijayjain2011@yahoo.com

Annexure 'A'

The Annexure referred to in paragraph 1 of Our Report on "Other Legal and Regulatory Requirements".

We report that:

Clauses I to XX are not applicable on consolidated financial statements.

(xxi) There has been no qualifications or adverse remarks by the respective auditors in the Companies (Auditor's Report) Order (CARO) reports of the companies included in the consolidated financial statements.

For VIJAY K JAIN & ASSOCIATES
Chartered Accountants
Firm Registration No: 006719C

CA SUNNY JAIN
Partner
Membership No. 429107

Place: Indore
Date: 27.07.2026
UDIN: 26429107BQNETC7419

VIJAY K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
Branches : UJJAIN | AGAR
H.O : 307, Manas Bhawan Extn., & 315-316, Sharti Bhawan 11 R.N.T. Marg, Indore - 452 001 (M.P.)
Ph.: (0731) 2524215 | 4224215 | Cell : 97137 00582
E-mail : cavijayjain2011@yahoo.com

Annexure 'B'

Report on Internal Financial Controls with reference to financial statements

<u>Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")</u>

We have audited the internal financial controls over financial reporting of BIO MEDICA LABORATORIES LIMITED ("the Company") as of March 31st 2026, in conjunction with our audit of the consolidated financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

<u>Auditors' Responsibility</u>

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

VIJAY K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
Branches : UJJAIN | AGAR

H.O.: 307, Manas Bhawan Extn., & 315-316 Bharti Bhawan
11 R.N.T. Marg, Indore - 452 001 (M.P.)
Ph.: (0731) 2524215 | 4224215 | Cell : 97137 00582
E-mail : cavijayjain2011@yahoo.com

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that

1. pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
2. provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and
3. provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For VIJAY K JAIN & ASSOCIATES
Chartered Accountants
Firm Registration No: 006719C

CA SUNNY JAIN
Partner
Membership No. 429107

Place: Indore
Date: 27.07.2026
UDIN: 26429107BQNETC7419

BIO MEDICA LABORATORIES LIMITED

(Formerly known as Bio Medica Laboratories Private Limited)

CIN : U24230MP2015PLC034576

Consolidated Balance Sheet as at 31st March 2026

Amount (in ₹ Lakhs)

Particulars	Note No.	As at 31st March 2026	As at 31st March 2025
I. EQUITY AND LIABILITIES			
(1) Shareholder's funds			
(a) Share capital	3	918.00	918.00
(b) Reserves and surplus	4	1733.36	555.30
(c) Money received against share warrants		-	-
		2651.36	1473.30
(2) Minority Interest	5	(617.40)	-
(3) Share application money pending allotment	-	-	-
(4) Non-current liabilities			
(a) Long-term borrowings	6	3155.62	1008.49
(b) Deferred tax liabilities (Net)		-	-
(c) Other long term liabilities	7	184.97	31.00
(d) Long-term provisions	8	38.09	31.58
		3378.68	1071.07
(5) Current liabilities			
(a) Short-term borrowings	9	843.31	492.95
(b) Trade payables	10		
(A) total outstanding dues of micro enterprises and small enterprises; and		49.44	32.71
(B) total outstanding dues of creditors other than micro enterprises and small enterprises		507.78	395.05
(c) Other current liabilities	11	189.36	94.07
(d) Short-term provisions	12	328.31	310.97
		1918.20	1325.75
TOTAL		**7330.84**	**3870.13**
II. ASSETS			
(1) Non-current assets			
(a) Property, Plant and Equipment and Intangible assets	13		
(i) Property, Plant and Equipment		1029.30	767.56
(ii) Intangible assets		-	-
(iii) Capital work-in-Progress		19.75	-
(iv) Intangible assets (Goodwill on acquisition)		671.35	-
(b) Non-current investments	-	-	-
(c) Deferred tax assets (net)	14	33.24	20.01
(d) Long-term loans and advances	15	89.46	4.00
(e) Other non-current assets	16	21.11	13.44
		1864.21	805.01

BIO MEDICA LABORATORIES LTD. INDORE

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

(2) Current assets			
(a) Current investments	-	-	-
(b) Inventories	17	3636.84	1813.79
(c) Trade receivables	18	1085.32	410.02
(d) Cash and cash equivalents	19	10.35	0.68
(e) Short-term loans and advances	20	501.73	752.52
(f) Other current assets	21	232.38	88.12
		5466.62	3065.12
TOTAL		**7330.84**	**3870.13**
Significant Accounting Policies & Notes To The Accounts	2		

The accompanying notes are an integral part of the financial statements.

As per our report of even date
For VIJAY K JAIN & ASSOCIATES
Chartered Accountants
Firm Registration No: 006718C

CA SUNNY JAIN
Partner
Membership No. 429107
Place: Indore
Date: 27.07.2026

For and on behalf of the Board of Directors
of Bio Medica Laboratories limited

Mukesh Mehta
Director
DIN: 03187420

Pradeep Mehta
Director
DIN: 07254802

Pratiksha Bhandari
Company Secretary
PAN: AQUPB2934M

Santosh Kale
CFO
PAN:

BIO MEDICA LABORATORIES LIMITED

(Formerly known as Bio Medica Laboratories Private Limited)

CIN : U24230MP2015PLC034576

Consolidated Statement of Profit and loss for the year ended 31st March 2026

Amount (in ₹ Lakhs)

Particulars	Note No.	For the year ended 31st March 2026	For the year ended 31st March 2025
I. Revenue from operations	22	4308.99	3831.97
II. Other income	23	2.32	0.53
III. Total Income (I + II)		4311.31	3832.50
IV. Expenses			
Cost of materials consumed	24	1847.66	1914.63
Purchase of stock-in-trade	25	47.20	12.22
Changes in inventories of finished goods work-in-progress and stock in-trade	26	(146.60)	(17.37)
Employee benefit expenses	27	305.06	194.53
Finance costs	28	225.62	119.51
Depreciation and amortization expenses	29	116.34	100.54
Other expenses	30	290.59	194.18
Total expenses		2685.90	2518.24
V. Profit before exceptional and extraordinary items and tax (III - IV)		1625.41	1314.27
VI. Exceptional items	-	-	-
VII. Profit before extraordinary items and tax (V - VI)		1625.41	1314.27
VIII. Extraordinary items	-	-	-
IX. Profit before tax (VII - VIII)		**1625.41**	**1314.27**
X. Tax expense:			
(1) Current tax		423.33	(343.52)
(2) Deferred tax	-	17.45	9.17
(3) Short /(Excess) Previous Year Income Tax		(4.11)	(9.51)
XI. Profit (Loss) for the period from continuing operations (IX - X)		**1188.74**	**970.41**
XII. Profit / (loss) from discontinuing operations		-	-
XIII. Tax expense of discontinuing operations		-	-
XIV. Profit/(loss) from Discontinuing operations (after tax) (XII - XIII)		**-**	**-**
XV. Profit (Loss) for the period (XI + XIV)		**1188.74**	**970.41**
XVI. Less: Minority Interest - Share of (Profit)/Loss		**(10.68)**	**-**
XVII. Profit/(Loss) for the year		**1178.06**	**970.41**
XVIII. Earnings per equity share	31		
(1) Basic		12.95	10.57
(2) Diluted		12.95	10.57

Significant Accounting Policies & Notes To The Accounts 2

The accompanying notes are an integral part of the financial statements.

As per our report of even date
For VIJAY K JAIN & ASSOCIATES
Chartered Accountants
Firm Registration No: 006715C

CA SUNNY JAIN
Partner
Membership No. 429107
Place: Indore
Date: 27.07.2026

For and on behalf of the Board of Directors
of Bio Medica Laboratories limited

Mukesh Mehta	**Pradeep Mehta**
Director	**Director**
DIN: 03187429	**DIN: 07264802**
Pratiksha Bhandari	**Santosh Kale**
Company Secretary	**CFO**
PAN: AQLPB2934M	**PAN:**

BIO MEDICA LABORATORIES LIMITED

(Formerly known as Bio Medica Laboratories Private Limited)

CIN : U24230MP2015PLC034576

Consolidated Cash Flow Statement for the year ended 31st March 2026

Amount (in ₹ Lakhs)

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
A. Cash Flow From Operating Activities		
Net Profit before tax and extraordinary items (as per Statement of Profit and Loss)	1625.41	1314.27
Adjustments for non Cash/ Non trade items:		
Depreciation & Amortization Expenses	116.34	100.54
Finance Cost	225.62	-
Extra Ordinary item (Prior period gratuity)	-	-
(Profit) / Loss on sale of asset	1.78	-
Operating profits before Working Capital Changes	**1969.15**	**1414.80**
Adjusted For:		
(Increase) / Decrease in trade receivables	(652.32)	(176.43)
Increase / (Decrease) in trade payables	(5.05)	225.26
(Increase) / Decrease in inventories	(1790.42)	(1077.10)
Increase / (Decrease) in other current liabilities	223.52	15.81
Increase / (Decrease) in other long term liabilities	153.97	31.00
Increase / (Decrease) in short term provisions	17.34	275.69
Increase / (Decrease) in long term provisions	6.50	-
(Increase) / Decrease in Short Term Loans & Advances	250.88	(735.32)
(Increase) / Decrease in Long Term Loans & Advances	(236.53)	-
(Increase) / Decrease in other current assets	(117.83)	(76.92)
(Increase) / Decrease in other non-current assets	(3.48)	(1.18)
Cash generated from Operations	**(184.25)**	**(104.39)**
Income Tax (Paid) / Refund	(419.22)	(353.03)
Net Cash flow from Operating Activities(A)	**(603.46)**	**(457.42)**
B. Cash Flow From Investing Activities	-	
Purchase of tangible assets	(300.90)	-
Proceeds from sales of tangible assets	12.05	-
Receipt of capital subsidy	58.10	4.62
Net Cash used in Investing Activities(B)	**(230.75)**	**4.62**
C. Cash Flow From Financing Activities		
Finance Cost	(225.62)	-
Increase in / (Repayment) of Short term Borrowings	200.56	324.23
Increase in / (Repayment) of Long term borrowings	848.53	128.22
Increase / (Decrease) in share capital	-	-
Net Cash used in Financing Activities(C)	**823.47**	**452.44**

INDORE

BIO MEDICA LABORATORIES LTD. INDORE

BIO MEDICA LABORATORIES LIMITED

(Formerly known as Bio Medica Laboratories Private Limited)

CIN : U24230MP2015PLC034576

Consolidated Cash Flow Statement for the year ended 31st March 2026

Amount (in ₹ Lakhs)

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
D. Net Increase / (Decrease) in Cash & Cash Equivalents (A+B+C)	(11.23)	**(0.36)**
E. Cash & Cash Equivalents at Beginning of period	1.82	1.03
F. Cash & Cash Equivalents at End of period	10.35	0.68
G. Net Increase / (Decrease) in Cash & Cash Equivalents (F-E)	8.52	**(0.36)**

Notes:

1. The Cash Flow Statement has been prepared by Indirect Method as per AS-3 issued by ICAI.
2. Figures of previous year have been rearranged / regrouped wherever necessary
3. Figures in brackets are outflow / deductions

Significant Accounting Policies & Notes To The Accounts 2

The accompanying notes are an integral part of the financial statements.

As per our report of even date
For VIJAY K JAIN & ASSOCIATES
Chartered Accountants
Firm Registration No: 006719C

CA SUNNY JAIN
Partner
Membership No. 429107
Place: Indore
Date: 27.07.2026

For and on behalf of the Board of Directors
of Bio Medica Laboratories limited

Mukesh Mehta **Director** **DIN: 03187420**	**Pradeep Mehta** **Director** **DIN: 07254802**
Pratiksha Bhandari **Company Secretary** **PAN:** AQLPB2934M	**Santosh Kale** **CFO** **PAN:**

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Significant Accounting Policies and Notes to Consolidated Financial statements for the year ended 31st March 2026

Note 3: Share Capital

Particulars	As at 31st March 2026	As at 31st March 2025
Authorised		
1,60,00,000 (31st March 2025: 1,60,00,000) Equity shares of INR 10.00 par value	1600.00	1600.00
Issued		
91,80,001 (31st March 2025: 91,80,001) Equity shares of INR 10.00 par value	918.00	918.00
Subscribed and paid up		
91,80,001 (31st March 2025: 91,80,001) Equity shares of INR 10.00 par value	918.00	918.00
Total	918.00	918.00

A. Reconciliation of the Shares outstanding at the beginning and at the end of the reporting period

Equity shares

	For the year ended 31st March 2026 No. of Shares	For the year ended 31st March 2025 No. of Shares
At the beginning of the period	91,80,001	1,00,000
Issued during the Period	-	90,80,001
Redeemed or bought back during the period	-	-
Outstanding at end of the period	**91,80,001**	**91,80,001**

B. Right, Preferences and Restriction attached to shares

(i) The company has only one class of Equity having a par value Rs. 10.00 per share.

(ii) Each shareholder is eligible for one vote per share held.

(iii) The dividend proposed by board of directors is subject to the approval of the shareholders in ensuing Annual General Meeting, except in case of interim dividend.

(iv) During the year ended 31st March 2026, no dividend was declared by the company (31st March 2025: Nil)

(v) In the event of liquidation, the Equity shareholders are eligible to receive the remaining assets of the company after distribution of all preferential amounts, in proportion to their shareholding.

C. Details of shareholders holding more than 5% shares in the company

Name of Shareholders	As at 31st March 2026 No. of Shares	%
Pradeep Mehta	45,89,725	49.997%
Mukesh Mehta	45,89,816	49.998%
	91,79,541	**99.995%**

Name of Shareholders	As at 31st March 2025 No. of Shares	%
Pradeep Mehta	45,89,725	49.997%
Mukesh Mehta	45,89,816	49.998%
	91,79,541	**99.995%**

VIJAY K. JAIN & ASSOCIATES CA INDORE CHARTERED ACCOUNTANTS

BIO MEDICA LABORATORIES LTD. INDORE

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Significant Accounting Policies and Notes to Consolidated Financial statements for the year ended 31st March 2026

D. Details of shares held by Promoters

Equity Shares

Sr. No.	Promoter's name	As at 31st March 2026		
		Number of shares	% holding	% Change
1.	Pradeep Mehta	45,89,725	49.997%	0%
2.	Mukesh Mehta	45,89,816	49.998%	0%
Total		91,79,541	99.995%	

Sr. No.	Promoter's name	As at 31st March 2025		
		Number of shares	% holding	% Change
1.	Pradeep Mehta	45,89,725	49.997%	0%
2.	Mukesh Mehta	45,89,816	49.998%	0%
Total		91,79,541	99.995%	

E. Aggregate no. of shares allotted as fully paid up without payment of cash/in bonus and share bought back in last five years

Particulars	Aggregate No. Of Shares In Last 5 Years	
	Current Year	Previous Year
Equity Shares		
Fully paid up by way of bonus shares	90,80,110	90,80,110

Note 4: Reserves and Surplus

Particulars	As at 31st March 2026	As at 31st March 2025
Surplus		
Opening Balance	555.30	524.48
Add: Profit for the year	1178.06	970.41
Less: Issue of fully paid bonus shares	-	908.00
Less: Prior Period Gratuity	-	31.58
Closing Balance (b)	1733.36	555.30
Balance carried to balance sheet (a+b)	1733.36	555.30

Note 5: Minority Interest

Particulars	As at 31st March 2026	As at 31st March 2025
Balance as on acquisition date	(628.08)	-
Add: Profit / (Loss) for the year	10.68	
Balance as on end of period	(617.40)	-
Balance carried to balance sheet	(617.40)	-

VIJAY K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS INDORE

BIO MEDICA LABORATORIES LTD. INDORE

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Significant Accounting Policies and Notes to Consolidated Financial statements for the year ended 31st March 2026

Note 6: Long term borrowings

Particulars	As at 31st March 2026	As at 31st March 2025
(a) Term Loan		
From Banks		
Secured		
Kotak Mahindra Bank Term Loan	159.41	204.82
Kotak Mahindra Bank LAP	817.72	661.06
HDFC Bank Term Loan	957.67	-
Bank of India -Car Loan (409)	22.89	-
Bank of India -Car Loan (416)	44.75	-
Subtotal	**2002.44**	**865.88**
(b) Loans and advances from related parties		
Unsecured		
Directors		
Mukesh Mahta	344.74	156.55
Pradeep Mahta	385.14	154.74
Related Parties		
Lokesh Jain	20.18	20.72
Prajal Nutrifoods Pvt. Ltd.	675.00	-
Subtotal	**1425.06**	**332.00**
Less: Current maturities of long term debts	(271.88)	(189.40)
[Disclosed under short term borrowings. Refer Note 8]		
Net Amount	**3155.62**	**1008.49**

6A. Terms and Conditions of Borrowings

Name of Loan	ROI	No of EMIs	Amount of EMI
Kotak Mahindra Bank (5933CL0100000119)	8.30%	60	1.90
Kotak Mahindra Bank (5933TL0100000400)	8.80%	84	1.12
Kotak Mahindra Bank (5933TL01000000521)	8.05%	60	2.03
Kotak Mahindra Bank (LAP-13622800)	9.90%	120	1.35
Kotak Mahindra Bank (LAP-18312485)	8.00%	120	1.52
Kotak Mahindra Bank (LAP-18400788)	7.40%	120	1.77
Kotak Mahindra Bank (LAP-18782388)	9.10%	84	3.30
Kotak Mahindra Bank (LAP-19028771)	9.00%	144	2.85
Kotak Mahindra Bank (LAP-19461797)	9.35%	120	3.09
Bank of India -Car Loan (409)	11.00%	84	0.38
Bank of India -Car Loan (416)	11.00%	84	0.73
HDFC Bank Term Loan	8.00%	84	15.49

VIJAY K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS INDORE

BIO MEDICA LABORATORIES LTD. INDORE

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Significant Accounting Policies and Notes to Consolidated Financial statements for the year ended 31st March 2026

Loans guaranteed by directors and others

Name of loan	Guaranteed By	Guarantee Amount
Kotak Mahindra Bank (5933CL0100000119)	Pradeep Mehta, Mukesh Mehta, Bio Medica Parentals	60.00
Kotak Mahindra Bank (5933TL0100000400)	Pradeep Mehta, Mukesh Mehta, Bio Medica Parentals	70.00
Kotak Mahindra Bank (5933TL01000000521)	Pradeep Mehta, Mukesh Mehta, Bio Medica Parentals	100.00
Kotak Mahindra Bank (LAP-13622800)	Pradeep Mehta, Mukesh Mehta, Bio Medica Parentals	102.50
Kotak Mahindra Bank (LAP-18312485)	Pradeep Mehta, Mukesh Mehta,	125.00
Kotak Mahindra Bank (LAP-18400788)	Pradeep Mehta, Mukesh Mehta, Bio Medica Parentals	150.00
Kotak Mahindra Bank (LAP-18782388)	Pradeep Mehta, Mukesh Mehta, Bio Medica Parentals	220.00
Kotak Mahindra Bank (LAP-19028771)	Pradeep Mehta, Mukesh Mehta, Bio Medica Parentals	250.00
Kotak Mahindra Bank (LAP-19461797)	Pradeep Mehta, Mukesh Mehta, Bio Medica Parentals	240.00
Bank of India -Car Loan (409)	Pradeep Mehta, Mukesh Mehta	24.30
Bank of India -Car Loan (416)	Pradeep Mehta, Mukesh Mehta	47.00
HDFC Bank Ltd. CC	Pradeep Mehta, Mukesh Mehta	495.00
Kotak Mahindra Bank O.D.	Pradeep Mehta, Mukesh Mehta, Bio Medica Parentals	500.00
HDFC Bank Term Loan	Pradeep Mehta, Mukesh Mehta and Bio Medica Parentals	988.00

Nature of security for secured borrowings

Name of loan	Nature of security
Kotak Mahindra Bank (5933CL0100000119)	First charge on plant and machinery and other fixed assets of the company (primary security) and equitable mortgage of factory land and building and factory land and building of promoter's partnership firm (Collateral security).
Kotak Mahindra Bank (5933TL0100000400)	
Kotak Mahindra Bank (5933TL01000000521)	
Kotak Mahindra Bank (LAP-13622800)	Equitable mortgage of factory land and building of promoter's partnership firm.
Kotak Mahindra Bank (LAP-18312485)	Equitable mortgage of factory land and building of company.
Kotak Mahindra Bank (LAP-18400788)	Equitable mortgage of factory land and building of company and factory land and building of promoter's partnership firm.
Kotak Mahindra Bank (LAP-18782388)	
Kotak Mahindra Bank (LAP-19028771)	
Kotak Mahindra Bank (LAP-19461797)	
Bank of India -Car Loan (409)	Earmarked Vehicle
Bank of India -Car Loan (416)	Earmarked Vehicle
HDFC Bank Term Loan	Corporate Guarantee Of Bio Medica Laboratories Private Limited, PG of Director Pradeep Mehta And Mukesh Mehta, Plant And Machinery, Property Plot No1101 and 1101-A Pithampur Sector-3 Industrial Area Pithampur Indore Madhya Pradesh

6B. Unsecured Loans taken from directors

Unsecured loans have been taken from the directors at 10.00% rate of interest and there is no written agreement for repayment terms. Though the same are generally repayable on demand, but keeping in view the terms of bank loans i.e. "Unsecured loans not to be withdrawn during the currency of bank loan", the same is considered to be of long term nature and have been classified accordingly.

6C. Continuing default of repayment of Loans and interest

The company does not have any continuing defaults in repayment of loans and interest as at the reporting date.

Note 7: Other Long Term Liabilities

Particulars	As at 31st March 2026	As at 31st March 2025
Advance Against Property	62.00	31.00
Advance Against Machinery	122.97	-
Total	**184.97**	**31.00**

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Significant Accounting Policies and Notes to Consolidated Financial statements for the year ended 31st March 2026

Note 8: Long-term provisions

Particulars	As at 31st March 2026	As at 31st March 2025
(a) Provision for employee benefits		
Provision for gratuity	38.09	31.58
Total	**38.09**	**31.58**

Note 9: Short-term borrowings

Particulars	As at 31st March 2026	As at 31st March 2025
(a) Loans repayable on demand		
From Banks		
Secured		
HDFC Bank Ltd. CC	331.17	-
HDFC Bank Ltd. OD	66.67	-
Kotak Mahindra Bank O.D.	173.59	303.55
Subtotal	**571.43**	**303.55**
(b) Current maturities of long-term debt (Refer Note 6)	271.88	189.40
Subtotal	**271.88**	**189.40**
Total	**843.31**	**492.95**

9A. Terms and Conditions of Borrowings

(i) Cash Credit limit from HDFC bank and Kotak Mahindra Bank is secured against all current assets of the company and carries interest rate of 9%. The loan is repayable on demand. Loan is secured by collateral security of factory land and building of the company

(ii) Current maturities of long-term debt: Refer Note 5A and 5B for terms and conditions

9B. Continuing default of repayment of Loans and interest

The company does not have any continuing defaults in repayment of loans and interest as at the reporting date.

Note 10: Trade Payables

Particulars	As at 31st March 2026	As at 31st March 2025
Total outstanding dues of micro enterprises and small enterprises [Refer Note 9(a) below]		
Trade payables	49.44	32.71
Subtotal	**49.44**	**32.71**
Total outstanding dues of creditors other than micro enterprises and small enterprises		
Others	507.78	395.05
Subtotal	**507.78**	**395.05**
Total	**557.22**	**427.76**

Note 10(a) : Disclosure Under Micro Small And Medium Enterprises Development Limited

Particulars	As at 31st March 2026	As at 31st March 2025
The principal amount and interest due thereon outstanding	-	-
The Principal amount paid beyond appointed dates	-	-
The Interest amount paid on delay payments	-	-
The Amount Interest Due and Payable (Principal already paid)	-	-
The Amount of Interest Accrued and unpaid	-	-

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Significant Accounting Policies and Notes to Consolidated Financial statements for the year ended 31st March 2026

Note 10(b): Trade Payables Ageing Schedule

Particulars	Not due	Outstanding from due date of payment				Total
		Less than 1 year	1-2 years	2-3 years	More than 3 years	
As at 31st March 2026						
(i) MSME	–	49.29	0.15	–	–	49.44
(ii) Others	–	435.87	40.64	31.27	–	507.78
(iii) Disputed dues - MSME	–	–	–	–	–	–
(iv) Disputed dues- Others	–	–	–	–	–	–
Total	–	**485.16**	**40.79**	**31.27**	–	**557.22**
As at 31st March 2025						
(i) MSME	–	32.71	–	–	–	32.71
(ii) Others	–	395.05	–	–	–	395.05
(iii) Disputed dues - MSME	–	–	–	–	–	–
(iv) Disputed dues- Others	–	–	–	–	–	–
Total	–	**427.76**	–	–	–	**427.76**

Note 11: Other current liabilities

Particulars	As at 31st March 2026	As at 31st March 2025
(a) Statutory dues		
GST RCM Payable	0.02	0.02
TDS/TCS Payable	3.41	2.22
Professional Tax	0.05	0.18
Employee Provident Fund	1.72	0.16
ESIC	0.65	0.04
Subtotal	**5.85**	**2.61**
(b) Employee benefits payable		
Salary Payable	37.93	36.69
Director Remuneration	5.52	5.96
Bonus Payable	4.09	4.05
Subtotal	**47.54**	**46.70**
(c) Interest accrued and due on borrowings		
Interest payable (TL and LAP)	5.45	5.19
Subtotal	**5.45**	**5.19**
(d) Other payables		
Audit Fees	0.94	0.30
Electricity Payable	5.41	8.26
Telephone Exp. Payable	0.01	0.01
Creditors for expenses	54.62	31.00
Advance from Customers (Due for settlement within 12 months)	69.54	–
Subtotal	**130.52**	**39.58**
Total	**189.36**	**94.07**

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Significant Accounting Policies and Notes to Consolidated Financial statements for the year ended 31st March 2026

Note 12: Short-term provisions

Particulars	As at 31st March 2026	As at 31st March 2025
(a) Provision for employee benefits		
Gratuity	11.87	7.45
Subtotal	**11.87**	**7.45**
(b) Other Provisions		
Current Tax (refer note 12(a))	316.44	303.52
Subtotal	**316.44**	**303.52**
Total	**328.31**	**310.97**

Note 12(a): Current Tax

Particulars	As at 31st March 2026	As at 31st March 2025
Current Tax	423.33	343.52
Less: Advance Tax	(100.00)	(40.00)
Less: TDS/TCS	(6.89)	-
Total	**316.44**	**303.52**

Note 13: Property, Plant and Equipment and Intangible assets

Particulars	As at 31st March 2026	As at 31st March 2025
(i) Property, Plant and Equipment [Refer Note 12A]	1029.30	767.56
(ii) Intangible assets	-	-
(iii) Capital work-in-Progress	19.75	-
Total	1049.05	767.56

Note 14: Deferred tax assets (net)

Particulars	As at 31st March 2026	As at 31st March 2025
Opening Balance	50.69	10.84
Deferred Tax Asset / (Liability) [Refer Note 32]	(17.45)	9.17
Total	**33.24**	**20.01**

VIJAY K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS INDORE

BIO MEDICA LABORATORIES LTD. INDORE

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Significant Accounting Policies and Notes to Consolidated Financial statements for the year ended 31st March 2026

Note 15: Long-term loans and advances

Particulars	As at 31st March 2026	As at 31st March 2025
(a) Capital advances		
Unsecured, considered good		
Advance for machinery	21.87	4.00
(b) Other loans and advances		
Unsecured, considered good		
Advance to Others	67.59	
Less: Allowance for bad and doubtful loans and advances	-	-
Total	**89.46**	**4.00**

Note 16: Other non-current assets

Particulars	As at 31st March 2026	As at 31st March 2025
(a) Security Deposits		
MPEB	14.76	7.45
National Stock Exchange	1.17	0.90
Natural Gas	5.17	5.10
Total	**21.11**	**13.44**

Note 17: Inventories

Particulars	As at 31st March 2026	As at 31st March 2025
(a) Raw Material [Valued at cost]	2839.93	1152.41
(b) Finished Goods [Valued at lower of cost or NRV]	224.30	113.00
(c) Work in Progress [Valued at cost]	79.50	36.04
(d) Others		
Packing Material [Valued at lower of cost or NRV]	493.11	512.33
Total	**3636.84**	**1813.79**

Note 18: Trade Receivables

Particulars	As at 31st March 2026	As at 31st March 2025
Secured, Considered good	-	-
Unsecured, Considered Good	1085.32	410.02
Doubtful	-	-
Less: Allowance for bad and doubtful debts		
Total	**1085.32**	**410.02**

VIJAY C. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS INDORE

BIO MEDICA LABORATORIES LTD. INDORE

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Significant Accounting Policies and Notes to Consolidated Financial statements for the year ended 31st March 2026

Note 18(a): Trade Receivables ageing schedule

Particulars	Not due	Outstanding from due date of payment					Total
		Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
As at 31st March 2026							
(i) Undisputed Trade receivables – considered good	-	983.65	71.99	-	29.68	-	1085.32
(ii) Undisputed Trade Receivables – considered doubtful	-	-	-	-	-	-	-
(iii) Disputed Trade Receivables considered good	-	-	-	-	-	-	-
(iv) Disputed Trade Receivables considered doubtful	-	-	-	-	-	-	-
Total	**-**	**983.65**	**71.99**	**-**	**29.68**	**-**	**1085.32**
As at 31st March 2025							
(i) Undisputed Trade receivables – considered good	-	403.39	6.63	-	-	-	410.02
(ii) Undisputed Trade Receivables – considered doubtful	-	-	-	-	-	-	-
(iii) Disputed Trade Receivables considered good	-	-	-	-	-	-	-
(iv) Disputed Trade Receivables considered doubtful	-	-	-	-	-	-	-
Total	**-**	**403.39**	**6.63**	**-**	**-**	**-**	**410.02**

Note 19: Cash and cash equivalents

Particulars	As at 31st March 2026	As at 31st March 2025
Balances with banks	6.95	0.03
Cheques, drafts on hand	-	-
Cash on hand	3.39	0.64
Total	**10.35**	**0.68**

Note 20: Short-term loans and advances

Particulars	As at 31st March 2026	As at 31st March 2025
(a) Others		
Unsecured, considered good		
Advance to Staff	4.37	6.35
Advance to parties	497.36	746.17
Subtotal	**501.73**	**752.52**
Less: Allowance for bad and doubtful loans and advances	-	-
Total	**501.73**	**752.52**

Note 21: Other current assets

Particulars	As at 31st March 2026	As at 31st March 2025
Prepaid Expenses	3.91	3.42
Prepaid IPO Expenses	41.75	12.90
TDS/TCS	10.06	1.42
Accrued interest	0.04	-
GST Receivable	176.63	70.38
Total	**232.38**	**88.12**

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Significant Accounting Policies and Notes to Consolidated Financial statements for the year ended 31st March 2026

Note 22: Revenue from operations

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
(a) Sale of products		
Domestic sales of manufactured medical products	4189.74	3806.43
Export Sales of manufactured medical products	39.33	-
Trading sales of medical products	63.92	13.09
Less: Goods in transit	-	-
Subtotal	**4292.98**	**3819.52**
(b) Other operating revenues		
Other operating income	12.00	12.45
Sale of scrap	4.00	-
Subtotal	**16.00**	**12.45**
Net revenue from operations	**4308.99**	**3831.97**

Note 23: Other income

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
(a) Interest Income		
MPPKVVCL	0.68	-
Interest from Income Tax Refund	-	0.20
Subtotal	**0.68**	**0.20**
(b) Other non-operating income		
Exchange Rate Differences	0.25	0.32
Old liability reversed	0.92	-
Custom Duty Drawback	0.47	-
Subtotal	**1.64**	**0.32**
Total	**2.32**	**0.53**

Note 24: Cost of materials consumed

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
Inventory at the beginning		
Raw Materials	1166.25	100.34
Packing Materials	537.13	504.67
Subtotal	**1703.38**	**605.01**
Add: Purchase during the year		
Raw Materials	2765.74	2034.13
Packing Materials	711.50	940.24
Subtotal	**3477.34**	**2974.37**
Less: Inventory at the end		
Raw Material	2839.93	1152.41
Packing Materials	493.11	512.35
Subtotal	**3333.04**	**1664.75**

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Significant Accounting Policies and Notes to Consolidated Financial statements for the year ended 31st March 2026

Cost of materials consumed		
Raw Material	1092.06	982.06
Packing Materials	755.62	932.58
Subtotal	**1847.68**	**1914.63**
Total	**1847.68**	**1914.63**

Note 24(a): Value of import and indigenous material consumed

Particulars	Unit of Measurement	For the year ended 31st March 2026		For the year ended 31st March 2025	
		Value	% to total Consumption	Value	% to total Consumption
Raw Material					
Imported		-	-	-	-
Indigenous		1847.68	100.00%	1914.63	100.00%
Total		**1847.68**	**100.00%**	**1914.63**	**100.00%**

Note 25: Purchase of Stock in Trade

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
Trading Purchases	47.20	12.22
Total	**47.20**	**12.22**

Note 26: Changes in inventories of finished goods work-in-progress and stock in-trade

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
Inventory at the beginning of the year		
Work in Progress	36.04	34.65
Finished Goods	121.16	97.03
Subtotal	**157.20**	**131.68**
Inventory at the end of the year		
Work in Progress	79.50	36.04
Finished Goods	224.30	113.00
Subtotal	**303.80**	**149.04**
(Increase)/decrease in inventories		
Work in Progress	(43.45)	(1.40)
Finished Goods	(103.14)	(15.97)
Total	**(146.60)**	**(17.37)**

VIJAY K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS INDORE

BIO MEDICA LABORATORIES LTD. INDORE

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Significant Accounting Policies and Notes to Consolidated Financial statements for the year ended 31st March 2026

Note 27: Employee benefit expenses

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
Salaries and wages		
Direct wages (Manufacturing)	147.56	76.36
Bonus	4.09	12.83
Salary and wages	88.96	49.14
Director's remuneration	48.00	48.00
Gratuity	10.93	5.72
Subtotal	**299.53**	**192.05**
Contribution to provident and other funds		
ESIC	0.76	0.44
Employer Contribution EPF	3.31	1.82
Subtotal	**4.07**	**2.26**
Staff welfare expenses		
EPF Administration Charges	0.18	0.06
Staff welfare expenses	1.28	0.16
Subtotal	**1.45**	**0.22**
Total	**305.06**	**194.53**

Note 28: Finance costs

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
Interest expense		
Working Capital	36.56	24.21
Term Loan	118.49	80.76
Car Loan	2.57	-
Unsecured Loans	49.18	11.87
Subtotal	**206.80**	**116.84**
Other borrowing costs		
Loan renewal and processing exp	18.82	2.67
Subtotal	**18.82**	**2.67**
Applicable (net gain) / loss on foreign currency transactions and translation	-	-
Subtotal	-	-
Total	**225.62**	**119.51**

Note 29: Depreciation and amortization expenses

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
Depreciation on tangible Assets	116.34	100.54
Depreciation on intangible Assets	-	-
Total	**116.34**	**100.54**

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Significant Accounting Policies and Notes to Consolidated Financial statements for the year ended 31st March 2026

Note 30: Other expenses

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
Factory Expenses	21.12	2.64
Power and fuel	105.67	94.06
Repairs to machinery	10.66	2.68
Repairs to Building	2.23	2.88
Insurance	9.53	2.18
Rates and taxes, excluding, taxes on income	0.27	7.65
Interest Income Tax / TDS	32.64	15.91
Professional Tax	0.03	0.03
Property Tax	6.31	1.59
Statutory Audit Fees	1.00	0.50
Professional Fees	1.70	2.00
Carriage inward	10.97	10.98
Commission on Sales	12.28	2.00
Director Sitting Fees	4.20	1.20
Legal & Professional fees	9.00	30.30
Factory Rent and Maintenance	4.86	1.20
Vehicle Running	1.15	0.57
Corporate Social Responsibility	11.70	-
Miscellaneous expenses	41.88	14.96
Travelling Expenses	1.64	0.84
Loss on Sale of Plant and Machinery	1.78	-
Total	**290.59**	**194.18**

Note 31: Earnings per share

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
Basic EPS		
Net profit / (loss) for the year from Total operations	1188.74	970.41
Less: Preference dividend and tax thereon	-	-
(a) Net profit / (loss) for the year attributable to the equity shareholders	1188.74	970.41
(b) Year end number of equity shares	91,80,001	91,80,001
Par value per share (INR)	10.00	10.00
Earnings per share from continuing operations - Basic (INR) (a/b)	**12.95**	**10.57**
Diluted EPS **		
Net profit / (loss) for the year from Total operations	1188.74	970.41
Less: Preference dividend and tax thereon	-	-
Net profit / (loss) for the year attributable to the equity shareholders	1188.74	970.41
Add: Interest expense and exchange fluctuation on convertible bonds (net)	-	-
(a) Profit / (loss) attributable to equity shareholders (on dilution)	1188.74	970.41
Year end number of equity shares	91,80,001	91,80,001
Add: Effect of Warrants, ESOPs and Convertible bonds which are dilutive	-	-
(b) Year end number of equity shares - for diluted EPS	91,80,001	91,80,001
Par value per share (INR)	10.00	10.00
Earnings per share - Diluted (a/b)	**12.95**	**10.57**

Note: The diluted earnings per share has been computed by dividing the net profit after tax available for equity shareholders by the weighted average number of equity shares, after giving dilutive effect all the outstanding warrants, stock options and convertible bonds for the respective periods. Since, the effect of the conversion of preference shares was anti-dilutive, it has been ignored.

INDORE

Note: 13A

Property, plant and equipment and intangible assets

Amount (in ₹ Lakhs)

	Gross Block				Depreciation				Net Block	
Property, plant and equipment	Opening Balance	Additions During the Year	Deletion During the Year	Closing Balance	Opening Balance	Provided During the year	Deletions/Adjustments	Closing Balance	As at current year end	As at previous year end
Buildings	749.62	3.73	–	753.35	273.67	47.08	–	320.95	432.40	436.93
Furniture and fixtures	16.42	1.81	–	18.23	11.16	1.70	–	12.86	5.37	5.26
Land	22.51	–	–	22.51	–	–	–	–	22.51	–
Office equipment	35.38	0.30	–	35.68	20.46	3.08	–	23.53	12.14	8.71
Plant and equipment	967.81	190.95	58.10	1100.67	562.94	66.32	–	629.26	476.40	299.74
Plant and equipment (held for Sale)	41.30	–	26.56	14.74	19.80	–	12.73	7.07	7.66	21.50
Vehicles	30.11	79.36	–	109.47	26.09	9.08	–	36.67	72.80	3.42
Property, plant and equipment (Sub-total)	**1863.16**	**211.15**	**84.66**	**2089.66**	**914.12**	**128.16**	**12.73**	**1030.36**	**1029.30**	**787.56**
Capital work in progress	Opening Balance	Additions During the Year	Deletion During the Year	Closing Balance	Opening Balance	Provided During the year	Deletions/Adjustments during the year	Closing Balance	As at current year end	As at previous year end
Factory Building		19.75		19.75					19.75	–
Capital work in progress (sub-total)	–	19.75	–	19.75	–	–	–	–	19.75	–
GRAND TOTAL	**1863.16**	**230.90**	**84.66**	**2075.41**	**914.12**	**128.16**	**12.73**	**1030.36**	**1045.06**	**787.56**

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Significant Accounting Policies and Notes to Consolidated Financial statements for the year ended 31st March 2026

Note No. : 01
Company Information

This financial statements of Bio Medica Laboratories Limited (Formerly known as Bio Medica Laboratories Private Limited) (hereinafter referred to as the "Company"), for the year ended March 31, 2026.
The company is a public company domiciled in India and is incorporated under the provisions of the Companies Act, 1956 ("the Act"). The registered office of the Company is located at Plot No. 11B-11C,Sctor-E, Sanwer Road , Industrial Area , Indore (MP). The principal place of business of the Company is in India. The Company is in the business of manufacturing and selling of Medicals items such as Injection, Tablets etc.

Note No. : 02
Significant Accounting Policies
(1) Basis of accounting:-

These financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) including the Accounting Standards notified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and the relevant provisions of the Companies Act, 2013.
The financial statements have been prepared under the historical cost convention on accrual basis.
All the amounts included in the Financial Statements are presented in Indian Rupees ('Rupees' or 'Rs.' Or 'INR') and are rounded to the nearest Lakhs, except per share data and unless stated otherwise.

(2) Use of Estimates :-

The preparation of financial statements in conformity with Indian GAAP requires the management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the disclosure of contingent liabilities, at the end of the reporting period. Although these estimates are based on the management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

(3) Revenue Recognition: -

Revenue is recognised in accordance with the principles laid down in Accounting Standard (AS) 9 - Revenue Recognition, as notified under the Companies (Accounting Standards) Rules, 2021.
Revenue is only recognised to the extent that it is highly probable that a significant reversal will not occur. The specific revenue recognition criteria described below must also be met before revenue is recognized. Cash received before the sale of goods is recognised as a contract liability.

Sale of Goods

Revenue from sale of goods is recognized when all the significant risks and rewards of ownership of the goods have been passed to the buyer, there is no continuing managerial involvement with the goods, the amount of revenue can be reliably measured, and it is probable that economic benefits associated with the transaction will flow to the entity. Sales are presented net of GST collected on behalf of the Government, trade discounts and returns, as applicable.
In case where goods have been dispatched but the conditions for revenue recognition are not met as at the reporting date - particularly where delivery is in transit and the transfer of control or risk and rewards has not occurred - the sale is not recognised. Such goods are included under inventories as "Finished Goods in Transit", measured at cost in accordance with the company's inventory accounting policy.

Other Operating Revenue

Any revenue accruing during the normal course of business of the company other than by way of main business activity of selling of manufactured items is treated as other operating revenue.

Interest Income

Interest income is recognised on a time proportion basis taking into account the amount outstanding and the applicable interest rate. Interest income is included under the head "other income" in the statement of profit and loss account.

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Significant Accounting Policies and Notes to Consolidated Financial statements for the year ended 31st March 2026

(4) Property, Plant & Equipment :-

Property, Plant & Equipment including intangible assets are stated at their original cost of acquisition including taxes, freight and other incidental expenses related to acquisition and installation of the concerned assets less depreciation till date.

Subsequent costs are capitalized on the carrying amount or recognized as a separate asset, as appropriate, only when future economic benefits associated with the item are probable to flow to the Company and cost of the item can be measured reliably. When significant parts of property, plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their specific useful lives. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All repair and maintenance are charged to statement of profit and loss during the reporting period in which they are incurred.

Advances paid towards the acquisition of property, plant and equipment outstanding at each balance sheet date is classified as capital advances under the non-current assets and the cost of assets not ready to use before such date are disclosed under 'Capital work in progress'.

The gain or loss arising on the disposal or retirement of an item of property, plant and equipment is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognized in the statement of profit and loss on the date of disposal or retirement.

Company has adopted cost model for all class of items of Property Plant and Equipment.

(5) Depreciation :-

Depreciation on Fixed Assets is provided to the extent of depreciable amount on the Written down Value (WDV) Method. Depreciation is provided based on useful life of the assets as prescribed in Schedule II to the Companies Act, 2013.

All fixed assets individually costing Rs. 5,000/- or less are fully depreciated in the year of installation/purchase.

Depreciation on assets acquired/sold during the year is recognized on a pro-rata basis to the statement of profit and loss till the date of acquisition/sale.
The carrying amount of assets is reviewed at each balance sheet date if there is any indication of impairment based on internal/external factors. An impairment loss is recognized wherever the carrying amount of an asset exceeds its recoverable amount. The recoverable amount is the greater of the assets, net selling price and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and risks specific to the asset.

After impairment, depreciation is provided on the revised carrying amount of the asset over its remaining useful life.

(6) Financial Instruments - Trade Reeivables: -

Provision is made for doubtful trade receivables based on a management estimate of expected credit loss, considering ageing, specific identification and past recovery trends.
The Company provides for doubtful debts as follows:
- 20% of the value of undisputed trade receivables considered doubtful.
- 50% of the value of disputed trade receivables considered doubtful based on management's assessment of recoverability.

These estimates are reviewed periodically and adjusted as needed based on actual recoverability.

BIO MEDICA LABORATORIES LTD. INDORE

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Significant Accounting Policies and Notes to Consolidated Financial statements for the year ended 31st March 2026

(7) Segment Reporting: -
The company is operating in one segment only i.e. manufacturing and sale of medical items and hence no separate reportable segment.

(8) Investments: -
Investments, which are readily realizable and intended to be held for not more than one year from the date on which such investments are made, are classified as current investments. All other investments are classified as non-current investments.
On initial recognition, all investments are measured at cost. The cost comprises purchase price and directly attributable acquisition charges such as brokerage, fees and duties.
On disposal of an investment, the difference between its carrying amount and net disposal proceeds is charged or credited to the statement of profit and loss.

(9) Inventories :-
Raw materials are valued at cost, packing materials are valued at lower of cost and net realizable value. Cost of raw materials and packing materials are determined on First in First out (FIFO) basis.

Work-in-progress and finished goods are valued at lower of cost and net realizable value. Cost includes direct materials and labour and a proportion of manufacturing overheads based on normal operating capacity. Cost is determined on FIFO basis.

Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and estimated costs necessary to make the sale.

(10) Retirement Benefits :-
For defined benefit plans, the liability or asset recognized in the statement of assets and liabilities on the basis of actuarial valuation at each year-end. Separate actuarial valuation is carried out for each plan using the projected unit credit method. Actuarial gains and losses for are recognized in full in the period in which they occur in the statement of profit and loss.

The Company's contributions to defined contribution plans (provident fund) are recognized in statement of profit and loss when the employee renders related service. The Company has no further obligations under these plans beyond its periodic contributions.

(11) Foreign Currency Transactions :-
Transactions arising in foreign currencies during the year are converted at the rates closely approximating the rates ruling on the transaction dates. Liabilities and receivables in foreign currency are restated at the year-end exchange rates. All exchange rate differences arising from conversion in terms of the above are included in the statement of profit and loss.

(12) Government Grants :-

Government grants received in the form of capital subsidy related to specific assets are deducted directly from the gross block of the respective asset. Depreciation is charged on the net amount, i.e., after reducing the gross block by the amount of subsidy received. In cases where the amount of subsidy exceeds the carrying amount of the asset, no depreciation is charged and the carrying amount of the asset is reduced to nil.

The subsidy is recognized when there is reasonable assurance that the entity will comply with the conditions attached to it and the grant will be received.

VIJAY K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS INDORE

BIO MEDICA LABORATORIES LTD. INDORE

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Significant Accounting Policies and Notes to Consolidated Financial statements for the year ended 31st March 2026

(13) Taxes on Income :-

Provision for current tax is made on the basis of estimated taxable income for the current accounting year in accordance with the Income Tax Act, 1961.

The deferred tax for timing differences between the book and tax profits for the year is accounted for, using the tax rates and laws that have been substantively enacted by the balance sheet date. Deferred tax assets or liability arising from timing differences are recognized to the extent there is virtual certainty with convincing evidence that these would be realized or payable in future. At each Balance Sheet date, the carrying amount of deferred tax or liability is reviewed.

(14) Provisions, Contingent Liabilities and Contingent Assets (AS-29) :-

Provisions are recognized only when there is a present obligation as a result of past events and when a reliable estimate of the amount of the obligation can be made.

Contingent Liabilities is disclosed in Notes to the account for:-
(i) Possible obligations which will be confirmed only by future events not wholly within the control of the company or
(ii) Present Obligations arising from past events where it is not probable that an outflow of resources will be required to settle the obligation or a reliable estimate of the amount of the obligation cannot be made.

Contingent assets are not recognized in the financial statement since this may result in the recognition of the income that may never be realized.

(15) Borrowing costs :-

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalised as part of the cost of the asset. All other borrowing costs are expensed in the period in the statement of profit and loss in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.

(16) Cash and Cash Equivalents :-

The Company considers all highly liquid financial instruments, which are readily convertible into known amount of cash that are subject to an insignificant risk of change in value and having original maturities of three months or less from the date of purchase, to be cash equivalents.

(17) Presentation of financial statements :-

The Balance Sheet and the Statement of Profit and Loss are prepared and presented in the format prescribed in the Schedule III to the Companies Act, 2013 ("the Act"). The disclosure requirements with respect to items in the Balance Sheet and Statement of Profit and Loss, as prescribed in the Schedule III to the Act, are presented by way of notes forming part of accounts along with the other notes required to be disclosed under the notified Accounting Standards as applicable.

VIJAY K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS INDORE

BIO MEDICA LABORATORIES LTD. INDORE

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Significant Accounting Policies and Notes to Consolidated Financial statements for the year ended 31st March 2026

(18) Basis of classification of Current and Non-current assets and liabilities :-

Assets and liabilities are classified as either current or non-current as per company's normal operating cycle and other criteria's set out in Schedule III of the Companies Act, 2013. Based on nature of products and services and time between acquisition of assets for processing and their realization in cash and cash equivalents, 12 months period has been considered by the company as its normal operating cycle.

(19) Expenses :-

Expenses are accounted on accrual basis and provisions are made for all known expenses, losses, and liabilities.

(20) Prior period items :-

Income and expenses which arises in the current year as a result of errors or omission in the preparation of financial statements of one or more prior periods were shown as prior period adjustments during the year.

(21) Earning Per Shares :-

Basic earnings per share is computed by dividing the profit / (loss) after tax (including the post-tax effect of extraordinary items, if any) by the weighted average number of equity shares outstanding during the year. Diluted earnings per share is computed by dividing the profit / (loss) after tax (including the post-tax effect of extraordinary items, if any) as adjusted for dividend, interest and other charges to expense or income relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares. Potential equity shares are deemed to be dilutive only if their conversion to equity shares would decrease the net profit per share from continuing ordinary operations. Potential dilutive equity shares are deemed to be converted as at the beginning of the period, unless they have been issued at a later date. The dilutive potential equity shares are adjusted for the proceeds receivable had the shares been actually issued at fair value (i.e. average market value of the outstanding shares). Dilutive potential equity shares are determined independently for each period presented. The number of equity shares and potentially dilutive equity shares are adjusted for share splits / reverse share splits and bonus shares, as appropriate.

(22) General :-

Except wherever stated, accounting policies are consistent with the generally accepted accounting principles and have been consistently applied.
Previous year figures have been regrouped / reclassified, wherever necessary to conform to the current year presentation.

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Note No. 32: Other additional information to consolidated financial statements

(1) Classification of creditors as per MSMED Act

The classification of creditors as micro and small enterprise has been given for the parties from whom the confirmation has been received regarding their classification as per MSMED Act. The interest on delayed payment to such parties, if any, has been calculated and booked as payable.

(2) Additional information on the entities included in the consolidated financial statements

Bio Medica Laboratories Limited	Net assets i.e., total assets minus total liabilities		Share in profit and loss	
	As % of consolidated net assets	Amount	As % of consolidated profit or loss	Amount
1	2	3	4	5
(A) Parent - Holding company	181.40%	2471.77	3366.10%	1154.44
(B) Subsidiaries				
(1) Indian				
Vitamax Healthcare Private Limited	-81.40%	(1109.17)	100.00%	34.30
Total	**100.00%**	**1362.60**	**3466.10%**	**1188.74**

(3) Statement of Management

The current assets, loans and advances are good and recoverable and are approximately of the values, if realized in the ordinary courses of business unless and to the extent stated otherwise in the Accounts. Provision for all known liabilities is adequate and not in excess of amount reasonably necessary.

(4) Impairment loss

During the year, there was no impairment loss in the value of fixed assets and hence no provision is required as per AS-28

(5) Related party disclosures

Names of related parties and description of relationship and nature of transactions

A. Key Managerial Personnel

Name	Relation
Mukesh Mehta	Whole time Director
Pradeep Mehta	Managing Director
Divya Khandelwal	Director
Sumeet bansal	Director
Surbhi Mahajan	Director
Santosh Kale	CFO
Kavita Thakur	Company Secretary

VIJAY K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS INDORE

BIO MEDICA LABORATORIES LTD. INDORE

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Note No. 32: Other additional information to consolidated financial statements

Nature of transactions	For the year ended 31st March 2026	For the year ended 31st March 2025
Director's Remuneration		
Mukesh Mehta	24.00	24.00
Pradeep Mehta	24.00	24.00
Interest		
Mukesh Mehta	23.19	6.62
Pradeep Mehta	23.09	2.84
Director's Sitting Fees		
Divya Khandelwal	1.20	0.60
Sumeet bansal	1.20	0.60
Surbhi Mahajan	1.80	–
Salary		
Santosh Kale	3.40	3.60
Kavita Thakur	1.60	–
Professional Fees		
Kavita Thakur	–	2.40
Bonus		
Santosh Kale	–	0.32

Nature of transactions	For the year ended 31st March 2026	For the year ended 31st March 2025
Loan Taken		
Mukesh Mehta	289.64	–
Pradeep Mehta	321.54	–
Loan Repaid		
Mukesh Mehta	125.14	–
Pradeep Mehta	111.92	–
Interest		
Mukesh Mehta	23.69	–
Pradeep Mehta	23.09	–

Balances Outstanding	As at 31st March 2026	As at 31st March 2025
Loan Taken		
Mukesh Mehta	344.74	156.55
Pradeep Mehta	385.14	154.74

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Note No. 32: Other additional information to consolidated financial statements

B. Other related parties and Enterprises in which in which KMP / relatives of KMP have significant influence

Name	Relation
Bio Medica Parentals	Sister Concern
Sears Phytochem Pvt Ltd	Sister Concern
Italia pharmaceuticals pvt. Ltd	Common Director
Tara Mehta	Relative of Director
Garima Mehta	Relative of Director
Anju Mehta	Relative of Director
Lokesh Jain	Relative of Director
Prajal Nutrifoods Pvt. Ltd.	Sister Concern

Nature of transactions	For the year ended 31st March 2026	For the year ended 31st March 2025
Purchases		
Sears Phytochem Pvt Ltd	–	5.18
Godown Maintenance Charges		
Bio Medica Parentals	1.20	1.20
Salary		
Tara Mehta	7.20	5.70
Garima Mehta	6.60	5.10
Anju Mehta	6.60	5.10
Lokesh Jain	12.60	11.10
Interest on Unsecured Loan		
Lokesh Jain	2.40	2.40
Sales		
Italia pharmaceuticals pvt. Ltd	–	1.09
Loan Taken		
Prajal Nutrifoods Pvt. Ltd.	750.00	–
Loan Repaid		
Prajal Nutrifoods Pvt. Ltd.	75.00	–

VIJAY K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS INDORE

BIO MEDICA LABORATORIES LTD. INDORE

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Note No. 32: Other additional information to consolidated financial statements

Balance outstanding	As at 31st March 2026	As at 31st March 2025
Salary Payable		
Mukesh Mehta	2.22	2.24
Pradeep Mehta	3.30	1.34
Santosh Kale	0.76	0.52
Kavita Thakur	0.08	0.50
Tara Mehta	0.21	1.82
Garima Mehta	0.55	2.08
Anju Mehta	0.55	2.08
Lokesh Jain	0.99	2.45
Sitting Fees Payable		
Divya Khandelwal	0.08	0.20
Sumeet bansal	0.08	0.20
Surbhi Mahajan	0.54	-
Unsecured Loan		
Prajal Nutrifoods Pvt. Ltd.	675.00	
Lokesh Jain	20.18	20.72
Godown Maintenance Charges payable		
Bio Medica Parentals	4.04	3.91

(6) Additional Regulatory Information

(6.1) Revaluation of Property Plant & Equipments

No revaluation of property, plant and equipment.

(6.2) Loans or advances in the nature of loans to promoters, directors, KMPs and related parties

No loans and advances in the nature of loans to promoters, directors, KMPs and related parties.

(6.3) Capital work in progress

There is no Capital work in progress in the company

(6.4) Intangible assets under development

The company do not have any intangible assets under development

(6.5) Details of Benami Property held

No proceeding has been initiated or pending against the company for holding any Benami property under the Benami Transactions (Prohibition) Act, 1988, as amended, and rules made thereunder.

(6.6) Borrowings from banks or financial institutions on the basis of security of current assets

Company has borrowings from banks on the basis of security of current and quarterly returns or statements of current assets filed by the Company with are in agreement with the books of accounts.

VIJAY K. JAIN & ASSOCIATES CHARTERED ACCOUNTANTS INDORE

BIO MEDICA LABORATORIES LTD. INDORE

BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN : U24230MP2015PLC034576

Amount (in ₹ Lakhs)

Note No. 32: Other additional information to consolidated financial statements

(6.7) Wilful Defaulter

Where a company is a declared wilful defaulter by any bank or financial Institution or other lender, following details shall be given.

Company has not been declared wilful defaulter by any bank or financial institution or other lender.

(6.8) Relationship with Struck off Companies

No relationship of company with any struck off companies.

(6.9) Compliance with number of layers of companies

Not applicable during the year.

(6.10) Compliance with approved Scheme(s) of Arrangements

Effect of such Scheme of Arrangements have been accounted for in the books of account of the Company

Not applicable during the year.

(6.11) Corporate Social Responsibility (CSR)

Not applicable during the year.

(6.12) Undisclosed Income

No undisclosed income surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.

(6.13) Details of Crypto Currency or Virtual Currency

Not applicable during the year.

(6.14) Utilisation of Borrowed funds and share premium

(A) Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities.

(B) Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding that, the company shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

Signature to notes 1 to 32

Mukesh Mehta **Director** **DIN: 03187420**	**Pradeep Mehta** **Director** **DIN: 07254802**
Pratiksha Bhandari **Company Secretary** **PAN:** AQLPB2934M	**Santosh Kale** **CFO** **PAN:**

Place: Indore
Date: 27.07.2026

BIO MEDICA LABORATORIES LTD. INDORE

JAIN & ASSOCIATES CA INDORE CHARTERED ACCOUNTANTS